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ABSTRACT 
Mesenchymal stem cells (MSCs) are currently under investigation as repair agents 
in the preservation of cardiac function following myocardial infarction (MI).  
However concerns have emerged regarding the safety of acute intracoronary (IC) 
MSC delivery specifically related to mortality, micro-infarction and 
microvascular flow restriction post cell therapy in animal models.  This thesis 
aimed to firstly identify an optimal dose of MSC that could be tolerated when 
delivered via the coronary artery in a porcine model of acute MI (AMI).  Initial 
dosing studies identified 25x10
6
 MSC to be a safe MSC cell dose, however, 
angiographic observations from these studies recognised that on delivery of MSC 
there was a significant adverse decrease in distal blood flow within the artery.  
This observation along with additional supportive data in the literature (published 
during the course of this thesis) suggested MSC may be contributing to such 
adverse events through the propagation of thrombosis.  Therefore further studies 
aimed to investigate the innate prothrombotic activity of MSC.  Expression of the 
initiator of the coagulation cascade initiator tissue factor (TF) on MSC was 
detected in high levels on the surface of these cells.  MSC-derived TF antigen was 
catalytically active, capable of supporting thrombin generation in vitro and 
enhancing platelet-driven thrombus deposition on collagen under flow.  Infusion 
of MSC via IC route was associated with a decreased coronary flow reserve when 
delivered but not when coadministered with an anti-thrombin agent heparin.  
Heparin also reduced MSC-associated in situ thrombosis incorporating platelets 
and VWF in the microvasculature.  Heparin-assisted MSC delivery reduced acute 
apoptosis and significantly improved infarct size, left ventricular ejection fraction, 
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LV volumes, wall motion and scar formation at 6 weeks post AMI.  In addition, 
this thesis investigated the paracrine factors secreted by MSC, in particular 
focusing on the effect on cardiac repair of a novel MSC-paracrine factor 
SPARCL1. In summary this work provides new insight into the mechanism by 
which MSC may be deleterious when delivered by an IC route and a means of 
abrogating this effect. Moreover we present new data on the MSC secretome with 
elucidation of the challenges encountered using a single paracrine factor cardiac 
repair strategy. 
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1.1 Myocardial Infarction 
1.1-1 Epidemiology of Myocardial Infarction 
Ischemic heart disease is the leading cause of mortality and morbidity in the 
world, accounting for over 7 million deaths annually [1].  In the western world 
due to improvements in primary prevention and also in acute coronary care [2] 
mortality associated with acute events are on the decline however, figures indicate 
that the number of patients suffering from progressive heart failure (HF) are on 
the rise [3].  HF is now considered to be a substantial economic burden and in 
2007 the US health care expenditure devoted $30.2 billion to HF alone [4].  In 
developing countries increased adoption of adverse behavioural and metabolic 
risk factors linked to ischemic heart disease has led to an overall increase in the 
number of associated deaths and disabilities [5].  To date, current medical 
strategies for the treatment of myocardial damage in the setting of myocardial 
infarction have only achieved modest improvements and in recent times new 
efforts have pursued cellular therapeutic strategies aimed at preservation, 
regeneration or repair of cardiac tissue post myocardial infarction (MI). 
1.1.1 Cardiac Anatomy  
The heart is a predominantly muscular organ which is responsible for homeostasis 
by providing adequate circulation of oxygenated blood throughout the body. The 
heart is divided into four chambers, consisting of two atria and two ventricles. The 
left ventricle (LV) which receives oxygenated blood from the pulmonary 
circulation via the left atrium is responsible for pumping blood to every organ in 
the body except the lungs.  The right ventricle (RV), which is separated from the 
LV by the intraventricular septum, receives deoxygenated blood from the 
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systemic circulation through the right atrium which it then sends to the lungs.  The 
heart wall of each chamber is arranged into three main layers; the pericardium, the 
myocardium and the endocardium (Figure 1.1).  The myocardium is the main 
functioning body of the heart and hosts striated muscle cells known as 
cardiomyocytes which are embedded within a matrix of connective tissue.  
Cardiomyocytes are responsible for the involuntary contraction of the heart and 
like all cells within the body require a constant supply of oxygen and nutrients to 
order to function.  Within the heart, blood is supplied to these cells via the 
coronary arteries which are found on the surface and embedded within the 
myocardium.  There are two main coronary arteries which originate above the 
right and left cusp of the aorta, namely the left main and the right main coronary 
arteries.  The right coronary artery branches into the right posterior and acute 
marginal arteries and these are responsible for supplying blood to the right 
ventricle, the right atrium and the sinoatrial and atrioventricular nodes.  The left 
main coronary artery supplies the left ventricle and the left atrium and divides into 
the Left Anterior Descending (LAD) artery which supplies the antero-lateral part 
of the LV and the circumflex artery which supplies the poster-lateral region of the 
heart (Figure 1.2). 
1.1.2 Pathophysiology of Myocardial Infarction 
Cardiac ischemic events due to the interruption of blood flow within the coronary 
arteries preventing blood supply to a region of the heart muscle may lead to 
myocardial infarction [6].  Cardiac ischemia is predominantly a result of coronary 
rupture or erosion of atherosclerotic plaque, which is a term used to describe the 
slow and progressive hardening or narrowing of the coronary arteries.  
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Figure 1.1 The Heart Wall 
 
The heart is made up of three main layers, the outermost layer the Pericarduim, the 
middle layer known as the Myocardium and the inner layer the endocardium. 
Obtained from Blausen 0470, Heart Wall.png, Wikimedia Commons, the free 
media repository 
 
 
  
5 
 
 
 
Figure1.2 Cardiac Anatomy 
The heart consists of four chambers, namely two atria and two ventricles. The left 
ventricle (LV) receives oxygenated blood from the pulmonary circulation via the 
left atrium and sends this blood to the rest of the body via the aorta.  The right 
ventricle (RV) receives deoxygenated blood from the systemic circulation 
through the right atrium which it then sends to the lungs via the pulmonary 
arteries. 
Adapted from-Sylvia S. Mader, Inquiry into life, 8
th
 Edition, 
Copyright©1997 
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1.1.3 Atherogenesis and Vascular Occlusion 
Atherosclerosis is a chronic disease that can remain asymptomatic for decades.  
Pathological risk factors for atherosclerosis include, LDL cholesterol, smoking, 
systolic blood pressure, family history of premature MI, diabetes mellitus, and the 
presence of triglycerides [7].  The onset of atherosclerosis can occur as young as 
15 years of age [8] and it is thought to be initiated by disruptions to the 
endothelial layer of the coronary arteries[9].  Analysis of early plaque formation 
indicates that this endothelial dysfunction allows for the infiltration and 
accumulation of LDL cholesterol within the arterial sublayer (Figure 1.3) [10, 
11].  Infiltration of LDL cholesterol elicits local inflammatory responses which 
further activates endothelial cells and results in the migration and infiltration of 
circulating monocytes into the arterial wall [12, 13].  Within the artery wall the 
monocytes present mature into a macrophage phenotype where they begin to 
phagocytose the LDL to become what are known as foam cells.  As these foam 
cells mature further they begin to deposit their lipids, resulting in the progressive 
formation a rich necrotic lipid core beneath the endothelial layer [14, 15]. 
Subsequently, over many years, a fibrous cap consisting of vascular smooth 
muscle cells and matrix [16] form over this lipid core.  As the lipid core increases 
in size, the plaque begins to protrude, reducing the size of the artery lumen and 
thus the flow of blood to the myocardium.  As the plaque matures further, it may 
become more vulnerable to rupture, however, in some cases due to compensatory 
enlargement of the vessels, plaque progression can occur with no effect [17, 18].  
If a plaque rupture or erosion does occur, matrix proteins such as collagen, VWF 
and laminin present within the exposed endothelium come in contact with the 
blood, triggering platelet adhesion and activation [19].   
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Activation of platelets causes the release of modulating factors that recruit 
additional platelets and mediate the process of platelet aggregation.  Activated 
integrins on the surface of platelets bind fibrinogen, crosslinking platelets and 
leading to consequences including in situ complete or subtotal occlusion of the 
artery [19].   
 
Figure 1.3 Progression of Atherosclerosis 
Endothelial dysfunction causes the infiltration of LDL cholesterol into the 
endothelial sub-layer causing a local inflammatory response.  Monocytes adhere 
and migrate into the vessel wall and develop into lipid laden macrophages known 
as foam cells.  Foam cell, in turn releases chemokines and cytokines that promote 
the recruitment of smooth muscle cells which along with other matrix protein 
form a fibrous cap.  Over time this fibrous cap may become vulnerable to rupture. 
If a plaque rupture does occur it exposes circulating platelets and coagulants to 
the underlying matrix which initiates thrombosis and the triggering of a cascade 
of events that can lead to partial or complete occlusion of the artery and thus MI. 
Adapted from Kathyrn J. Moore and Ira Tabas, Macrophages in the 
pathogenesis of atherosclerosis. Cell, 2011;145(3):341-355. 
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1.1.4 Myocardial Ischemia and Reperfusion 
The physiological result of coronary occlusion is dependent on several factors, 
including the anatomical location of the occlusion, the degree of occlusion and the 
duration of time until reperfusion is achieved [20].  Cardiomyocytes, due to lack  
of oxygen, begin to undergo apoptotic and necrotic cell death within the first 20 
minutes of coronary artery occlusion [21].  If the occlusion persists the ability to 
salvage the myocardium is decreased considerably [22].  An average human 
infarct can result in the loss up to 1.7 billion cardiomyocytes (30%) [23]. Data 
shows that endogenous cardiac regeneration, through cardiomyocyte renewal, 
occurs at a rate of 1% at the age of 25 which declines to a rate of around 0.45% at 
the age of 75, [24] therefore, the heart is unable to regenerate enough 
cardiomyocytes to compensate for the those lost during MI.  Ischemic events as a 
result of arterial occlusion trigger a cascade of endogenous reparative processes.  
These process occur in three over lapping phases, an initial inflammatory phase, a 
proliferative phase and a healing phase [25].   
In the initial phase, myocardial ischemia induces immediate complement 
activation and free radical generation, triggering a cytokine cascade with induces 
the migration of inflammatory cells such as neutrophils, monocytes and 
leukocytes into the necrosing infarcted region [26].   
In the initial part of the repair process these cells are involved in the clearance of 
necrotic cell tissue and matrix debris.  Approximately 3-4 four days following the 
onset of MI inhibition of inflammation is achieved primarily though the release of 
TGF-β and IL-10 within the myocardium [25].  Pro-inflammatory monocytes 
which are initially involved in cellular clearance undergo a phenotypic switch at 
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approximately day 4 and begin to suppress local inflammation and aid in repair 
[27]. The proliferative phase of repair is characterised by angiogenesis and the 
formation of granulation tissue consisting of proliferative myofibroblasts.  The 
local cytokine milieu stimulates increased cardiac fibroblast infiltration and 
proliferation and collagen production which over time assemble to form a fibrotic 
scar within the infarct zone, replacing in part lost cardiomyocytes [26] (Figure 
1.4). Infarct area expansion associated with scar formation results in the 
myocardial wall thinning, distortion of the ventricular shape and some 
compensatory cardiomyocyte hypertrophy [28].  This adverse remodelling renders 
the muscle incapable of tolerating the stress involved in performing its normal 
physiological contractile function.  Over time this results in a negative cycle of 
progressive dilation and further scar expansion. As adverse remodelling continues 
cardiac function deteriorates further leading to decreased ejection fraction (EF) 
and changes in diastolic and systolic volumes which can eventually lead to HF.  
Currently available medical treatments for MI and subsequent HF can only 
achieve modest results in abrogating this negative remodelling pathology and will 
be discussed in detail in section 1.1.5 (Figure 1.4).  
1.1.5 Current treatments for Myocardial Infarction  
Over the past 30 years there have been major medical advancements in both the 
diagnosis and treatment of MI.  The first line of treatment for an acute MI event is 
always restoration of blood flow to the myocardium, through the use of either 
pharmacological agents and mechanical interventions [29].   
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Figure 1.4 Ventricular remodelling after myocardial infarction  
Acute ischemia is followed by a number of cellular and molecular events that 
result in pathological ventricular remodelling. Initially repair and remodelling is 
characterised by the influx of a pro-inflammatory cells such as neutrophils and 
monocytes which secrete an array of molecules that aid in initial repair process.  
Monocytes are then activated to become M2 macrophages known to be anti-
inflammatory and play a phagocytic and reparative role within the myocardium 
post MI.  Cardiac fibroblasts also infiltrate and proliferate within the 
myocardium, in order to replace the lost myocytes these CFs form an immature 
scar to try and maintain cardiac function.  However as these cell do not have the 
contractile ability of myocytes the region of myocardium loses its ability to 
contract which results if the alteration of the global myocardium and 
subsequently leads to functional deterioration of the heart and in many cases 
results in HF. 
Adapted from Yan X et al. J Am Heart Assoc 2012;1(5) 
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Thrombolytics such as tissue plasminogen activator and streptokinase achieve 
reperfusion by lysing occlusive thrombi thus restoring coronary blood flow [30]. 
Mechanical restoration of flow is achieved through primary percutaneous 
coronary inventions (PPCI), in which the artery at the site of thrombosis or 
occlusion is wired and then dilated by means of balloon inflation or through the 
placing of a stent.  Both methods have proven successful in decreasing mortality 
however adverse events such as haemorrhagic stroke, and significant time related 
acute failure and reocclusion rates associated with the administration of 
thrombolytics have resulted in PPCI being the preferred method of clinical MI 
reperfusion [31].   
The benefits of reperfusion therapy are reduced dramatically if patency is not 
achieved rapidly and in recent times there have been great efforts to shorten the 
time between onset of symptoms and the time to PPCI known as symptom onset-
to-Balloon times [32] (Figure 1.5).  Despite PPCI being effective at preserving 
LV function and reducing the incidence of progressive HF, the process of 
reperfusion can itself cause additional injury to the myocardium [33] (Figure 1.5).  
Reperfusion can independently accelerate inflammatory responses, induce 
ventricular arrhythmias and myocardial stunning, increase microvascular 
obstruction and cause additional cell necrosis within the infarct border zone [33].  
In addition reactive oxygen species (ROS) which are generated in the ischemic 
myocardium especially after reperfusion are also capable of directly or indirectly 
causing additional cell death.  The main sources of ROS in the post ischemic 
environment include mitochondria, xanthine oxidase and phagocyte nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase[34].  As ROS are generated 
they can stimulate the production of inflammatory cytokines and which are then in 
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turn capable of stimulating further ROS formation[35].  Cytokines such as TNF´-
α, IL-1β and IL-6 stimulate apoptosis through a TNF-α receptor/caspase pathway, 
however ROS generation causes necrosis by causing a CA
2+
 overload, enhancing 
mitochondrial membrane permeability and inducing cell death[34].  At present, 
there is no successful cardioprotective therapeutic strategy available for 
preventing this additional injury associated with reperfusion [36]. Other 
pharmacological agents’ routinely used in treating events post MI, include beta-
adrenergic blockers and angiotensin converting enzyme (ACE) inhibitors.   
 
Figure 1.5 Effects of ischemia and reperfusion on infarct size over time 
Contributions of acute myocardial ischemic injury and myocardial reperfusion injury to 
final MI size (expressed in arbitrary units) in STEMI patients up to 24 hours following 
PPCI. The black solid line depicts the individual contributions to final MI size of acute 
myocardial ischemic injury and of myocardial reperfusion injury. The green dashed line 
depicts the theoretical MI size following PPCI based on acute myocardial ischemia alone 
in the absence of myocardial reperfusion injury. The red dashed line depicts the 
theoretical MI size based on acute myocardial ischemia alone in the absence of PPCI. The 
presence of myocardial reperfusion injury attenuates the benefit of PPCI in terms of the 
reduction of MI size. Therefore, the administration of a therapeutic strategy as an adjunct 
to PPCI that is capable of reducing myocardial reperfusion injury would result in a 
smaller MI size (as depicted by the green dashed line) and take advantage of full benefits 
of myocardial reperfusion.  
Obtained from Derek J. Hausenloy, Derek M. Yellon, Myocardial ischemia-
reperfusion injury: a neglected therapeutic target, J Clin Invest, 2013;123(1):92-100. 
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Beta-adrenergic blockers act by decreasing cardiac afterload associated with 
excessive catecholamine levels and decrease injury by limiting cardiac 
hypertrophy post MI [37]. ACE inhibitors act as an angiotensin II antagonist and 
decrease hypertension, cardiac hypertrophy and cardiac fibrosis associated with 
the renin-angiotensin-aldosterone system [38]. Although these therapies are 
capable of successfully modulating post MI hemodynamics they do not facilitate 
extensive regeneration which is required in order to prevent HF associated with 
large MIs that present late for reperfusion.  The annual mortality of patients with 
MI and resultant left ventricular systolic dysfunction currently stands at 13% and 
rehospitalisation for HF in this cohort is approximately 6-8% annually [39]. 
1.2 Emerging treatments for MI 
In the last decade scientific research has strived to find new therapeutic strategies 
to successfully repair the damage caused post MI. This research has focused 
mainly on attempting to harness the potential of stem and progenitor cells in the 
area of cardiac regeneration and repair.  It was first identified in 1997 by Asahara 
et al that cell therapy may be a viable option for the treatment of ischemic disease 
[40].  Ashara illustrated the ability of CD34+ cells to induce therapeutic 
neovascularisation, achieved through CD34+ endothelial cell differentiation [40].  
Since then different cell types have been evaluated for use in myocardial 
regeneration and repair post MI.    
Skeletal myoblasts were one of the first cells tested for their ability to induce 
cardiac repair.  Pre-clinically, skeletal myoblast obtained via a skeletal muscle 
biopsies were shown to be capable of differentiating into myotubes within the 
infarct region, resulting in improved cardiac functions[41].  Promising pre-clinical 
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results prompted the undertaking of a phase I clinical trial known as the MAGIC 
trial [41].  However, results from this trial did not live up to pre-clinical 
experimental data, as myoblasts failed to improve global or LV function and  
patients receiving these cells experienced increased incidences of ventricular 
arrhythmias.  Based on the findings of this trial the use of skeletal myoblasts for 
cardiac repair was abandoned.  
1.2.1 Bone Marrow Progenitors  
Both pre-clinically and clinically, the predominant source of cells used for cardiac 
repair and regeneration has been the bone marrow (BM) [42].  To date, cell 
isolates have been delivered as unfractionated whole BM, as selected 
subpopulations or as culture-derived out growth cells [43].  Unfractionated BM 
cells are used largely due to the fact that they are unselected, allowing for delivery 
of a cocktail of putative stem cells, their relative ease of harvest and the lack of 
required ex vivo expansion[42].  The first clinical trial using unfractionated BM 
cells or BM-MNCs for the treatment of MI began in 2001[44].  Initial safety 
results from this trial were positive and BM-MNC transplantation did result in 
improved cardiac function.  However, further BM-MNC trials have come to 
varied conclusions.  Trials such as the REPAIR-AMI [45] and the BOOST trial 
did demonstrate significant improvement in ejection fraction (EF) at 6 months 
after cell therapy [46], however the BOOST trial reported that this difference in 
EF was no longer significant between the control and cell group at 18 months post 
therapy [47] and recent evidence from the 5 year follow up has revealed a similar 
trend [48].  Subsequently, two other BM trials did not report any significant 
changes in LV function at 4-6 months after BM-MNC treatment [49, 50].  A large 
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multi-centre trial, the BAMI (NCT01569178) trial is now underway to determine 
if BM cells can reduce all cause mortality associated with MI. 
1.2.2 Cardiac Stem cells  
Since their discovery, cardiac stem cells (CSC) have proven to be a promising 
candidate for cardiac regeneration post MI.  CSC are isolated from cardiac tissue 
removed during heart surgery, expanded in culture and delivered back into the 
infarcted heart.  CSCs are described as multipotent clonogenic cells that are 
capable of both cardiomyocyte and vascular cell differentiation [51].  Although, 
no definitive markers for CSC isolation and characterisation have yet been 
identified the expression of C-kit and Sca-1 have been used extensively [52].  The 
efficacy of CSC in cardiac repair has been evaluated in two major clinical trials; 
the first-in-human, phase I SCIPIO trial demonstrated that C-kit+ CSC, isolated 
from the right atrial appendage during surgery and expanded in culture were 
capable of improving global cardiac performance [53].  CSC delivered via 
intracoronary injection increased LVEF by ~12% and significantly reduced infarct 
size one year after cell delivery [54].  In another phase I clinical trial, the 
CADUCEUS trial, patients received intracoronary injection of autologus cells 
grown from endomyocardial biopsies 1.5-3 months after MI.  The 6 month follow 
up analysed by MRI revealed that although there was no significant difference 
with regard global cardiac function there was a significant reduction in infarct scar 
mass and an increase in viable cardiac tissue [55].  Although CSC have been 
demonstrated to improve cardiac function, the invasive protocol required for CSC 
harvesting and the labour intensive cell expansion required has mitigated against 
their routine use and may be a hindrance when translating these progenitors to 
clinical practice.   
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Another potential candidate for cardiac regeneration over the last number of years 
has been the use of culture derived Mesenchymal Stem Cells (MSC).  MSC are 
the main focus of research of this thesis and their therapeutic potential thus will be 
discussed in detail. 
1.3 Mesenchymal stem cells 
1.3.1 Introduction 
Mesenchymal stem cells (MSC) were first described by Friedenstein and 
Petrakova in 1970 as multipotent stem cells capable of differentiating into a 
variety of different mesenchymal lineages both in vitro and after transfer in vivo 
[56]. Friedenstein identified a heterogeneous, adherent, non-hematopoietic cell 
population capable of forming fibroblast colony-forming units (CFU-Fs) and 
referred to them initially as Mesenchymal stromal cells [56, 57]. The term 
“Mesenchymal Stem Cells“ was first used by Caplan in 1991, so called because of 
their ability of differentiate into not fibroblast-like cells but osteoblasts, 
chondrocytes and adipocytes. [58, 59].  
MSC were initially thought to exist solely in the bone marrow but have since been 
cultured from many other tissues, including adipose, cord and liver blood, and 
lung tissue [60]. MSC are considered as rare, slow cycling cells and are thought to 
represent approximately 0.01–0.001% of total cells in human bone marrow[58].  
Since their discovery, MSC have been isolated from a number of non-human 
species, including mice, rats, rabbits, dogs, pigs and primates [61-66]. Isolated 
MSC have the ability to expand readily as plastic adherent cells in culture yet 
retain their growth and multi-lineage potential. However, cultured human MSC 
display signs of senescence after a limited number of cell doublings, ranging from 
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15-50 depending on the study [67, 68]. This phenomenon has raised questions 
surrounding the actual ‘stemness’ of MSC and clonal studies of MSC populations 
have highlighted the extent of heterogeneity between cultured MSC.  Cultured 
MSC display varying morphologies and express varying degrees of surface 
markers that in fact vary between passages. [69] 
In an attempt to exclusively define MSC, the International Society of Cellular 
Therapy (ISCT) recommended minimal criteria for characterising MSC.  In vitro 
cultured MSC are required to be plastic adherent, be capable of differentiating into 
adipocytes, osteocytes and chondrocytes and be positive for the surface markers 
CD73, CD90 and CD105 and the negative hematopoietic and co-stimulatory 
markers CD11b, CD14, CD 19 CD34, CD45, CD79a, HLA-DR and St ro-1 [70]. 
The ISCT recommended the use of the nomenclature multipotent Mesenchymal 
Stromal Cells when referring to MSC and this is due to their restricted tri-lineage 
‘stemness’. Although the ability of MSC to differentiate into bone and cartilage in 
vivo has been evident since the early 1980s, their ability to differentiate into other 
lineages has been somewhat more controversial. Studies have shown their ability 
to differentiate into non-mesodermal lineages such as neural cells, cardiomyocytes 
and endothelial cells but the lack of universal standards with regard to markers of 
differentiation and inability to reproduce these findings in multiple studies have 
cast doubt on MSC’s actual ability to differentiate into other lineages. [71-75] 
One of the most important properties of transplanted MSC is their ability to home 
to sites of injury and aid in the repair of these sites both by transdifferentiating, by 
supressing local inflammation and also by secreting trophic factors that simulate 
local and systemic repair [76-78].  MSC have a number of advantages including 
low immunogenicity, ease of isolation and expansion, reproducible 
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characteristics, high reparative potential and few ethical concerns such as those 
surrounding embryonic stem cells.  Cumulatively, these properties make MSC an 
interesting candidate cell type for tissue engineering and regenerative medicine. 
1.3.2 Mesenchymal stem cells engraftment and 
transdifferentation post myocardial Infarction (Figure 1.6) 
When MSC were initially suggested as a therapy post MI it was hypothesised that 
the benefits of MSC occurred through their ability to replace cells that are lost as a 
result of MI.  BM cells were first posited to be capable of differentiating along 
cardiac lineages by Orlic et al in 2001,[79] who suggested that the transplanted 
cells responded to signals within the myocardium causing them to differentiate 
into myocytes, endothelial cells and smooth muscle cells which in turn resulted in 
the regeneration of a new and functional myocardium [79].  This, along with in 
vitro studies which also showed the capacity of MSC to differentiate along cardiac 
lineages [71] prompted investigators to test the efficacy of MSC on tissue 
regeneration within the heart.  The first cardiac related MSC study demonstrated 
that when human MSC were injected into a mouse heart they were capable of 
engrafting into the myocardium where they appeared to differentiate into 
cardiomyocytes [73]. Following on from this initial study numerous in vivo 
animal studies have also revealed the ability of MSC to engraft and 
transdifferentiate [73, 80-82].  MSC were tested first in a porcine models in 2002, 
in which 6 billion MSC were directly injected into the infarcted region two weeks 
post MI.  MSC showed robust engraftment and muscle specific differentiation 
which resulted in significant functional and structural improvements within the 
MSC treated groups [80].  In a porcine model of myocardial infarction, Quevedo 
et al hypothesised the observed repair effect of MSC was solely due to their 
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engraftment and tri-lineage differentiation potential [82].  Twelve weeks post MI, 
200 million MSC were delivered via endocardial injection and followed out for a 
period of 3 months at which time MSC engraftment was still observable within 
infarct regions [82]. Additionally 14% of the tracked cells showed co-expression 
with the cardiac associated factors such as GATA-4, Nkx2.5, sarcomeric actinin 
and tropomyosin.  MRI data indicated increased contractile function and 
decreased infarct size in the MSC treated animals when compared to saline treated 
controls [82].  Due to modest observable MSC engraftment and cardiac lineage 
differentiation in vivo subsequent studies were aimed at trying to improve the 
engraftment and differentiation potential of MSC [83].  Stimulation of MSC ex 
vivo with various cytokines and growth factors, such as 5-azacytidine which is 
capable of demethylation of genes implicated in cardiac differentiation [71, 84], 
induced MSC expression of the cardiac specific markers Nkx2.5/Csx, GATA4, 
TEF-1, and MEF-2C mRNA [71].  This group also claimed that after three weeks 
in culture stimulated MSC were capable of forming myotube structures and 
beating spontaneously. Ultimately delivery of these cells in vivo resulted in 
engrafted MSC displaying the expression of myosin heavy chain, myosin light 
chain and α-actin [71].  However, MSCs capability for cardiomyocyte 
differentiation remains controversial within the field and a number of groups have 
been unable to reproduce similar results regarding in vitro and in vivo MSC 
differentiation. [85, 86]. 
In addition to cardiomyocyte differentiation MSC have also displayed capacity for 
endothelial differentiation and new vessel formation.  In vitro when exposed to 
stimulation such as VEGF [74], MSC are capable of acquiring an endothelial 
phenotype, capable of forming de novo tubular structures and of secreting pro-
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angiogenic cytokines [87-89].  In vivo evidence supporting neovascularisation was 
illustrated by Barbash et al who showed that the observed therapeutic benefit of 
MSC was achieved though both smooth muscle and endothelial cell 
differentiation [81].  There continues to be interstudy variability and lack of 
consensus with regard the engraftment and differentiation potential of MSC, 
however, evidence supporting the paracrine effects of MSC therapy is more 
robust.   
1.3.3 Mesenchymal stem cell secreted factors and their effect post 
Myocardial Infarction (Figure 1.6) 
The paracrine hypothesis surrounding MSC ability for regeneration and repair was 
first reported as far back as 1996 [90].  Since then, MSC have been shown to 
secrete a wide array of reparative growth factors, cytokines, chemokines, 
extracellular matrix proteases and hormones.  Due to their extensive secretory 
profile, Caplan, who first coined the term ‘MSC’, has now suggested changing the 
acronym MSC to mean ‘Medical Signalling Cell’[91]  Factors released from MSC 
have pro-angiogenic, immunomodulating, anti-scarring and anti-apoptotic 
properties [92].   The secretory profile of MSC varies considerably dependant on 
the local microenvironment and ex vivo modification of MSC using methods such 
as hypoxia or mechanical stress has been used to enhance the therapeutic benefit 
of MSC in relation to cardiac repair [93].  In vitro studies have shown that MSC 
secretory profile includes Vascular endothelial growth Factor (VEGF), 
Hepatocyte Growth Factor (HGF), Insulin Growth Factor (IGF-1), Transforming 
Growth Factor-β (TGF-β), Leukaemia Inhibitory Factor (LIF), Stromal cell-
derived Factor-1 (SDF-1) [92]. 
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Figure 1.6 MSC Mechanisms of Action in Cardiac Repair 
MSC mechanisms of repair were considered originally to occur through 
transdifferentiation and vascular regeneration. More recently however, it has been 
demonstrated that paracrine factors released from MSC strongly influence the cardiac 
repair benefits observed after their delivery post MI.  
Adapted from Wen et al, Repair mechanisms of bone marrow mesenchymal stem 
cells in myocardial infarction, J. Cell. Mol. Med, 2013; 15(5):1032-1043. 
 
1.3.4 MSC and Apoptosis 
Cardiomyocyte apoptosis is a form of cell death that occurs as a result of ischemic 
events within in the infarcted myocardium.  The ability to salvage cardiomyocytes 
from apoptotic cell death represents one strategy in preventing the progression of 
MI related adverse remodelling and subsequent HF [94].  Therefore the capacity 
to prevent apoptosis is an important property of MSC that may be exploited with 
regards cardiac repair.   
The anti-apoptotic benefits of MSC were first established in a rat model of acute 
kidney injury, these initial studies observed that infused MSC attached to the renal 
microvascular circulation and induced a renoprotective effect through prevention 
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of apoptosis [95].  In an attempt to elucidate the factors responsible for the 
observed renoprotective effect subsequent MSC-conditioned media experiments 
focused on the presence of cytokines VEGF, HGF and IGF [95].   
Within the cardiac field, Gnecchi et al provided novel evidence for the 
cytoprotective capabilities of the MSC secretome.  Initial studies showed that 
transducing MSC with Akt, a pro-survival gene and delivering them post MI 
inhibited adverse ventricular remodelling and restored cardiac function.  Gnecchi, 
however suggested that the magnitude of early improvements could not be 
attributed solely to delivery and engraftment of donor cells and therefore 
hypothesised that additional mechanisms such as paracrine actions must be at 
play.  In concurrence, conditioned media from Akt transduced MSC when 
injected into LV in a rat MI model significantly reduced infarct size and improved 
LV function.  It was suggested that these improvements were mediated through 
the up-regulation of genes such as VEGF, IGF, FGF-2, HGF [96].  Similar results 
were observed in large animal studies with intracoronary injection of concentrated 
MSC media reducing cardiac troponin-T levels, improving cardiac functional 
parameters and decreasing fibrosis [97]. Mechanistically MSC may prevent 
apoptosis through the activation of multiple pro-survival pathways including, 
PKC, PI3K/Akt, NF-κB and STAT3 signalling [98, 99].   
1.3.5 MSC and cardiac inflammation post MI 
Inflammation after MI is a prerequisite for the initiation of reparative processes, 
yet activated immune cells can cause additional damage to the infarcted 
myocardium. Although the negative effects of excess inflammation have been 
known for decades, no clinical treatment exists that is capable of positively 
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influencing these responses.  Post MI inflammation is considered to be an active 
process that is influenced by factors secreted from cells and matrix within the 
myocardium[100].  Through the release of paracrine mediators MSC have 
exhibited the capacity to modulate cells of the innate and adaptive immune system 
[92].  MSC may exert their therapeutic benefit post MI, in part, by shifting the 
local microenvironment from a pro-inflammatory to an anti-inflammatory 
environment [101-103].  
The ability to modulate inflammation has been demonstrated in a rat model of MI, 
in which MSC inhibit NF-κB activity, mitigate TNF-α and IL-6 release and 
subsequently to increase the expression of IL-10 within the heart, preventing both 
ventricular dilation and cardiac dysfunction [102].  The capacity of MSC delivery 
to improve cardiac function in a murine model of myocarditis, an inflammatory 
heart disease, provides further evidence of immunomodulative properties of MSC 
[104].  IFN-γ primed MSC delivered into the myocardium was associated with 
decreased TNF-α mRNA expression and decreased cardiac mononuclear cell 
activation which resulted in improved heart contractility [103].  The observed 
paracrine anti-inflammatory effect of MSC can also occur systemically. Lee et al 
demonstrated in a murine model of permanent LAD ligation, that TGS-6 secreted 
remotely from MSC, embolized within the lungs after IV delivery, was capable of 
decreasing the inflammatory response, decreasing infarct size and improving 
overall cardiac function.   
However, delivering a cultured cell to an unstable in vivo environment can also 
enhance inflammation which may not always be beneficial for cardiac repair. For 
example, MMP-2, MMP-9 and IL-6 which are known to be secreted by MSC may 
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hamper the positive of effects of MSC delivery by causing additional adverse 
myocardial damage as opposed to being beneficial [105, 106].   
Since their discovery one of the major benefits of MSC therapy has been their 
ability for potent immunomodulation. However because we still do not fully 
understand how the local environment influences what MSC secrete and the 
mechanisms involved, the full potential of MSC as an immunotherapy cannot be 
fully exploited.   
1.3.6 MSC and cardiac remodelling 
With an increasing number of patients suffering from HF and with no cardiac 
regenerative options currently available in current clinical practice, research has 
focused its attention on improving post MI remodelling.  Factors released from 
MSC may alter the extracellular matrix resulting in improved post infarction 
remodelling and increased infarct scar strength.   MSC secrete an array of 
cytokines that have anti-fibrotic properties and studies have identified the main 
factors involved to be hepatocyte growth factor (HGF), IL-10 and adrenomedullin 
[107-109].   
Matrix metalloproteinases (MMPs) are a family of enzymes that are responsible 
for the degradation of extracellular matrix post MI.  Increased amounts of MMPs 
have been linked to diseased hearts and their expression is tightly regulated by 
inhibitors known as tissue inhibitors of metalloproteinase (TIMPs).  MSC 
secretory profile includes high levels of TIMPs and altered in vivo dynamics of 
MMPs and TIMPs may be a mechanism for this cells benefit.  Delivery of 
mesenchymal precursor cells in a large model of MI resulted in modified LV 
remodelling and was associated with decreased collagen and modified TIMP and 
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MMP expression [110].  Authors suggested, that although the mechanism of 
action remains speculative, the study does demonstrate that alteration in MMPs 
associated with MSC delivery can positively influence chamber remodelling 
[110].  MSCs interaction with ECM components is not the only method of action 
of MSC with regard to remodelling.  MSC have also been shown to suppress the 
proliferation of and modulate the phenotype of cardiac fibroblasts (CFs) through 
which adverse remodelling is prevented [111].  CFs play a crucial role in the 
maintenance of ECM post MI [112].  Experimentally, MSC conditioned media 
has been shown to decrease the proliferative capacity of CFs which positively 
alters regional cardiac fibrosis through decreasing both the expression and 
synthesis of collagen type I and type III [112-114] 
MSC have thus been implicated nearly every facet of cardiac repair post MI such 
as cell differentiation, neovascularisation, apoptosis and cardiac remodelling.  
However, optimised cell numbers, routes of delivery and source of MSC remain 
unresolved topics with respect to clinical application. 
1.3.7 Allogeneic vs. Autologous MSC 
For MSC to be a clinically viable therapy in an acute MI setting they need to be 
available as an 'off the shelf’ product and therefore need to be allogeneic. 
Autologous cell harvest and required expansion renders MSC delivery for acute 
MI impractical.  Allogeneic cells have a number of important advantages over 
autologous cells, including; cells can be acquired in large quantities, they are 
available on demand, they can be obtained from one healthy donor and cell 
quality and efficiency is not dependent on patient characteristics such as age and 
health status.  As MSC are considered to be immunoprivileged, potentially they 
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can be used as allogeneic cells.  However whether they remain immunoprivileged 
when injected into the heart remains controversial [115].  With this in mind recent 
experimental findings have questioned the long term retention and therapeutic 
potential of allogeneic MSC in vivo.  One study suggests that autologous MSC 
may have more persistence potential than allogeneic MSC and that this may be 
due to the formation of not only alloreactive antibodies but an alteration in HLA 
antigen expression [116].  Improved cell retention is also observed in models 
where immunosuppression is used, suggesting an immune clearance reaction may 
be associated with allogeneic MSC delivery [117]. Despite these findings, Hare et 
al has carried out phase I/II clinical trial evaluating the effect of allogeneic and 
autologous MSC for the treatment of ischemic cardiomyopthy [118].  
Interestingly, this study demonstrated that both allogeneic and autologous cells 
were deemed safe and that both cell types demonstrated similar regenerative 
potential and that evidentially the majority of patients receiving allogeneic cells 
did not experience a reactive antibody response [118].  However, more extensive 
and sensitive immune tolerance studies may be required in order to address if 
allogeneic cells illicit immune responses particularly in relation to repeat cell 
dosing. 
1.4 MSC delivery strategies 
1.4.1 Introduction 
Since their discovery MSC have been delivered to the heart both clinically and 
pre-clinically via a number of different routes.  However, to date, there still has 
been no universal agreement as to the optimal route of cell delivery.  The route by 
which cells are delivered may influence the engraftment, retention, and survival of 
the cells and may therefore have a downstream impact on the therapeutic outcome 
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of the treatment [119].  To date, MSC have been delivered intravenously (IV), via 
the coronary artery (IC), and intramyocardially (IM) (Figure 1.7).  Each route has 
its own advantages and disadvantages. 
 
Figure 1.7 MSC delivery routes 
 
To date MSC have been delivered via the coronary artery (IC), via transendocardial and 
transepicardial routes (IM) delivery and systemically (IV) (not Illustrated) 
 
Adapted from Naofumi Takehara , Hiroaki Matsubara, Cardiac regeneration 
therapy: connections to cardiac physiology, Ajpheart, 2011;301(6):2169-2180 
 
 
1.4.2 Intravenous MSC delivery 
Although intravenous MSC delivery is the least invasive and least expensive 
method of cell delivery, it is also the least efficacious.  In order for cells to reach 
the injured myocardium after IV administration they must first past thorough the 
systemic circulation, where pulmonary passage may become an issue [78, 120].  
Dynamic tracking of MSC using a single-photon emission CT (SPECT)/CT 
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demonstrated that up to 24 hours after IV administration, the majority of MSC are 
retained within the lungs [120].  Interestingly however, imaging after 24 hours 
and up to 8 days after administration revealed that MSC had homed from the 
lungs to the infarcted region of the myocardium and that this homing ability was 
only evident in infarcted animals [120].  To determine the therapeutic effect of IV 
MSC administration Halkos et al delivered MSC in increasing doses (1, 3, or 10 
million cells/kg) in a porcine model of MI.  Endpoint analysis revealed no 
differences in EF between the groups.  There was however a difference in PV 
loop functional analysis and histological analysis post mortem revealed increased 
angiogenesis in the MSC treated groups compare to placebo treated group.  This 
study concluded that IV administration is an effective modality for the treatment 
of myocardial injury despite relatively modest cardiac improvements. A 
comparative study that set out to identify the optimal route of MSC delivery for 
cardiac repair demonstrated that 14 days post IV delivery of 50x10
6 
MSC, none of 
the infarcted region of six animals had a detectable number of MSC compared to 
the other two routes of delivery [119].  Due to low retention and engraftment 
levels post IV delivery this study recommended that IM and IC delivery are more 
favourable options than IV delivery [119] .   
1.4.3 Intramyocardial MSC Delivery 
1.4.3.1 Transepicardial 
Cell delivery via transepicardial IM involves the direct injection of MSC into the 
epicardium; this route allows for direct visualisation of the infarcted region. 
However, it requires an open thoracotomy and is usually only performed during 
coronary artery bypass surgery. The invasive nature of transepicardial cell 
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delivery and the risk of myocardial perforation limit the use of this method in 
patients.   
1.4.3.2 Transendocardial  
Transendocardial IM delivery involves the direct injection of the MSC in to the 
endocardium.  Transendocardial IM injection can be performed percutaneously 
using three dimensional electrophysiological mapping which allows for the 
identification of targeted regions within the myocardial wall.  Freyman et al [119] 
has demonstrated that transendocardial IM injection leads to a significant increase 
in the number of engrafted MSC within the infarct region and that remote organ 
retention of cells is significantly reduced when compared to IV cell delivery.  
Transendocardial IM injection of MSC has, in recent years become one of the 
most widespread methods of MSC administration.  In particular, the Hare group 
have published a number of papers in which MSC are delivered via this route in 
various porcine infarct models [121-124]. Transendocardial IM administration of 
MSC 3 days after MI induction was capable of improving cardiac function and 
decreasing infarct scar by 50% at 8 weeks [121].  A dose escalation study showed 
similar results in that there was a significant reduction in infarct size at 12 weeks.  
This observation however was not dose dependent and cell delivery had no 
sustained effect on EF [125].  In addition to these acute studies further studies 
aimed at elucidating the effect of transendocardial IM MSC delivery on chronic 
porcine models of MI.  To demonstrate this, cells were delivered to infarct scar 
region at 3 months post MI and functional analysis at 12 weeks was carried out by 
MRI.  Results showed 30% reduction in scar size, improved contractility and 
subsequently improved global LV function when compared to placebo treated 
animals [124].   
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Despite these positive results there remains a number of safety issues that are 
associated with IM injections.  Experimental evidence has demonstrated that IM 
injection can lead to increased local inflammation due to mechanical perforation 
of the myocardium and that inhibiting this inflammation can improve donor cell 
survival and proliferation. [126]  Another established drawback associated with 
IM delivery is the apparent presence of localised islet like regions of donor cells 
sequestered within the myocardium post cell administration.[127]  Although 
mainly associated with skeletal myoblast transplantation, these islets are known to 
induce disturbances to electrical impulses within the myocardium and can 
therefore be associated with ventricular arrhythmias [128].  Notwithstanding these 
adverse pre-clinical observations, IM injections have been reported to be safe and 
feasible in clinical settings.  In the phase I/II randomised POSEIDON trial an 
increasing number of allogeneic or autologous MSC were delivered by 
transendocardial IM injection to patients with chronic ischemic left ventricular 
dysfunction.  The effects of MSC treatment in this study were modest but the 
study did confirm that no serious adverse events, including arrhythmias were 
associated with endocardial delivery [118].   
A head to head comparative study of IM and IC infusion of MSC in a porcine MI 
model suggests no superiority between the routes of delivery [129].  Cell retention 
was the same between the groups, however, IC delivery did show less variability 
in efficiency but more remote organ distribution when compared to IM delivery 
[130]. 
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1.4.4 Intracoronary MSC delivery 
IC delivery involves the delivery of cells directly into the coronary circulation. 
Cells are infused via the lumen of a catheter placed within the target coronary 
artery.  The main benefit of IC delivery is that it can be performed during routine 
primary PCI and unlike IM delivery that requires specialised electro-physiological 
mapping most interventional cardiologists are familiar with coronary 
catheterization techniques.  IC MSC delivery has been proven to be 
therapeutically beneficial post MI in both the preclinical and clinical settings. For 
instance IC MSC delivery has been shown to decrease infarct size [131, 132], 
improve cardiac function [132-135], increase cardiac perfusion [133] decrease 
adverse remodelling [132, 133] and increase angiogenesis post therapy [134, 135].  
Despite these beneficial findings however, there has also been a number of safety 
issues raised regarding MSC delivery via this route.   
One of the first publications of IC MSC delivery involved the delivery of 0.5 
million MSC∕kg via the left circumflex coronary artery into a healthy canine 
myocardium in the absence of MI.  IC delivery was associated with adverse 
events such as ST segment elevation and T wave changes during cell 
administration.  Post mortem macroscopic and microscopic analysis 7 day after 
cell administration also revealed the presence of micro-infarctions within the 
region of cell delivery [136].  Similarly, a study in which sheep received IC 
delivery of gadolinium
 
labelled MSC, demonstrated, by cardiac magnetic 
resonance, the presence of cell associated microvascular obstruction and resultant 
regions of myocardial infarction [137].  Published data comparing IC and IM 
delivery also allude to adverse cell related events.  Although IC delivery did result 
in comparatively higher cell retention at the 14 day follow up, IC delivery was 
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associated with a higher incidence of decreased blood flow within the coronary 
arteries.  Histological evaluation of the infarcted region demonstrated capillary 
plugging due to MSC interactions with neutrophils and red blood cells [119].  Due 
to these findings, methods for alleviating coronary flow reduction post IC MSC 
delivery have been proposed.  Wilensky et al has suggested that delivering cells at 
high flow rate can prevent reductions in myocardial blood  flow and decrease 
mortality associated with MSC delivery.  Wilensky evaluated three cell delivery 
rates, 5 serial 2 ml infusions, a single 60ml/minute infusion and 20ml/minute 
infusion.  Results revealed that serial infusion of cells significantly reduced 
coronary blood flow and that this reduction in flow was sustained out to 14 day 
and was also associated with increased animal mortality.  The study however did 
not show any long term functional benefits of such MSC administration [138].   
Many studies have alluded to safety issues surrounding MSC IC delivery but none 
of these pre-clinical studies have provided a mechanistic reasoning as the why this 
may be occurring.  As reductions in coronary blood flow are associated with 
microvascular obstruction which is linked with thrombotic events, it is plausible 
to suggest that MSC augmentation of coagulation in situ may be at play we thus 
hypothesise that MSC may be causing thrombotic events due to their expression 
of procoagulant factors such as Tissue Factor 
1.5 Tissue Factor 
Tissue factor is a 46kDa membrane associated glycoprotein, consisting of a 219-
amino-acid extracellular domain, a 23-amino-acid transmembrane domain and an 
intracellular 21-amino acid C-terminus [139, 140].  Tissue Factor is the principal 
initiator of the extrinsic coagulation cascade and under normal physiological 
33 
 
conditions contributes to maintaining vascular homeostasis.  TF activates 
coagulation through interaction with factor VIIa, resulting in activation of factors 
V and X leading ultimately to thrombin generation and fibrin deposition (Figure 
1.8).  TF has been shown to be expressed in both vascular and non-vascular 
cells[141].  TF is expressed by fibroblasts, smooth muscle cells, and pericytes 
[141], however TF expression by platelets remains controversial and although 
resting endothelial cells do not express TF, ex vivo stimulation has been shown to 
induce its expression [141].  It was originally believed that TF was not expressed 
in the blood however active TF has been recently detected in the circulation [142].  
This blood-borne TF has been associated with cell secreted microparticles (MPs) 
which are small lipoproteins vesicles produced and released from activated or 
apoptotic eukaryotic cells.  MPs have been associated with various cells types 
including monocytes, endothelial cells, VSMCs and more recently MSC [143, 
144].   
In addition to coagulation, TF is involved in a number of other biological 
processes including angiogenesis, cell migration, cell adhesion, wound repair, 
immunity and embryonic development [145].  TF exerts its biological function 
through interaction both directly and indirectly with a number of cell receptors.  In 
vitro studies have shown that coagulation factor FVIIa, FXa and thrombin are 
capable of activating protease-activated receptors (PARs) which go on to activate 
platelets.  Expression of TF may have beneficial biological properties, the 
presence of TF being essential for embryogenesis, since knocking out TF gene 
results in an embryonic mortality rate of approximately 90% [146].  In wound 
healing models the presence of excess amounts of TF is associated with 
angiogenesis through indirect increases in secretion of growth factor such as 
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VEGF, PDGF, bFGF [147, 148].  TF may also be responsible for cell migration 
and this property of TF has been implicated in cancer metastasis [149].  Enhanced 
presence of TF is associated with negative events during atherogenesis, however 
under normal physiological conditions TF is essential.  The role of TF in vivo 
appears to be multifunctional, its role in stem cell delivery has yet to be 
established.  The aim of this thesis was therefore, to establish if TF is associated 
with MSC and if so what is its impact post MSC cell delivery with respect to 
immediate intravascular events, MSC homing and late functional effects of MSC 
post MI therapy. 
 
Figure 1.8 Extrinsic coagulation cascade 
Model of the extrinsic coagulation cascade.  TF initiates coagulation though its initial 
interaction with FVII which is activated to form a TF-FVIIa complex.  This complex then 
rapidly activates FX to FXa.  FV is activated to FVa which is a cofactor in the formation 
of prothrombin.  FXa along with cofactor FVa converts prothombin to thrombin which in 
turn converts circulating fibrinogen to fibrin.  Fibrin is then stabilised by FXIIIa produced 
by the conversion of FXII by thrombin.  
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1.6 Aims 
The main objectives of this thesis based are based on the concepts raised 
throughout the preceding introduction.  As it stands, MI and resultant HF are the 
leading cause of mortality and morbidity in the world.  MSC cell therapy, through 
the various mechanisms discussed is becoming a realistic strategy for improving 
cardiac function post MI.  However, there are still major obstacles facing the 
efficient application of MSC in a clinical setting.  To date, the majority of pre-
clinical studies have raised issues surround the safety of MSC therapy.  Despite 
this, clinical trials have gone ahead without understanding the mechanisms behind 
these observed safety issues.  The specific aims of this thesis are as follows. 
Specific Aims 
1. To establish an expandable and reproducible porcine MSC culture for 
use in vivo studies 
2. Thorough MSC dose ranging studies to determine a dose that can be 
delivered safely via the coronary artery in a clinically relevant porcine 
model of AMI  
3. To investigate the role of TF in mediating the prothrombotic effect of 
MSC delivery  
4. To determine, in vivo, the effect of abrogating TF effects on MSC 
delivery in a porcine model of AMI  
5. To determine the long term benefits of MSC when delivered in the 
presence of a TF inhibiting agent 
6. To determine the in vivo cardiac repair effect of the MSC secreted 
cytokine Sparcl1 and to investigate other possible cardiac repair 
factors secreted by MSC 
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Chapter 2  
Materials and Methods 
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2.1 Isolation of Porcine Bone Marrow 
Female Landrace Pigs (25-30 kg) were obtained from Teagasc, Moorepark, 
Fermoy, Co. Cork.  Pigs were anesthetised by intramuscular injection of ketamine 
(10 mg/kg) (Vetoquinol UK Ltd, Buckingham, UK) and xylazine (2 mg/kg) 
(Vetoquinol UK Ltd, Buckingham, UK).  Ethical approval was obtained for all 
animal experiments from Cork University animal ethics committee.  Bone marrow 
biopsies were performed as previously described [150].  Firstly, to identify the 
iliac bone, the animal was placed in either the right or left lateral position and the 
surgical site is aseptically prepared.  The iliac crest is located at the centre of the 
iliac spine and was identifiable as the projecting structure or ridge at the border of 
the bone.  Once located, the aspiration needle (11 gauge 6”) was held horizontally 
and advanced through the skin until it contacted bone.  To engage the bone, the 
needle was rotated while applying steady pressure and when the bone cavity was 
entered a change in resistance was observed.  Once the needle was in the marrow, 
the stylet of the aspiration needle was removed and a heparinised luer-lock 
syringe was attached. Bone marrow (BM) (15-20ml) was collected from the iliac 
crest in 10ml syringes (BD) and transferred into 9 ml vacuette® containers.  Bone 
marrow was processed according to previous described protocols [151].  Aspirates 
were maintained at room temperature until further processing was performed 
under sterile flow conditions in laminar flow hood (ThermoScientific).  
Approximately 5ml of BM aspirate was added to 45ml of sterile PBS (Fisher 
Scientific) in a 50ml tube (Sarstedt) and mixed thoroughly before the suspension 
was centrifuged (Centra®-CL-3 Series) at 900g for 10 minutes. Supernatant was 
carefully discarded with particular care being taken not to disturb the soft pellet. If 
multiple tubes were used pellets were combined and washed with approximately 
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5ml of PBS (Sigma) and total BM suspension was measured. To quantify cell 
number a diluted BM suspension (1:5) was added to 4% (v/v) acetic acid (Sigma) 
solution (1:2) and allowed to sit for approximately 1 minute to allow for sufficient 
lysing of erythrocytes (solution should turn brown). Cell numbers were counted 
using a haemocytometer. Primary pMSC were plated at a cell density of 41.5-
59.3x10
6 
cells/T175 flask (Sarstedt). Complete pMSC α-MEM (30ml) (PAA 
#E15832) media consisting of 10%FBS (Gibco-Invitrogen) and 1% 
penicillin/streptomycin (Sigma) was added to each T175 flask before being placed 
in an incubator at 37ºC, 5% CO2, 90% (Forma ™ Series II 3110) humidity. 
At Day 3, 15 ml of complete pMSC media was added to each flask and flasks 
were incubated again until day 5 when media was removed and flasks were 
washed with D-PBS (Sigma) in order to remove any unattached cells.  
Fresh complete pMSC media (35ml) was added and cells were maintained until 
confluent monolayer colonies were observed. Cells were then passaged, 
characterised and expanded until their use in both in vitro and in vivo experiments. 
2.1.1 MSC culturing and preparation 
For in vivo experiments, cells were expanded in culture using complete pMSC 
media.  pMSC were expanded in round tissue culture flasks (growth area 152cm
2
) 
(Starstedt).  In order to have sufficient numbers for in vivo experiments 2x the 
amount of cells required were cultured for the day of in vivo studies.  Cells were 
in culture for at least one week after thawing before being used in order to allow 
cells to recover and to ensure viability.   
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2.2 Characterisation of MSC differentiation 
capacity 
Tri-lineage differentiation capacity was determined using standard chondrogenic, 
adipogenic and osteogenic differentiation assays [151, 152]  
2.2.1 Characterisation of MSC osteogenic differentiation capacity 
Cells were typsinized using 0.25% trypsin/EDTA (Gibco-Invitrogen) solution and 
seeded at a density of 2x10
4 
cells in 8 wells of a 24 well plate (Sarstedt) with 
complete pMSC media.  Cells were maintained in complete pMSC media for 2-3 
days until they reach confluency. Once confluent 1 ml of osteogenic medium 
(Table 2.2) and 1 ml of complete pMSC medium was added to test wells and 
control wells respectively.  Media was changed twice a week and the assay was 
harvested after 10-17 days depending on the condition of the monolayer.  Samples 
were tested for osteogenic differentiation by staining cells with Alizarin Red 
(Sigma).  In order to stain with Alizarin red the medium was removed and cells 
washed in PBS and then fixed in 10% (v/v) neutral buffered formalin for 20min at 
room temperature.  Formalin was removed and cells were washed in 2ml of PBS.  
1ml of Alizarin Red solution was added to the fixed cells and allowed to stain for 
20min. Excess stain was removed and the cells were washed with dH2O.  Finally, 
1ml of dH2O was added to each well and cells were examined under the 
microscope for red deposits indicating the presence of osteogenesis.  
2.2.2 Characterisation of MSC adipogenic differentiation 
capacity 
Cells were typsinized and seeded at a density of 2x10
4 
cells in 8 wells of a 24 well 
plate with complete pMSC media.  Cells were maintained in complete pMSC 
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media for 2-3 days until they reached confluency. Once confluent 1 ml of 
adipogenic induction medium (Table 2.2) and 1 ml of complete pMSC medium 
was added to test wells and control well respectively. Test well media was 
replaced with adipogenic maintenance media (Table 2.3) every 3 days for 24 
hours to allow cells to recover.  This was then repeated until 3 cycles of induction 
and maintenance were completed.  On the final cycle of maintenance, 
maintenance media was left for a total of 5-7 days. Cells were then stained for 
adipogenic differentiation by Oil Red O staining. Before cells were first washed in 
PBS and then fixed in 10% neutral buffered formalin for 20min at room 
temperature. Formalin was removed and cells were washed in 2ml of PBS.  Oil 
Red O (1ml) was added to the fixed cells and allowed to stain for 20min. Excess 
stain was removed and the cells were washed with PBS.  60%(v/v) isopropanol 
(2ml)(Sigma) solution was added to each well and rinsed with tap water, this was 
then followed by the addition of 1ml of 1:5 Haematoxylin(Cell Path)in distilled 
H2O solution for 1 minute.  Haematoxylin was washed with warm tap water until 
water was clear. Finally, 1ml of PBS was added to each well and cells were 
examined under the light microscope for red fat globules indicating the presence 
of adipogenesis. 
2.2.3 Characterisation of MSC chondrogenic differentiation 
capacity 
pMSC monolayers were trypsinized and counted. Cells (2-2.5x10
5
) were placed 
into a 15ml tube (Sarstedt) and pelleted by centrifugation at 500g for 5 minutes. 
Supernatant was removed and pellet was resuspended in either incomplete 
chondrogegenic medium (Table 2.4) for control tubes or in complete 
chondrogenic medium (Table 2.4) for test tubes. Tubes were centrifuged again at 
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100g for 5 minutes in a swing out rotor and were then transferred to an incubator 
and maintained at 37ºC, 5% CO2, 90% humidity. The caps of tubes were loosely 
closed to allow for adequate gas exchange. Medium was changed every other day 
for 14-21 days at which time pellets were harvested by aspirating off all medium 
and washing twice in D-PBS. Pellets were allowed to air dry and fixed in 10% 
formalin before being embedded in OCT embedding matrix (CellPath) in 
cryomoulds (TissueTek, Sakura, USA) and placed at -80ºC. OCT embedded 
pellets were then sectioned at 5µm onto superfrost slides (ThermoFisher) using a 
cryostat (Leica). Toluidine blue staining was then carried out for the detection of 
glycosaminoglycans in sections of chondrocyte pellets according to the following 
staining procedure. Sections were initially fixed in 4% PFA for 10 minutes, 
followed by immersion of slides in the following solutions- 3 x 2 minute in 
Xylene, and 2x2 minutes in 100%, 95% and 17% ethanol. Slides were then 
washed in tap water and blotted dry.  A 0.5% (w/v) Toluidine blue solution was 
warmed to 57-60ºC and slides were immersed in solution for 5 minutes before 
being washed with tap water again and immersed in 100% Xylene for 2 minutes.  
Slides were then mounted with DPX mount and coversliped before being 
visualised under light microscopy. 
2.3 Staining of MSC with DiI 
DiI staining was carried out as per manufactures protocol (Appendix 9.1).  
Accordingly, MSC were trypsinized, counted and centrifuged at 600g for 5 
minutes before being resuspended at a density 1 x10
6 
in 1 ml of serum free media. 
After cell resuspension 5µl of a 2.5mg/ml DiI in DMSO solution was added per 
ml of cell solution and mixed well by gentle pipetting.  Cells were then incubated 
for 20 minutes at 37ºC.  The labelled suspension was centrifuged again at 600g for 
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5 minutes, supernatant was removed and pellet was resuspended with warm 
complete pMSC medium to neutralise the DMSO for 10 minutes and to allow ce 
for cell recovery.  
2.4 MSC delivery and Infarct model 
2.4.1 MSC preparation 
MSC (25x10
6
) were trypsinized, counted and centrifuged at 600g for 5 minutes 
before being resuspended at a density 1 x10
6 
in 1 ml of serum free α-MEM. Cells 
were stained with DiI according to methods 1.3. Cells were combined in a single 
15 ml falcon tube, counted, centrifuged again at 600g for 5 minutes and washed in 
PBS twice before being resuspended at a density of 12.5 x10
6
 cells in 8 ml of 
Saline in two 10ml luer-lock syringes (BD). 2500IU of heparin (Wochardt®) was 
added to each cell suspension in experiments were heparin was used. Cells were 
tested for viability by 7AAD (Sigma) staining (Appendix 9.2) before their use in 
vivo.  
2.4.2 Myocardial Infarction model  
The myocardial infarction protocol was derived from previous porcine MI models 
performed in our laboratory and others [153, 154].  Pigs were orally administered 
aspirin 75 mg (Aspar Pharmaceuticals Ltd, Capitol Way, London) daily for two 
weeks prior to surgery. Anaesthesia was induced by intramuscular injection of 
ketamine (10 mg/kg) (Vétoquinol UK Ltd, Buckingham, UK) and xylazine (2 
mg/kg) (Vétoquinol UK Ltd, Buckingham, UK). IV access is obtained via the 
posterior auricular vein.  Propofol, 40 mg (Fresenius Kabi Ltd, Cheshire, UK) was 
administered intravenously before intubation. Endotracheal intubation was 
achieved using a 6.5- to 7.5-mm endotracheal tube. Mechanical ventilation was 
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maintained using a large animal Harvard Apparatus ventilator and supplemental 
oxygen (4-6 L/min) combined with isofluorane (1.5%) to maintain general 
anaesthesia (Abbott Laboratories Ltd, Maidenhead, UK). Heparin (10,000IU) 
were administered intravenously before starting the procedure. ECG was 
monitored continuously by way of a 3 lead wire ECG system. In order to gain 
access to the carotid artery the pig was placed in a dorsal position with its front 
hooves slightly splayed and secured backwards. A 3-4 cm perpendicular cutdown 
was then made over the jugular furrow in order to access to the right carotid 
artery. Once the artery was identified by finger palpation of pulse the artery was 
isolated and exposed. The artery was then cannulated by the Seldinger technique, 
briefly, a micropuncture needle is inserted into the artery, upon entry a wire is 
inserted through the needle and the needle was then removed and replaced by a 6 
French sheath. The left anterior descending artery was subsequently catheterised 
under fluoroscopy guidance using a 6 French JL 4.0 G-stage PTCA guide catheter 
over a J-type guide wireand a TREK rapid exchange 3.5mm x 8mm/ 2.75x8mm 
coronary dilation balloon catheter placed in the coronary artery. The balloon was 
positioned proximal to the second diagonal branch of the LAD and balloon was 
inflated to 14-15mmHg. Complete LAD occlusion was confirmed by angiography 
using the contrast agent iodixanol (Visipaque 320, Amersham Health). 
Arrhythmias were treated by both defibrillation and intravenous administration of 
50-100mg of Lidiocaine. The balloon remained inflated for 90 minutes during 
which time a 64-slice contrast CT (GE Discovery VCT RX scanner) was 
performed to assess the area of risk. After 90 minutes the balloon was deflated 
and the LAD was then allowed to reperfuse for 120 minutes before treatment was 
delivered. Post procedure the sheath was removed and the carotid was tied. The 
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surgical incision site was then closed and disinfected. The wound was sealed 
using an aluminium powder based spray (Vétoquinol UK Ltd, Buckingham, UK).  
All pigs received a subcutaneous post-operative injection of 5mg of Carprofen 
(Norbrook Laboratories Ltd, Newry, Northern Ireland) for pain relief.  At 
appropriate time points (24 hours for acute MSC study and 6 weeks for chronic 
MSC and Saprcl1 study) (Table 2.1) animals were sacrificed by IV delivery of 
5mg of pentobarbitone (Merial Animal Health Ltd, Essex, UK). Functional 
parameters analysed by CT included End-Systolic Volume (ESV), End-Diastolic 
Volume (EDV), Ejection Fraction (EF), Cardiac Output (CO) or Stroke Volume 
(SV) (See Appendix 9.8 for additional details). 
Animals Used (Table 21) 
Acute MSC Study(24 hours) 36 (8 MSC, 15, MSC+H, 12 Saline 
Chronic MSC Study(6 weeks) 12 (6 MSC, 6 Saline) 
Chronic Sparcl1 Study(6 weeks) 8 (4 Sparcl1, 4 Saline) 
 
2.4.3 Anaesthesia and intubation 
The effect of ketamine and xylazine administration should occur within 5-10 
minutes. Once the pig became unresponsive it was transported to the operating 
table where a mask is applied to deliver 3-4% isoflourane in order to safely 
administer propofol.  After IV administration of propofol immediate intubation 
and ventilation was required as propofol is a strong respiratory depressant.  For 
adequate intubation the pig was in placed in a prone position and mouth held 
open.  Due to the pig’s narrow mouth, its limited jaw movement and profuse 
salivation visualization of the aditus laryngis can be difficult.  To adequately 
insert the intubation tube the pharynx was illuminated with a laryngoscope, saliva 
aspirated if required and with the tongue extended the epiglottis was depressed 
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using the tip of the laryngoscope. The tube was pushed past the closed vocal folds 
and when the tube was in the right position the pig coughed reflexively and 
expelled air through the tube.  
2.4.4 Treating Arrhythmias and maintenance of arterial pressure 
Ventricular arrhythmia and fibrillation (VF) can occur during the induction of MI 
in porcine models.  Most VF episodes occur within the first 30 minutes of 
induction of the infarction or within the first 10 minutes of reperfusion.  All 
episodes were treated with external electrical defibrillation (Defibrillator, Hewlett-
Packard) by using 360 J of shock and repeat applications were applied until 
arrhythmia ceased. After MI induction and prior to VF a decrease in arterial 
pressure was usually observed.  Decreases in arterial pressure were alleviated by 
reductions to the dose of isoflourane administered for a period of time until 
arterial pressure increased.  
2.4.5 Animal Housing 
Pigs were maintained for 6 weeks post MI.  Landrace pig rapidly gain weight and 
size as they reach maturity, a pig weighing 20-25Kg at the initial procedure would 
weigh 40-45Kg by week 6.  This needs to be kept in mind when housing animals 
as additional pen numbers may be required.  The number of personnel required 
may also need to be increased due to increased weight burden.  During the 6 
weeks follow up pigs were observed and their well-being was assessed twice daily 
by the animal technician. If there were observed behavioural or health changes a 
veterinarian was contacted 
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2.4.6 Coronary Flow Reserve  
Coronary Flow (Velocity) Reserve (CFR) measurements by thermodilution were 
carried out post reperfusion and post MSC delivery using commercially available 
pressure guide wires (PressureWire-3, Radi Medical Systems).  CFR is defined as 
the ratio of hyperemic to baseline blood flow and it is an accurate evaluator of 
resistance within microvasculature as a result of microvascular obstruction [155]. 
Maximal hyperaemia is required to correctly assess CFR, as suboptimal 
microcirculatory vasodilalation result in underestimation of the severity of 
microvascular obstruction [156, 157].  CFR by thermodilution uses the 
micromanometer tip of the pressure wire as a thermistor to generate a 
thermodilution curve and to measure the velocity of the intracoronary delivered 
saline bolus [158, 159] (See Appendix 9.3 for theory of CFR).  In order to carry 
out measurements the pressure wire was placed at the site of balloon occlusion 
within the coronary artery.  A 3-ml bolus of saline was then delivered in triplicate 
followed by the induction of maximal hyperemia by the rapid injection of 5ml of 
0.3mg/ml adenosine solution.  Measurements were then repeated again in 
triplicate (3ml Saline) during maximal hyperaemia [160, 161].  The pressure wire 
used was connected to a dedicated interface (RADI Analyzer, Radi Medical 
Systems) with integrated software for the analysis of the thermodilution curves 
and the automatic calculation of CFR.  Administered adenosine is known to cause 
microvascular coronary dilation through the activation of an adenosine receptor 
on the cell membrane of coronary myocytes [162]. These receptors are coupled to 
Gi-proteins and activation of this pathway opens potassium channels, which 
hyperpolarizes the cell leading to relaxation [163].  Adenosine was chosen for 
these studies as it is regarded the clinical gold standard for the induction of 
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maximal hyperemia due to its rapid onset, short duration of action, high safety 
profile, and simplicity of use [155].  
2.4.7 Intracoronary MSC delivery 
The protocol used was adapted from previous protocols verified in the CRVB 
[164]. After two hours of reperfusion a 1.5 F proxis infusion catheter (Pro-great) 
was positioned at the site of prior balloon inflation using a using a 6 French JL 4.0 
G-stage PTCA guide catheter. Simultaneously 5000IU of heparin was 
administered. All 16 ml of the cell suspension or saline was then infused via the 
catheter at a rate of 1ml/min with 2 minutes rest between each 1ml injection. Cells 
were infused over a total of 48 minutes. Angiography was performed at the 
midpoint of cell delivery to determine if a no-reflow phenomenon was occurring. 
If flow appeared to be diminished a longer time interval between cell injections 
was adopted.  
2.4.8 Sacrifice and tissue collection 
Pigs were sacrificed at either 24 hours or at 6 weeks post procedure. Initial 
induction of anaesthesia and ventilation followed the same protocol as the 
myocardial infarction model protocol (Section 2.4.2). However, in order to access 
the LAD a sheath left carotid access was used. In order to determine the patency 
in the LAD an angiograph was carried out.  A repeat 64-slice contrast CT was 
then also performed to allow determination of infarct size at 24 hours and at 6 
weeks. Animals were then sacrificed via intravenous administration of 5mg of 
pentobarbitone (Merial Animal Health Ltd, Essex, UK). To expose the heart, the 
thoracic cavity was then opened and the aorta clamped. A 50ml 4% ThioflavinS 
(w/v) solution was injected into the left ventricle and allowed to perfuse for 30 
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seconds. Following this 50ml of 1% methylene blue (w/v) in saline solution was 
injected into the left ventricle and again allowed to perfuse for 1-2 minutes. Heart 
was then excised, washed and weighed. The heart was sectioned from base to 
apex in 5mm transverse sections. Section were then incubated in the dark in a 2% 
(w/v) 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma Aldrich, MO, USA) for 
10 minutes at room temperature. TTC staining allows us to delineate the infarct 
region clearly in the heart sections. TTC was used to differentiate between 
metabolically active and inactive tissues. The white compound is enzymatically 
reduced to red TPF (1,3,5-triphenylformazan) in living tissues due to the activity 
of various dehydrogenases (enzymes important in oxidation of organic 
compounds and thus cellular metabolism), while it remains as white TTC in areas 
of cell death\necrosis since these enzymes have been either denatured or 
degraded.  Images of heart sections were taken using a cannon EOS550D 18 
megapixel camera.  The ThioflavinS injected at the time of sacrifice allowed us to 
identify regions of microvascular obstruction (MVO) within the infarct region.  
When observed under a UV light the regions of MVO correlated to dark regions 
on the heart sections in which no ThioflavinS was able to penetrate. Images of 
MVO were captured in the dark under a UV light again using a cannon EOS550D 
18 megapixel camera. Tissue samples for each heart section were then taken from 
three regions, the infarct zone (IZ), the border zone (BZ) and the remote zone 
(RZ). Samples were embedded in OCT cryomolds and placed directly onto dry ice 
for freezing, placed in cryotubes and snap frozen by liquid nitrogen or placed in 
15ml falcons in PFA for paraffin embedding. OCT embedded and snap frozen 
samples were stored at -80ºC until required for further analysis. Infarct area was 
planimeterized using Image J software (U.S. National Institutes of Health, 
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Maryland, USA).  Gross hemorrhagic areas were also delineated using Image J 
and expressed as a percentage of total heart area. 
2.5 Tissue sampling 
2.5.1 Apoptosis and cell infiltration in border zone 
Analysis of apoptosis within the border region of infarcted tissue was carried out 
using a terminal deoxynucleotidyl-mediated dUTP nick-end labelling (TUNEL) 
method according to the manufacturer’s instructions (See Appendix 9.9) (In Situ 
Cell Death Detection Kit, Fluorescein, Roche Diagnostics).  Briefly, 5µm thick 
OCT section were cut using a cryostat and sections were placed on superfrost 
slides, all sections were maintained at -20ºC until analysis. Just prior to TUNEL 
staining sections were placed in room temperature for 30 minutes. Sections were 
then fixed with 4% PFA for 20 minutes at room temperature followed by 30 
minute wash in PBS. Slides were incubated in 0.1% (v/v) TritonX, 0.1%(w/v) 
sodium citrate solution for 4 minutes at 4ºC followed by two PBS washes. 50 µl 
of TUNEL reaction mixture was placed on each section and incubated in a 
humidified chamber for 60 minutes at 37ºC. Again 3x PBS washes were carried 
out following TUNEL reagent incubation. The nuclei of cells were stained with a 
1:2000 DAPI (v/v) (in dH2O) solution. Slides were washed again in PBS before 
being mounted with antifade (Thermo) and coversliped.  The number of TUNEL 
positive cells was counted in 45 images (magnification: 60X) per animal, derived 
from BZ taken from a midventricular slices.  Data was expressed as a percentage 
of TUNEL positive cells/DAPI positive cells. Number of DiI positive cells was 
also counted and expressed as a percentage of the total number DAPI positive 
cells. 
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2.5.2 Trichrome staining for analysis of microvascular plugging 
Trichrome staining was performed on paraffin embedded sections. PFA fixed 
tissue samples were dehydrated using an automatic tissue processer (Histokinet) 
before being embedded in paraffin matrix. Slides were deparaffinised, hydrated 
and fixed before being stained. To deparaffinise, slides are placed in a couplin jar 
and the following washes performed. Two washes in xylene for 3 minutes, a 3 
minute incubation with a 1:1 xylene in 100% ethanol solution, two 3 minute 
incubations in 100% ethanol, a 3 minute incubation in 95% ethanol and a 3 
minute wash in 75% ethanol followed by a 3 minute wash in 50% ethanol. Finally 
slides are placed under running tap water and kept in tap water until required for 
analysis. For Trichrome staining slides were first placed in a coplin jar containing 
Bouin’s solution for 15 minutes at 56ºC before being washed under running tap 
water. Slides remained under the tap until the water was free of yellow coloration. 
The slides were then immersed in Hematoxyline Z solution for 15 minutes and 
washed again under tap water for 15 minutes before being rinsed in distilled 
water. Sections were then stained with a Ponceau 2R/ Acid Fuchsin stain for 2 
minutes and then dipped in distilled water to remove any residual stain. Slides 
were subsequently treated with phosphtotungstic acid solution for 5 minutes and 
counter stained with Aniline blue for 3 minutes. For the second last step slides 
were immersed in 1% Acetic acid solution before a final rinse in distilled water. 
Slides were then dehydrated and mounted with DPX and coversliped. 
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2.6 Analysis of Tissue Factor  
2.6.1 Surface Tissue Factor expression by immunocytochemistry 
MSC were seeded at a density of 1000-2000 cells in an 8 well glass Nunc 
chamber. Cells were allowed to adhere and proliferate for 2-3 days until 
approximately 60% confluency was reached. All cell types adhered to glass and 
visual analysis demonstrated that glass has no apparent effect on the cell viability.  
Media was then removed and the cell monolayer was washed in PBS before 
fixation with ice cold methanol for 5 minutes.  Methanol fixation was the used for 
cellular TF antigen expression analysis by immunostaining as PFA is known to 
reduce the antigenicity of cells and crosslinking can obstruct antibody binding.  A 
permeabilization step was added for TF detection as previous work revealed that 
TF antibody staining in nonpermeabilised fibroblasts demonstrated staining only 
on the cell periphery[165]. . Cells were washed again with PBS. Blocking buffer 
was then added to each well for 30 minutes in order to block any nonspecific 
antibody binding. The blocking solution consisted of 5% normal goat serum and 
0.1% (v/v) TritonX in PBS. After blocking, cells were incubated with Tissue 
Factor primary antibody (Bioss, Woburn, MA 01801) or IgG control antibodies 
(Abcam, Cambridge, UK) at a dilution of 1:50 in blocking buffer at 4ºC 
overnight.  The next day cells were washed 3 times in PBS before the secondary 
antibody (goat anti-rabbit Alexa Fluor 488, 1:1000 Abcam, Cambridge, UK) was 
added. Cells were then incubated for 45 minutes with a goat-anti rabbit 488 
antibody. Nuclei of cells were stained with a 1:2000 DAPI (v/v) solution for 5 
minutes before being mounted with antifade and coverslipped. Tissue Factor 
immunostaining was analysed by confocal microscope Nikon D-Eclipse confocal 
microscope system) and analysed using Nikon EZC1-3.30 software 
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2.6.2 Analysis of surface Tissue Factor expression by FACS 
Porcine MSC and porcine fibroblasts were trypsinized and counted to a 
concentration of 1x10
6 
cells. Cells were centrifuged and washed in PBS twice to 
ensure the adequate removal of serum. Cells were then incubated with a 1:100 
dilution of Tissue factor antibody (Rabbit anti-tissue factor, Bioss, Woburn, MA 
01801) in FACS buffer for 1 hour at 4ºC in the dark. After primary antibody 
incubation cells were washed and centrifuged, before being incubated with a 
secondary antibody (goat anti-rabbit Alexa Fluor 488, 1:1000 Abcam, Cambridge, 
UK) at a concentration at a 1:1000 for 45 minutes at 4ºC in the dark. IgG control 
incubations were carried out for each experiment (Abcam, Cambridge, UK). 
Tissue Factor expression was analysed on a FACS aria flow cytometer using BD 
FACSDiva™ software (Becton Dickinson, Franklin Lakes). 
2.6.3 Assessment of Tissue factor Protein Expression by 
Immunoblotting 
MSC or porcine aortic fibroblasts were lysed using 1X lysis buffer (50 mM Tris 
HCL, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulphate (SDS), pH 8) containing 1X Complete Protease inbibitor 
cocktail (Roche). The protein concentration was assessed using a BCA Protein 
assay, and resolved by 12% SDS-PAGE. Following electrophoretic transfer onto 
nitrocellulose membranes, TF was detected by immunoblotting with 1:500 anti-
TF rabbit polyclonal (Bioss, Woburn, MA 01801) and visualized by a 1:5000 
dilution of a horse radish peroxidise-conjugated goat anti-rabbit IgG antibody 
(Jackson Laboratory) and chemiluminescence (Supersignal West Pico, Thermo 
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Scientific). TF was quantified by densitometric comparison with a 1:5000 dilution 
beta-actin loading controls (Sigma Aldrich, MO, USA) 
2.6.4 Analysis of thrombin generation and coverage under 
physiological flow conditions [166, 167] 
In vitro flow experiments were carried out to identify MSC contribution to 
thrombin generation and platelet adhesion. Initially, flow chambers were coated 
with collagen for 2 hours and then washed with PBS just prior to starting 
experiments. MSC and fibroblasts were trypsinized and counted to a 
concentration of 5x10
5 
cells. Cells were labelled using DiI as previously described 
in section 1.3. Whole blood was collected in a 0.4% (w/v) sodium citrate and 
labelled with a 10µM quinacrine dihydrochloride (w/v) solution (Sigma) for 30 
minutes at room temperature. The assembled flow chamber (Ibidi) (Figure 2.1) 
was then placed on the stage of an inverted confocal microscope. Whole blood; 
whole blood + MSC; whole blood, MSC + Heparin were perfused over the 
collagen-coated flow chamber at a controlled flow rate of 10dyn/cm
2 
using a 
syringe pump and software (Ibdi, pump control software V1.3.4)  Basal shear 
stress within the coronary circulation averaged 10dyn/cm
2  
[168] and was 
therefore used at the shear flow rate for all in vitro flow studies.   
Five images were captured every 5 minutes for a 15 minute time period. 
Thrombus coverage was calculated using NIS-elements BR software and 
expressed as average percentage of thrombus coverage.    
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Figure 2.1 Ibidi Flow system 
 
Figure adapted from Ibidi.com 
 
2.6.5 Analysis of Tissue Factor activity 
Tissue factor activity was quantified using a chromogenic activity assay 
(Actichrome 
® 
TF, American diagonisticia, Stanford, USA) (Appendix 9.4).  The 
Actichrome TF assay measured the peptidyl activity of human tissue factor in cell 
lysates.  MSC, FB, EC (2x10
5
) were lysed by repeated freeze thaw cycles in 
recommended cell lysis buffer. The lysates were then mixed with human factor 
VIIa and human factor X and incubated at 37ºC during which time the TF in the 
sample forms a complex with FVIIa which converts the human factor X to factor 
Xa. The amount of Xa generated was measured by its ability to cleave 
SPECTROZYME FXa, a highly specific chromogenic substrate for Xa, which 
was added to the reaction solution.  The cleaved substrate released a para-
nitroaniline (pNA) chromophore into the reaction solution and absorbance was 
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measured at 405nm wavelength using a plate reader. A standard curve was 
constructed by plotting the mean absorbance value measured by each TF standard 
against its corresponding concentration. The TF concentrations were then 
interpolated directly from the standard curve. 
2.6.6 Thrombin generation 
The TECHNOTHROMBIN® TGA assay is based on monitoring the fluorescence 
generated by thrombin cleavage of a fluorogenic substrate over time upon 
activation of the coagulation cascade by TF (Appendix 9.5).  The fluorogenic 
substrates are designed with an amino acid that is cleavable by Thrombin and 
upon substrate cleavage a fluorescent dye is released and starts emitting a 
fluorescent signal.  The changes in fluorescence over time allows for the 
calculation of the concentration of thrombin (nM) respective to the thrombin 
calibration curve over time.  The reagents used in the assay did not contain TF but 
did contain concentrations of micelles of negatively charged phospholipids.  
Citrated plasma was re-calcified by Ca
++ 
present in the substrate solution and TF 
bearing MSC were capable of triggering thrombin generation in plasma.  AUC 
refers to the total concentration of thrombin generated over time.  Technoclone 
software (Technoclone, GmbH) provided required only the addition of raw data to 
construct thrombin generation curves. 
2.7 Analysis of secretome of porcine and human 
MSC 
The secretome of human and porcine MSC was compared using a human antibody 
cytokine array kit (Quantibody
® 
Human cytokine array 5, Raybiotech, Medical 
supply Co., LTD, Dublin). The protocol was performed according to 
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manufacturer’s instructions (Appendix 9.7). Briefly, 5x 105 human and porcine 
MSC were plated in a T25flask. After 24 hrs cells had adhered and were 
approximately 80-90% confluent. Cells were washed three times with PBS to 
fully remove any residual serum. Cells were incubated with serum free α-MEM 
basal media for 48 hours. After 48 hours the media was collected, centrifuged and 
filtered through a 2µm filter to remove any remaining cells. Cytokine analysis was 
carried out using the antibody array kit. Basal media was used as a control and 
signal intensities were determined using ImageJ software.  Data was represented 
as % of cytokines which refers to normalisation of results to positive control. 
2.8 Sparcl1 study 
2.8.1 Sparcl1 ElISA 
Sparcl1 concentration in conditioned MSC media was measured using human 
Sparcl1 Elisa kit (Sino Biological Inc.).  MSC were seeded at a concentration 
1x10
5 
MSC in a 24 well plate and allowed to adhere overnight.  At 24 hrs media 
was changed and allowed to incubate for a further 48 hours.  Media was collected 
and ELISA was carried out according to full manufacturer’s protocol (Appendix 
9.6).  Briefly, capture antibody was added to 24-well plate and allowed to 
incubate overnight. The next day standards and samples were added to the plate 
and allowed to incubate at room temperature for two hours before adding 
detection antibody.  Substrate was added and optical density of each well was 
analysed using a microplate reader set to 450nm. A standard curve was 
constructed by plotting the mean absorbance value measured by each Sparcl1 
standard against its corresponding concentration. The Sparcl1 concentrations in 
samples were then interpolated directly from the standard curve. 
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2.8.2 Sparcl1 MI model 
The MI model was similar to that used in the chronic MSC study, however, 10µg 
of reconstituted recombinant human Sparcl1 (R&D systems) was delivered via the 
coronary artery directly after the 120 minutes of reperfusion using the Progreat® 
delivery catheter.   
2.8.3 Dose of SPARCL1 
Dose of SPARCL1 was extrapolated from the MSC CM Elisa to match the 25x10
6 
MSC delivered in previous studies as this number of cell conferred functional 
benefits.  (1ml of CM was collected from 1x10
5 
MSC – ~ 40ng extrapolated to the 
equivalent of 25x10
6 
MSC =10µg).  Recombinant Sparcl1 was reconstituted in 8 
ml of saline before delivery.   
2.9  Statistics 
2.9.1 Power calculation 
The sample size for each experiment was estimated based on power analysis to 
detect a minimum 20% difference between mean in experimental and control 
groups with less than 15% variance within the means. The power of the test was 
set at probability (power) 0.95.  The Type I error probability associated with the 
test was set at 0.05. 
2.9.2 Analysis  
All data are represented as mean ± SEM.  Difference between groups was 
analysed by unpaired Student t-test or multiple analysis of variance by ANOVA 
followed by Bonferroni’s post-hoc testing.  All statistics were carried out using 
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Graphpad Prism Version 4 (GraphPad Software, Inc., California, USA).  *P<0.5 
was considered significant, *p<0.05, **: p<0.01*** p<0.001. 
Reagent Volume 
(100ml) 
Final Concentration 
DMEM (LG) 87.5ml  
Dexamethasone 1mM 10µl* 100nM 
Ascorbic acid 2-P 10mM 0.5ml 50µM 
β glycerophosphate 1M 1ml 10mM 
FBS** 10ml 10% 
Penicillin/Streptomycin 1ml 100U/mL penicillin 
100g/mL streptomycin 
Table 2.2 Osteogenic Media  
 
Reagent Volume 
(100ml) 
Final Concentration 
DMEM (HG) 87.6ml  
Dexamethasone 1mM 100µl 1µM 
Insulin 1mg/ml 1ml 10µg/ml 
Indomethacin 100mM 200µl 200µM 
500mM MIX 100µl 500µM 
Penicillin/Streptomycin 1ml 100U/mL penicillin 
100g/mL streptomycin 
FBS 10ml 10% 
Table 2.3 Apipogenic Induction Media 
 
Reagent Volume (100ml) Final Concentration 
DMEM (HG) 88ml  
Insulin 1mg/ml 1ml 10µg/ml 
Penicillin/Streptomycin 1ml 100U/mL penicillin 
100g/mL streptomycin 
FBS 10ml 10% 
Table 2.4-Adipogenic Maintenance Media 
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Reagent Volume 
(100ml) 
Final Concentration 
DMEM (HG) 95ml  
Dexamethasone 1mM 10µl* 100nM 
Ascorbic acid 2-P: 5mg/ml 1ml 50µg/ml 
L-Proline: 4mg/ml 1ml 40µg/ml 
ITS+ supplement 1ml 6.25 g/mL bovine insulin 
6.25 g/mL transferrin 
6.25 g/mL selenous acid 
5.33 g/mL linoleic acid 
1.25 mg/mL BSA 
Sodium pyruvate 1ml 1mM 
Penicillin/Streptomycin 1ml 100U/mL penicillin 
100g/mL streptomycin 
Table 2.5- Incomplete Chondrogenic medium 
 
Complete Chondrogenic medium (CCM) 
To 1ml of ICM add 0.5µl of TGFβ-3 to give a final concentration of 10ng/ml 
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Chapter 3  
Porcine MSC isolation and cell 
delivery optimization in MI 
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3.1 Introduction 
Before the benefit of any therapeutic agent can be established, efficacy must be 
first demonstrated in accurate and relevant models of the disease state in question.  
This chapter will begin to introduce the models and procedures used for all in vivo 
work described in this thesis and provide experimental reasoning as to why these 
models were chosen in relation to the delivery of MSC therapy.   
The main objective of any pre-clinical research is to act as a bridge in translating 
basic science into clinical practice.  Therefore, to accurately replicate the clinical 
scenario of acute MI experimentally, large animal models were used.  In the area 
of cardiovascular research pigs are increasingly seen as superior to other large 
animal models such as dogs and primates [169].  The main advantage of using 
pigs is their close anatomical, physiological and immunological resemblance to 
that of human subjects [170].  Most importantly however, experimentally, it has 
been demonstrated that the porcine heart responds biochemically and 
metabolically in similar ways to that of human after the induction of MI [169]. 
Previously, the majority of early cardiovascular research was carried out on dogs, 
however, their extensive collateral circulation and more recent ethical limitations 
has decreased usage of this species [171, 172]   
The age of the animal model used is an important experimental consideration.  
Due to the fast growth rate of domestic pigs and the holding facilities available, 
the pigs used in these studies are generally 3-5 months old.  Studies confirm that 
this is sufficient age for fully developed central nervous system regulation of 
cardiovascular function [173].  For all in vivo experiments female Landrace pigs 
were used.  Females were chosen primarily for ease of handling as male non 
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castrated landrace pigs tend to be more aggressive.  The preclinical use of 
landrace pigs has been experimentally verified in other studies at the CRVB 
laboratory [94, 174] and due to local breeding suppliers, the use of Landrace was 
a convenient and inexpensive model to use. 
The target artery selected for induction of MI and the position of the balloon 
occlusion catheter are also important experimental design considerations.  In the 
majority of preclinical studies ischemia is induced through the occlusion of the 
LAD artery; however ischemia has also been induced via the circumflex artery 
[175, 176].  The LAD artery of a pig heart is anatomically similar to that of a 
human, therefore occlusion of the LAD in pigs creates an infarct that is similar in 
size and distribution to that of human presenting with a LAD infarct [177]. 
Circumflex occlusion would have yielded a much smaller infarct with greater 
difficulty in detecting small differences between groups. Additionally this 
approach may have required much greater sample sizes.  The more proximal 
(closer to the origin) the occlusion in a coronary artery, the greater the territory 
damaged.  A study which evaluated two occlusion positions and two times of 
occlusion recommended that a mid-LAD occlusion can fulfil most of the key 
criteria for a reproducible, low risk and minimally invasive experiential model of 
MI[178].  Proximal LAD occlusion led to increase mortality compared to that of 
mid-LAD occlusion and a 30 minute occlusion did not substantially affect cardiac 
function [178].  A 90 minute mid-LAD induced a significant infarct in a 
previously well-established model used and verified within the CRVB and was 
therefore used in all in vivo studies. 
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Restoration of blood flow to an artery post infarction can lead to what is known as 
ischemia/reperfusion (I/R) injury [179].  Oxygen free radicals released on the 
restoration of blood flow cause additional damage to the myocardium including 
myocardial haemorrhage, MVO and arrhythmias [179].  In clinical setting 
revascularization whether via thrombolytics or PCI is standard practice and 
therefore I/R injury is unavoidable.  Using a model which represents I/R injury is 
clinically relevant and our studies therefore used a reperfusion model as opposed 
to an ischemia alone model.  The I/R model used for these studies consisted of a 
90 minute LAD occlusion followed by 120 minutes of reperfusion before therapy 
was delivered (Figure 3.4).  This allowed comparative analysis with prior studies 
in our lab and studies reported in the literature.   
Before beginning to test the effect of MSC in vivo, a reproducible porcine MSC 
cell culture that could be easily isolated and expanded from porcine bone marrow 
needed to be established.  The isolated MSC from our in-house production 
protocols had to be capable of meeting the minimal criteria set by the 
International Society for Cellular Therapy, such as adherence to plastic, tri-linage 
differentiation and specific surface marker expression before they could be 
defined as MSC and used for in vivo studies [70].   
MSC cell numbers, routes and models used in pre-clinical research for the 
treatment of ischemic heart disease has varied significantly (Table 3.1).  
Therefore the main aims of this study were to firstly isolate and characterise our in 
house derived MSC and then to identify and optimise an MSC cell dose and 
delivery strategy that was reproducible and safe when delivered in the established 
acute porcine MI protocol.  The protocol used was designed based on the concepts 
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described with the aim to represent a clinical MI scenario as accurately as 
possible. 
Cell  
number 
10
6
 
Route   Time 
after 
MI 
Animal  Type of 
infarction 
Model  Follow 
up 
Weeks 
Author 
2  IC  1 h  Pig  LAD  I/R  4  Valina[133]   
5  IC  28d  Pig  LAD  No I/R  4  Yang  [134] 
5  IC  28d  Pig  LAD  I/R  4  Yang[135]  
7.1  TE  16d  Pig  LAD  I/R  1.5  Gyongyosi[180]  
10  IC  3d  Pig  LAD  I/R  4  Lim [131] 
10  IC  1 h  Pig  LAD  I/R    13 Jiang [181] 
17  TE  14d  Pig  LCX No I/R  4  Schneider[182] 
50  Trans  1 h  Pig  LAD  I/R  4  Wang[183] 
50  IC  20m  Pig  LAD  I/R  2  Llano[184] 
50  IC/TE/IV  15 m Pig  LAD  No I/R  6  Freyman[119]  
80  TE  28d  Pig  LAD  No I/R  4  Li 
60  TE  14d  Pig  LAD  I/R  2-4  Shake[80] 
75  TE  3d  Pig  LAD  I/F  2-8  Hatzistergos[122]  
100  TE/IC  7d  Dog  LAD  I/R  2  Perin[185] 
100  Surgical  28d  Pig  LAD  No I/R  4  Tomita[186] 
100  IC  5d  Pig  LAD  I/R  4–8  Qi [187] 
200  TE  3d  Pig  LAD  I/R  1-8 Amado[188] 
200  IC  84d  Pig  LAD  I/R  12 Queved[82]o  
200  TE  2d  Pig  LAD  I/R  8  Schuleri[189]  
320  IV  1 h  Pig  LAD  I/R  13  Price [190] 
39-370  IV  1 h  Pig  LAD  I/R  12  Halkos [191] 
24-440  TE  3d  Pig  LAD  I/R  8–12  Hashemi[125] 
23-440  Surgical  1 h  Sheep  LAD  No I/R  4–8  Hamamoto [192] 
1000  IC  7d  Pig  LAD  I/R  6  Qian [193] 
 
Table 3-1 Pre-clinical MSC cell studies 
Preclinical cell therapy studies in large animals with acute MI and chronic ischemic 
cardiomyopathy. 
IC, Intracoronary injection, IV, intravenous injection, TE, Transendocardial injection, 
I/R, Ischemia Reperfusion, d, Day, h, Hour, m, minute, LAD, Left Anterior 
Descending Artery, LCX, Left Circumflex 
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3.2 Results 
3.2.1 Isolation and expansion of porcine MSC 
MSC were easily isolated and expanded from the iliac crest from our in-house 
pigs (Figure. 3.1 A,B).  On average 15-30ml of bone marrow was collected and at 
10 days approximately 6-10x10
6 
MSC were present in culture.  For in vivo 
experiments approximately 30-40 days was required from initial isolation 
allowing for approximately 4 population doublings and 100x10
6
 MSC.  Isolated 
pMSC were capable of adhering to plastic when maintained in standard culture 
conditions and microscopic examination of isolated cells revealed a homogenous 
fibroblastoid spindle like shaped MSC population.(Figure. 3.1 B, 3.3 A).   
3.2.2 MSC differentiation and surface marker expression 
Culture expanded MSC were analysed more extensively according to their relative 
expression of mesenchymal markers.  Flow cytometric analysis showed that the 
pMSC populations were positive for the characteristic MSC markers CD90, 
CD29, CD105 but lacked the expression of myeloid CD11b and CD14 markers 
(Figure 3.2 A-G).  Culturing of MSC in differentiation promoting conditions 
revealed that the isolated pMSC were capable of differentiating along all three 
lineages.  Control cells were stained with the corresponding dyes. (Figure. 3.3 A-
D) 
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Figure 3.1 Porcine MSC Isolation 
A. Porcine MSC were isolated from bone marrow extracted  from the Iliac crest and were 
expanded in culture B. Light Microscopic image of plastic adherent pMSC at P0 in culture.  
pMSC at P0 are initially capable of forming colonies within culture conditions.  Scale bar 
represents 200µm. 
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Figure 3.2 MSC surface marker expression. 
pMSC were characterised by their surface marker expression. MSC were positive A. 
Isotype B. CD29 C. CD90 D. CD105 and negative for E. CD14, f. CD11b. A and G. 
Isotype and Unstained respectively  (n>3) 
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Figure 3.3 Porcine MSC are capable of tri-linage differentiation 
pMSC were characterised by ability to differentiate into adipocytes, chondrocytes, and 
osteocytes. A. MSC control B. Adipocytes stained with oil red O, C. chrondrocytes 
stained with alcian blue and D. osteocytes stained with alizarin red. Scale bar represent 
100µm (n>3) 
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3.2.3 Efficiency of Dil cell labelling and viability of MSC 
In order to track MSC within the myocardium post-delivery, MSC were stained 
using the lipophilic membrane stain DiI.  Flow cytometric analysis revealed a 
high percentage of DiI positive staining indicating efficient uptake with over 99% 
of MSC staining positive after 20 minute incubation with the DiI solution (Figure 
3.5 A).  In addition, fluorescence microscopy analysis revealed uniformly vibrant 
staining MSC after incubation with DiI solution (Figure 3.5 B).  To determine if 
DiI had an effect on cell viability and to ensure delivered MSC were viable and 
there was no loss during cell preparation DiI labelled MSC were counterstained 
with 7AAD (Figure 3.5 C).  Flow cytometric analysis confirmed that DiI 
labelling had no effect on the viability of MSC in vitro.  In addition, labelling 
efficiency of MSC is maintained after transfer in vivo up to 24 hours after MSC 
administration (Figure 3.5 D).  
3.2.4 Initial dosing studies 
A 90 minute proximal LAD occlusion resulted in an anterolateral infarct of 
approximately 50% of left ventricle. (Figure 3.6, A-B) Figure 3.6 C illustrates a 
typical LV cross-section outlining infarct by TTC staining.  In order to determine 
the optimal MSC dose tolerated by our pigs initial dosing studies were carried out 
according to Table 3.2.  Delivery of 100x10
6 
MSC at high flow rates of 20ml/min 
resulted in 100% pig mortality and post mortem analysis revealed that severe 
tissue extravasation was the casual factor (Figure 3.7).  Subsequently, lower 
doses MSC were delivered at lower flow rates, 30x10
6
 delivered at lower flow 
rate of 2ml/min was tolerated until the last injection at which point the VF 
occurred and defibrillation strategies failed to resuscitate the animal.  The 
concentration of cells per injection also had an impact on pig mortality, delivery 
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of
 
MSC at a low flow rates but at concentrations higher that 25x10
6
 resulted again 
in fibrillation and animal mortality.  Subsequent dosing studies used significantly 
lower cell numbers at lower delivery flow rates with the additional intervals of 2 
minute between each injection.  15x10
 6 
MSC were well tolerated at low flow 
rates and so the dose was then increased to 25x10
6 
which could also delivered 
with no significant adverse events occurring.  25x10
6 
MSC delivered at 2ml/min 
at a concentration of 1.5x10
6 
with a 2 minutes interval between each injection was 
the optimum tolerated dose of MSC when delivered via the coronary artery. 
However, no re-flow directly after MSC administration within the coronary artery 
was observed by angiography. (Figure 3.8 A-C) 
 
Figure 3.4 Infarct and MSC delivery protocol 
Protocol included a 90 minute mid LAD occlusion followed by 120 minutes of 
reperfusion before cell therapy was delivered.  24 hours after initial procedure the 
animal was sacrificed and heart was explanted and stained to identify region of 
infarct 
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Figure 3.5 MSC DiI labelling 
pMSC were labelled with DiI in order to track their infiltration in vivo.  A. Post 
DiI staining, 99.92% of MSC stained positive for DiI as analysed by FACS. B. 
Immunoflouresence analysis of DiI stained MSC revealed that DiI labelled cells 
displayed diffuse whole cell labelling C. DiI labelling had no effect on cell 
viability as evident by 7AAD staining as analysed by FACS. D. OCT section of 
the Border Zone of the infarct region revealed the presence of DiI labelled MSC 
24 hours post infusion.  The in vivo delivery of labelled cells had no effect on the 
DiI labelling efficiency and MSC were readily observed within the myocardium.  
Scale bars represent B.50µm D.100µm (n>3) 
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Figure 3.6 Macroscopic images of infarcted porcine heart 
A. Macroscopic image depicting balloon positioning during infarct induction.  B. 
Image displaying the typical region affect by balloon occlusion which 
corresponds to the sampled region.  Explanted hearts were typically cut into 5, 
0.5-1cm cross section from apex to base.  C. A typical LV cross-sectional slice. 
The non-infarcted myocardium (RZ) on the left stains red with TTC while the 
infarcted myocardium (IZ) on the right does not stain with TTC and remains pale. 
TTC= triphenyltetrazolium chloride.  Explanted hearts typically weighed 200-
250g.  The infracted region following a mid LAD infarct affected approximately 
50% of the total LV area as displayed above.  
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Table 3.2 MSC Dosing study 
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Figure 3.7  MSC tissue extravasation 
Post mortem image illustrating MSC infiltration out into the extravascular tissue 
at the MSC infusion site post-delivery of 100x10
6 
MSC in one bolus injection at a 
delivery rate of 20ml/min.  Scale bar represents 1cm 
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Figure 3.8 Angiography at MI,  during MSC delivery and post MSC 
delivery 
A. Representative image illustrating position of balloon inflation and no re-flow 
beyond balloon. B. Image illustrating positioning of catheter during MSC 
delivery. 
C. Representative image showing no re-flow within the LAD post MSC 
administration 
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3.3 Discussion 
This initial study demonstrated the feasibility of isolating MSC from porcine BM.  
Isolated MSC were expandable to high cell numbers, while maintaining the MSC 
characteristics as described by the ISCT.  This study also highlighted the 
maximum cell dose that could be safely tolerated from a mortality and arrhythmia 
perspective when cells were delivered via the coronary artery in an acute MI 
model. 
Due the heterogeneous nature of MSC a single definite MSC maker has yet to be 
identified.  All of the antigens recommended by the ISCT can also be expressed 
by other cells and without a distinct marker it remains difficult to definitely 
identify our cells as MSC although they are as well characterised as any MSC 
used in pre-clinical studies in the literature.   However, for these studies, having 
two other reproducible characterizing criteria such tri-lineage cell differentiation 
and adherence to plastic allowed us to define our cells as MSC. 
The advantages of Dil labelling over other cell labelling strategies were its ease of 
application, the quality of staining, its low cell toxicity and lack of known 
immunogenicity.  DiI which is a lipophilic carbocyanines has an extremely high 
extinction coefficient and diffuses laterally within the membrane resulting in 
whole cell staining.  A study comparing the labelling efficiency of bone marrow 
stromal cells with three cell tracing dyes BrdU, FISH and DiI confirmed that DiI 
in addition to having the highest labelling efficiency also retain its high labelling 
efficiency after two subcultures, thus, allowing for longer in vivo tracking 
capability [194]. 
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Initial dosing studies used a cell number of 100 million MSC, as per Table 3.1.  
The number of MSC used in numerous pre-clinical studies has varied 
substantially.  No study has to date addressed the question of the optimal 
therapeutic MSC dose when delivered via the coronary artery.  The phase I/II 
POSEIDON trial carried out by Hare et al begun to address this by comparing 
three different doses of MSC when delivered by transendocardial IM injection.  In 
this study 20, 100 and 200 million MSC were delivered in patients with ischemic 
cardiomyopathy.  CT analysis at 30 days post MSC injection revealed an inverse 
dose response in which the low dose concentration of 20 million MSC produced 
the greatest reductions in LV volumes and the greatest increases in EF [118].  
This concept of lower cell dosing having improved therapeutic benefit over higher 
doses was also demonstrated in a pre-clinical study in which pre-cursor MSC 
were delivered in a sheep model of coronary ligation.  Increasing doses of 25, 75, 
250 and 450 million MSC were injected into the myocardium.  Echocardiography 
at 4 and 8 weeks illustrated that the lower doses of 25 and 75 million significantly 
improved infarct expansion and increased left ventricular end diastolic volumes 
and left ventricular end systolic volumes (LVEDV and LVESV) [195].   
To date most cell therapy studies within the cardiac field have assumed that the 
higher the dose of cells the more efficacious the treatment and a number of small 
studies although not in relation to MSC have supported this concept.  In a 
mononuclear bone marrow stem cell trial, 100 million and 10 million cells were 
delivered via the coronary artery after acute MI.  Follow up at 3 months 
demonstrated improved regional myocardial function in a dose dependent manner 
[196]. 
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Determining an optimal MSC dose is important in order to maximize the benefit 
of MSC as a therapy.  Future studies should aim to establish this by carrying out 
extensive pre-clinical large animal studies using a wide range of MSC doses.  A 
previous MSC study has delivered up to 60 billion MSC
 
via the coronary artery in 
a porcine acute MI model
 
 and no adverse events were reported [197].  This study 
however used MSC that were only cultured for 10 days with no cell 
characterisation or differentiation analysis.  Due to the short period of cell 
expansion it could be possible that the cells used in this study were more similar 
to bone marrow MNCs.  The lack of specific methodologies from these studies 
leaves it unclear as what the optimal MSC dose really is.   
Freyman et al demonstrated that IC delivery of MSC after infarction resulted in 
decreased distal blood flow [119]. In a follow on study members of the same 
group proposed that delivery of a single, continuous infusion at increased flow 
rate decreased mortality and preserved blood flow [138].  Delivery of MSC using 
the same methods in our initial dosing studies resulted in tissue extravasation of 
cells.  The main differences between Wilensky`s and this current study include, 
increased cell number from 50 million
 
MSC to 100 million, increased LAD 
occlusion time and reperfusion time (20 vs. 120 minutes) in our study.  Although 
these differences may not explain the cause of tissue extravasation it may explain 
the reductions in flow observed and arrhythmias observed in our studies.   
Similar to other IC MSC delivery studies [198-200] this study has highlighted 
that, by delivering 25x10
6
 MSC via the coronary artery, although no major 
adverse events such as mortality occurred,  a reduction in coronary flow could still 
be observed after cell delivery.  At present no study has provided a mechanistic 
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reason for the reduction of flow associated with microvascular plugging other 
than the large MSC cell size and high cell numbers.  Therefore further studies 
over the remainder of this thesis will provide mechanistic insight into the possible 
cause of adverse events associated with IC MSC delivery in the setting of M 
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Chapter 4  
Identifying the in vitro procoagulant 
nature of Mesenchymal Stem Cells 
  
81 
 
4.1 Introduction 
Within the cardiac repair\regenerative medicine field a number of adverse events 
have been associated with the delivery of MSC via the coronary artery in animal 
models of MI. Observed events include, intravascular cell aggregation, significant 
reductions in arterial flow [201], microvascular obstruction, ST elevation and the 
presence of microinfarcts [136, 137].  Although these events have illustrated the 
possible risks associated with this type of cell delivery many mechanistic 
questions remain unanswered such as the proximate cause of diminished  
microvascular flow and the likelihood that MSC are contributing to MVO. 
MSC cell size has been suggested to be one of the key factors in these events 
[119, 137].  Cultured MSC are typically reported to be 10-30 µm in diameter 
which may [136, 202-205] explain the evident lodging of MSC within small 
diameter capillaries (10-15 µm) in organs such as the lungs and liver.  This 
concept is partially supported by an experiment in which systemic delivery of 
MSC in conjunction with the nitric oxide donor vasodilator sodium nitroprusside 
could in part counteract cell lodging within the lung, liver, kidney and spleen 
[206].  Fisher et al designed a study based on the hypothesis of cell size which 
aimed at comparing the first pass distribution of four labelled cell types after 
systemic delivery [202].  MSC (18µm), multipotent adult progenitor cells 
(MAPCs-16µm), bone marrow mononuclear cells (BMNMC-7µm) and neural 
stem cells (NCS-16µm) were infused intravenously in a rat animal model.  In 
agreement with the nitroprusside study there was a 30-fold increase in lung 
passage for the smaller BMMNC when compared to the other larger cell types.  
This suggests there may be a size threshold above which cells contribute to MVO.  
Surprisingly however, they also found a significant 2-fold increase in first passage 
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for MAPCs and NCSs when compared to MSC, even though their cell sizes were 
relatively comparable.  Blocking of cell surface adhesion receptors such as P-
selectin or VCAM-1did not enhance pulmonary MSC passage.  Based on these 
findings Fisher suggested that factors other than cell size and the expression of 
surface adhesion molecules were responsible for cell lodging post delivery.  [202].   
The pre-clinical findings mentioned above [202, 207] along with our own 
observations underscore our hypothesis that MSC may in fact be promoting a 
prothrombotic state upon exposure to blood.  Accordingly, we decided to 
investigate whether therapeutic MSC may have surface expression of TF, a key 
initiator of the soluble coagulation cascade (Figure. 1.8) and whether this 
expression profile could have functional consequences for thrombosis in vitro. 
4.2 Results 
4.2.1 MSC expressed significant surface TF 
To assess whether prothrombotic activity was innate to the cultured MSC 
population under investigation, TF expression by porcine MSC, FB and EC was 
determined using immunofluorescence, flow cytometry and immunoblotting. 
Significant TF immunostaining was detected in MSC and FB but was near absent 
in EC (Figure 4.1). Surface TF expression of FB and MSC was also confirmed by 
flow cytometry which showed that MSC TF levels were higher than that of FB, 
20.7% vs. 12% respectively (Figure 4.2). Western blot analysis confirmed these 
surface expression data in that MSC expressed approximately 2-fold more TF 
protein compared to FB (Figure 4.3).  
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Figure 4.1 MSC expression of TF by immunocytochemistry 
Cultured Mesenchymal Stem cell (MSC), Fibroblasts (FB) and endothelial cells 
(EC) were immunostained for TF (Green) and isotype controls respectively.  
MSC and FB displayed the presence of both surface and nuclear expression of 
TF; EC however displayed negligible amounts of TF.  To highlight the nuclei, 
cells were counter-stained with DAPI. 60X images were captured using Nikon D-
Eclipse confocal microscope system. Scale bars represent 10µm (n=3) 
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Figure 4.2 MSC express surface TF 
 
Flow cytometric analyses showing that cultured MSC and FB stained positive for 
TF (Red overlay), surface TF was more highly expressed on MSC than on FB 
(20.7% vs. 12% respectively)(n=3)  
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Figure 4.3 MSC express TF 
Immunoblot of TF expression and β-actin by MSC and FB.  Quantification of 
relative expression of TF by MSC and FB cells lysates corrected for β-actin 
loading, showing a significant increase in the relative expression in MSC 
compared to FB. *: p<0.05 (n=3 samples) 
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4.2.2 TF expressed by MSC was catalytically active and 
supported thrombin generation in vitro 
To identify if the TF expressed was biologically active, the TF catalytic activity of 
MSC, FB and EC was analysed by chromogenic TF activity assay.  In MSC, TF 
activity was significantly greater than that for both FB and EC (Figure 4.4). To 
determine if MSC, due to high TF activity, were also capable of supporting 
thrombin generation, a fluorogenic substrate assay was used to measure levels of 
thrombin. Thrombin generation was significantly elevated in the presence of MSC 
compared to platelet poor plasma and MSC + heparin controls (Figure 4.5).  
4.2.3 MSC augment thrombus build-up under flow conditions 
The capacity of innate procoagulant activity observed in MSC to influence 
platelet thrombus deposition on collagen at arterial shear rates [208] was also 
assessed by an in vitro flow system designed to model the initiation of arterial 
thrombosis in response to endothelial damage. In comparison to whole blood only 
the presence of MSC significantly increased thrombus deposition on collagen. 
Importantly, it was also observed that when heparin an antithrombin agent was 
added along with MSC, thrombus deposition was reduced to similar levels as seen 
with unheparinized whole blood controls (Figure 4.6 A, B). An equivalent 
augmentation in thrombus coverage was observed in human blood supplemented 
with human MSC, which was also abrogated by heparin (Figure 4.6 C). 
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Figure 4.4 MSCs express active TF 
Quantification of TF activity of MSC, FB and EC cells lysates as assessed using a 
chromogenic substrate (ACTICHROME®).  MSC TF activity is significantly 
higher when compared to both FB and EC (n=3) (*:p<0.05, *** p<0.001) 
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Figure 4.5 MSC are capable of inducing thrombin generation in vitro 
Thrombin generation was measured at 37°C in platelet poor plasma alone or 
supplemented with MSC in the presence or absence of heparin by use of the 
Techonothrombin® TGA assay.  Area under curve (AUC) refers to the amount of 
thrombin generated over time.  MSC potential for thrombin generation was 
abrogated by the addition of heparin (n=3)( **: p<0.01) 
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Figure 4.6 MSC potentiate thrombus build-up on collagen during ex-vivo flow 
at arterial shear 
A. Whole blood labelled with mepacrine (Green) was perfused at a shear stress 
of 10 dyn/cm2 over collagen in absence or presence of MSC and heparin. 
Representative images of thrombus deposition (x20 magnification) B, 
Quantification of thrombus coverage using pig MSC and pig blood C. 
Quantification of thrombus coverage using human MSC and human blood 
shows significant enhancement of thrombus coverage in the presence of MSC, 
which was inhibited by 25 U/ml heparin (n=3) (*p<.0.05, **: p<0.01,*** 
p<0.001, ) 
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4.3 Discussion 
A possible candidate protein that is known to cause reductions in coronary flow 
associated with microvascular obstruction is the prothrombotic protein TF [209, 
210]. Due to our in vivo observations (Figure 3.8) that MSC delivery was causing 
a reduction in coronary blood flow it was reasonable to speculate the MSC could 
be expressing TF.  Since our identification of the expression of TF by MSC, other 
groups have also identified the same phenomenon.  Stephenne et al demonstrated 
that cells of mesenchymal lineages such as BM-MSC, hepatocytes, fibroblast, 
myofibroblasts and adult liver derived mesenchymal progenitor cells (ALPCs) all 
have pronounced procoagulant activity (PCA) [211].  Clotting time of whole 
blood with the addition of BM-MSC, hepatocytes, fibroblast, myofibroblasts and 
ALPCs as analysed by Rotational thromboelastometry (ROTEM), was decreased 
by up to 90% when compared to the control cell bone marrow- hematopoietic 
stem cell BM-HSCs.  This PCA was associated with TF expression and similar to 
our data only negligible amounts of TF were associated with ECs.  ECs for the 
most part do not express TF as EC within the vasculature are in constant contact 
with blood and therefore require high degree anticoagulant activity [212].  
Following the evaluation of this PCA Stephenne and co-authors determined 
whether this activity could be modulated.  Supplementary data suggested that 
heparin was capable of abrogating the PCA of BM-MSC and fibroblasts however 
both heparin and bivaluridin were required to completely abrogate PCA of 
hALPCs [211].  This study highlighted also that the source of MSC isolation 
appeared to have an effect on the cells PCA.  MSC isolated from different sources 
had varying expression levels of TF and this suggests that TF may be responsible 
for diverse biological functions depending on the MSC niche.   
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TFs involvement in thrombus build up under flow conditions is associated with 
the initial interactions between von willebrand factor (VWF) and collagen (Figure 
4.7).  High sheer exposes binding sites for platelet GPIbα and VWF which results 
in loss of platelet velocity and facilitates platelet tethering and rolling on the 
collagen matrix[213].   Stable binding and platelet arrest is mediated through 
activation of GPIIbIIIa [213].  Thrombus growth is propagated through 
platelet/platelet interactions which are mediated by the binding of fibrinogen, 
fibrin and VWF to activated GPIIbIIIa and the binding of GP1bα (Figure 4.7).  In 
parallel to this, TF by means of activation of extrinsic coagulation pathway is 
further activated by GPIIbIIIa mediated platelet aggregation via the production of 
thrombin [213] (Figure 4.7). 
 
Figure 4.7 TF role in thrombus build up on collagen during ex-vivo flow at 
arterial shear 
Collagen binds von Willebrand factor (VWF), which promotes platelet adhesion 
and activation through the glycoprotein Ibα (GPIbα).  Rolling platelets adhere 
and spread on the collagen matrix via the interaction of GPIIbIIIa.  Thrombus 
aggregation and growth is caused by platelet/platelet interaction which is 
mediated by the binding of fibrinogen, fibrin and VWF to activated GPIIbIIIa and 
the biding of GP1ba .  TF through the activation of the extrinsic coagulation 
pathway produces thrombin which further activates GPIIbIIa propagating further 
thrombus formation 
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Recently it has been suggested that the expression of TF by MSC may be due to 
cell culturing and expansion [214, 215].  A study carried out by Tatsumi et al 
showed that adipose derived MSC (ADSCs) were associated with high TF 
expression [215].  Intravenous administration of cultured ADSC in mice lead to 
85% mortality due primarily to pulmonary embolism. Interestingly however, this 
did not occur after infusion of uncultured adipose derived cells.  Upon further 
analysis it was identified that uncultured ADSC did not express TF, however, both 
TF and expression and coagulation were increased after expansion in culture.  
This finding was corroborated by Moll et al who wanted to ascertain if human 
MSC are compatible with human blood [214].  Here it was illustrated that human 
BM-MSC of low passage displayed only weak PCA which could be increased 
significantly by passaging.  PCA was correlated with TF expression and this was 
confirmed by demonstrating that the PCA effect could be abrogated by blocking 
the TF pathway.  Due to the extensive expansion of our MSC required for our in 
vivo studies cells were expanded up to P8 and it is therefore plausible the events 
that we have observed are due to cell culturing.  Additional studies are required to 
definitely determine the effect of culture on MSC in particular in relation to 
expression of TF.  Casual factors within the culture environment that result in this 
increase in TF expression still need to be further explored.  TF induction could be 
due to various ex vivo factors such as, biological aging, culture additives such as 
calf serum, passaging protocols or freeze-thawing. 
The procoagulant activity of our MSC may also be caused in part, by expression 
of other surface molecules.  Moll et al in addition to the expression TF also 
demonstrated that MSC expressed Collagen I and fibronectin [214].  Collagen I is 
responsible for platelet adhesion and activation and may have been a contributing 
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factor to the platelet thrombus formation observed in our studies.  Further 
experiments would be required to fully elucidate these factors.   
As we cannot identify MSC in vivo without culturing we cannot definitely say that 
MSC do not express TF under normal physiological conditions within the body.  
The ability to increase TF expression suggests that TF may in fact be responsible 
for some of MSCs biological functions.  TF has multiple biological functions in 
vivo, in addition to it being an activator of blood coagulation it is also recognised 
as an important signalling receptor.  TF is capable of activating signalling 
cascades involved in cell proliferation, cell migration and cell survival such as the 
mitogen-activated protein kinase and the phosphoinositide 3-kinase/AKT 
pathways [216].  MSC are mobilised and found within the circulation during 
injury [217-219].  For this to occur MSC are unlikely to express TF, however, it is 
conceivable that MSC, upon reaching the site of injury may up-regulate TF, which 
activates signalling required for various reparative biological functions.   
Subsequent studies aimed to determine if TF expression could have functional 
consequences when delivered in a porcine model of acute MI in vivo. Since 
elevated TF levels may be associated with hypercoagulability and thrombosis 
[145], we hypothesized that MSC, through the expression of TF could give rise to 
intravascular thrombosis when administered by an intracoronary route in an in 
vivo porcine model of myocardial ischemia.  Subsequent studies also aimed at 
identifying if by using an adjunctive therapeutic approach we could abrogate 
thrombotic events associated with MSC delivery thus facilitating safer cell 
administration. 
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Chapter 5  
The acute effect of intracoronary 
delivery of TF expressing MSC in a 
porcine model of MI 
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5.1 Introduction 
Identifying the presence of TF on MSC and confirming it was catalytically active  
and thrombogenic in vitro provides a biologically plausible mechanism whereby 
MSC may promote reductions in coronary blood flow and MVO during MSC IC 
delivery[220].  Based on the findings from in vitro studies (Section 4), we aimed 
to identify in vivo the effect of TF bearing MSC after IC delivery with specific 
focus on abrogating TF effects using an antithrombin strategy. 
The term ‘No-reflow’ refers to the reduction in blood flow within the coronary 
arteries despite being supplied by an ostensibly patent artery following 
percutaneous revascularization of ischemic myocardium [221]. The principal 
cause of no-reflow is MVO which is caused by vasoconstrictions and 
microvascular thrombus within the microvessel bed (microvessels ≤ 200 µm in 
diameter) of the myocardium [222].  No-reflow is reported to occur in 
approximately 5-50% [223, 224] of MI patients, depending on the study, despite 
successful opening of the culprit lesion.  No-reflow is considered an adverse event 
as it is associated with poor prognostic outcomes such as increased mortality, 
increased risk of arrhythmias, adverse LV remodelling and increased incidence of 
heart failure [225]. Over the past decade, advancements in diagnostic modalities 
used for assessing coronary flow have been made including coronary flow 
reserve, contrast echo perfusion, PET and MRI are now being used in clinical 
practice [226].  To accurately assess if our MSC were causing a reduction in 
coronary flow after administration coronary flow reserve (CFR) measurements as 
the gold standard were utilised.   
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As a reduction in CFR may be a manifestation of MVO, it can also be speculated 
that administering exogenously additional cells which expresses TF into a post MI 
microcirculatory environment would further exacerbate the degree of MVO that 
occurs post MI.  A small study in which MSC were delivered via the coronary 
artery in a sheep model of MI did reveal the presence of cells that were ‘consistent 
in size and morphology of MSC’ occluding microvessels within the infarct region 
[227].  Therefore, in order to assess the microscopic effect of TF bearing MSC 
delivery post MI extensive histological and immunohistological analysis were 
also performed ex-vivo 24 hours after cell delivery.  
From a clinical perspective it is also important to assess if MSC are improving 
heart function.  In order to assesses heart function the following in vivo studies 
utilised multi-detector computed tomography (MDCT) analysis at 24 hours post 
MSC delivery.   
As global functional improvements, measured by CT, may not be observable 
within only 24 hours of cell delivery, as evident in previous studies carried out in 
the CRBV [94], looking at the effects of MSC delivery at a cellular level may 
reveal more of the acute benefits associated with delivery of this cell.  There is 
ever increasing evidence that improved cardiac function is associated with the 
reversal of cellular apoptosis linked to the secretion of paracrine factors such as 
VEGF, FGF-2, HGF and IGF after the delivery of MSC in vivo [95-97, 228].  
Within our own lab, the paracrine beneficial effect of EPC condition media has 
been associated with the secretion of the cytokine IGF-1 [94, 229].  Delivery of a 
low dose IGF-1 in a porcine model of MI was associated with a significant 
reduction in apoptosis within the border zone at 24 hours and consequently a 
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significant improvement in global heart function at 2 months [94].  Based on 
findings from the studies carried out by the CRVB and findings from others that 
suggest that MSC secrete a similar array of cytokines[95-97] the following in vivo 
studies were performed to assess the acute anti-apoptotic effect of MSC post MI.   
5.2 Results 
5.2.1 MSC administration was associated with intramyocardial 
haemorrhage and reduced coronary flow reserve.  
Having established that MSC exhibit robust PCA and prothombotic potential in 
vitro, the relationship between MSC delivery and microvascular flow in vivo was 
examined. Preliminary experiments identified 25 x 10
6
 MSC as the maximum cell 
number that could be safely infused via a porcine coronary artery without causing 
arrhythmias or intramyocardial oedema.  Additional heparin + saline controls are 
not required for the following experiments as heparin is routinely delivered via the 
coronary prior to cell delivery, therefore it can be assumed that additional heparin 
added to saline would have no additional effect of the functional outcome of the 
study. and Macroscopic analysis of explanted hearts 24 hours post MI and MSC 
administration showed significant areas of haemorrhage in the myocardium 
(Figure 5.1 A, B). In contrast, when MSC were co-administered with an anti-
thrombin (heparin), hemorrhagic areas were reduced to levels equivalent to those 
observed with saline treatment alone (Figure 5.1 A, B). Measurements of CFR 
were obtained both pre and post IC delivery of 25x10
6 
MSC post MI. MSC 
administration resulted in a significant reduction in CFR compared to saline alone. 
This reduction in flow was again improved significantly by the co-administration 
of heparin with MSC (Figure 5.2).   
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Figure 5.1 MSC delivery increases myocardial haemorrhage at 24 hours post 
intracoronary administration in a porcine model of acute MI  
A. Macroscopic images of hearts post MI with infarct territory (white dashed 
lines) and haemorrhaged areas (green dashed lines) indicated. (n=6) B. 
Quantification of hemorrhagic areas expressed as a percentage of the 
myocardium are shown. Heparin co-administration with MSC significantly 
abrogates myocardial haemorrhage. (n=6) (**: p<0.01) 
 
  
99 
 
 
 
 
 
 
 
 
Figure 5.2. MSC delivery reduces coronary flow reserve 24 hours post 
intracoronary administration in a porcine model of acute MI 
Quantification illustrating the changes in coronary blood flow as analyses by 
CFR within the LAD artery before and after the delivery of 25x10
6
MSC in the 
presence and absence of heparin and saline control alone.  Delivery of MSC 
without heparin caused a significant reduction in coronary blood flow when 
delivery in an acute MI setting, whereas delivering MSC in the presence of 
heparin did not affect coronary blood flow and flow remains similar to that of 
when saline alone was administered. (n≥8) (*: p<0.05)  
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5.2.2 Intracoronary MSC administration was associated with in 
situ microvascular thrombosis and ameliorated by heparin co-
administration 
To examine the mechanism of MSC-induced reduction in CFR and whether MSC 
actively participated in microvascular thrombosis, histological evaluation of the 
microvasculature in the infarcted myocardium was carried out. Occluded 
microvessels were visualised by Masson Trichrome staining (Figure 5.3 A). 
Quantification of the number of occluded vessels (normalised to total vessel 
number) revealed a significant increase in the number of occluded microvessels 
(≤200 µm diameter) in the MSC treated group when compared to both the MSC + 
Heparin and saline treated group (Figure 5.3 B).  To further elucidate the 
participation of TF positive MSC in microvascular thrombosis (MVT) multicolour 
confocal microscopy was utilized to co-localize DiI-labelled MSC with TF, von 
Willebrand factor and platelet antigen-positive in areas of microvascular 
thrombosis. Immunofluorescence imaging within the infarct regions showed co-
localization of fluorescent DiI signal (red-used to track delivered MSC) with the 
platelet antigen CD61, indicating the presence of MSC in platelet rich thrombus. 
Moreover, VWF and TF, implicated in situ arterial thrombosis, co-localized with 
labelled MSC in regions of microvascular obstruction suggesting TF rich MSC 
were also likely implicated in de novo thrombosis generation in vivo (Figure 5.4). 
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Figure 5.3 MSC promote microvascular thrombus formation in vivo post MI 
A. Representative images of infarct zone stained with trichrome reveal occluded, 
thrombus filled microvessels (black arrows) 24 hours post MSC delivery. White 
inset shows occluded microvessels at high magnification. B. Quantification of 
occluded microvessels in the infarct zone expressed as a percentage of the total 
microvessels evaluated per HPF showing a signification reduction in the 
percentage of in microvessel occlusion associated with heparin co-administration 
with MSC or control saline treatment. Scale bars represent 200µm. (~750 
microvessels ranging from 20-200µm analysed.) (*:p<0.05, **:p<0.01) (n≥5) 
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Figure 5.4 MSC are associated with in situ microvascular thrombosis post MI 
Representative immmunoflourescent images of MSC related microvessel 
thrombus formation in vivo shows co-localization of MSC (red) with the platelet 
marker CD61(Green), the initiator of arterial thrombosis VWF (green) and TF 
(green). Nuclei counterstained on each image with DAPI (blue). IgG control 
images for rabbit and mouse primary antibodies used are also shown. Scale bars 
represent 200µm 
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5.2.2.1 Heparin enhanced MSC delivery to the infarct 
territory and decreased apoptosis 
Since heparin co-administration with MSC ameliorated associated side effects 
including CFR reduction, microvascular obstruction and thrombosis, the effect of 
heparin on improving MSC delivery efficiency was determined. 24 hours after 
MSC delivery, the percentage of DiI positive cells within the border zone was 
quantified.  The percentage of MSC (over total nucleated cells) within the infarct 
border zone (BZ) was significantly increased with the addition of heparin (Figure 
5.5 A, B).  The cytoprotective efficacy of MSC administration with respect to 
cardiomyocyte apoptosis within the BZ, was assessed by TUNEL staining. 
Apoptotic signal was significantly decreased with MSC treatment compared to 
saline and there was no significant difference between the two MSC groups with 
or without heparin co-administration signifying that heparin administration had no 
adverse effect on MSC therapeutic outcome (Figure 5.5 C, D).  
5.2.3 MSC delivery has no effect on acute infarct size or on acute 
hemodynamic function 
MSC delivery in the presence or absence of heparin did not have an effect on 
acute infarct size as analysed by TTC and CT when compared to saline controls 
24 hours after cell administration (Figure 5.6 A, B, C, D).  In addition MSC also 
had no effect on the cardiac function parameters analysed by CT at 24 hours post 
cell administration.  Functional parameters analysed included End-Systolic 
Volume (ESV), End-Diastolic Volume (EDV), Ejection Fraction (EF), Cardiac 
Output (CO) or Stroke Volume (SV).(Figure 5.7 A-E) 
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Figure 5.5 Heparin increases MSC infiltration in infarct border zone and 
decreases apoptosis post MI 
A. Representative image of DiI (Red) stained MSC in infarct border zone (IBZ). 
Nuclei counterstained on each image with DAPI (Blue), translucent light 
microscope image (trans) within cardiac muscle. B. Quantification of MSC 
infiltration 24 hours post MSC delivery, heparin significantly increased the 
number of MSC within the border zone compared to MSC treatment alone. C. 
Representative images of TUNEL staining of IBZ sections from saline- and 
MSC-treated animals. Nuclei were stained in blue with DAPI. Apoptotic cells are 
TUNEL positive (Green). D. Quantification of apoptotic cells in the IBZ by 
determining the percentage of apoptotic cells. MSC lowered IBZ apoptosis 
compared to saline controls and this was unchanged by heparin (DAPI and 
TUNEL positive) of total cells (DAPI positive). Approximately 25,000 nuclei 
were counted (n=6) Scale bars represent 100µm  
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Figure 5.6 Acutely MSC delivery has no impact on acute infarct size post MI 
A. Macroscopic images of triphenyltetrazoliumchloride-stained transverse heart 
sections from saline-treated and MSC treated pigs. Broken lines delineate the area 
of infarction. B. Quantification of the percentage of infarct area relative to LV. C. 
Representative CT images of infarcted regions 24 hours post MSC delivery. 
Arrowheads indicated the regions of infarct. D. Quantification of the percentage 
of infarct area relative to area at risk assessed by CT. (n≥6) 
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Figure 5.7 Acutely MSC delivery has no impact on cardiac function post MI 
MSC delivery had no effect on acute cardiac functional parameters as analysed 
by CT 24 hours after cell delivery.  Parameters assessed included A. End diastolic 
volume (EDV), B. End systolic volume (ESV), C. ejection fraction (EF), D. 
stroke volume (SV) or E. cardiac output (CO) at 24 hours as analyzed by CT. 
Left columns show heart function at baseline and right at 24 hours post MSC 
therapy. (n≥6) 
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5.3 Discussion 
The work in the current section characterizes the TF-dependent prothrombotic 
activity innate to MSC in the context of in vivo arterial thrombosis. Here we 
demonstrate that TF-mediated in situ thrombosis is most likely responsible for 
MSC induced microvascular obstruction in the setting of MSC therapy post MI. 
Moreover, we show that co-administration of an anti-thrombin agent significantly 
ameliorates these adverse events associated with MSC delivery providing a viable 
and safe means of MSC-based cell therapy via the intracoronary route. 
5.3.1 Mechanisms of Tissue Factor induced adverse events post 
MSC delivery 
Emerging studies of MSC from other sources and species demonstrate varying 
levels of expression of TF by MSC and allude to the procoagulant nature of MSC 
[211, 214, 230]. Cellular TF is known to be expressed in three forms, as surface, 
encrypted and as an intracellular protein [231, 232]. TF containing microparcticles 
are also known to be released from cells [233].  Therefore it is conceivable that 
delivered MSC may potentially disseminate procoagulant activity through not 
only cellular TF but through the release of coagulant TF positive microparticles. 
[143] Within the vasculature TF may trigger in situ microvascular thrombosis 
through platelet activation and aggregation.  Platelets express PAR-1 and PAR-4 
receptors and thrombin activation of either is sufficient to initiate aggregation. In 
addition to PAR activation, VWF through its interaction with platelets plays an 
integral part in the initiation of arterial thrombus formation [234].  Our 
experiments have provided the first demonstration of the co-localisation of VWF 
with platelets and TF on MSC within a thrombus post IC MSC delivery.  
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TF also plays a role in driving the coagulation-inflammation cycle in which 
thrombin generation, also via PAR-1 and PAR-4 lead to G protein and NF-κB 
mediated expression of P-selectin, E-selectin, VCAM1 and ICAM1.  Induction of 
these adhesion molecules enhances leukocyte migration and activation within the 
infarcted region [235].  Also indirectly, TF, through the production of fibrin 
increase local proinflammatory activation of endothelial cells and increases their 
expression of adhesion molecules.[236-238].  Fibrin degradation also acts as a 
chemoattractant for neutrophils which release proteolytic enzymes and oxygen 
free radicals which further exacerbate myocardial injury after MI [239]. Soluble 
murine TF (sTF1-219) has also been shown to increase IL-6 secretion which is 
accompanied by fibrin overproduction and platelet aggregation.  TF driving the 
coagulation-inflammation circuit induces further cardiovascular complication 
including arrhythmias [240] and hypertension [241].  Evidence also suggests that 
cardiac exposure to exogenous TF can lead to pump dysfunction through the 
induction of cardiac hypertrophy [242]. Co-culturing of MSC with activated 
lymphocytes increases MSC prothrombotic properties by increasing surface 
expression of TF [214].  Although this has not been confirmed in vivo it can be 
speculated that delivering MSC into an infarcted area where MSC are likely to 
encounter activated lymphocytes may further increase the adverse thrombotic 
effect of MSC.  
Activation of PAR-1 via thrombin can also contribute to microvascular flow 
reductions giving rise to local vasoconstriction [243].  Other than coagulation TF 
plays a role in other cellular processes such as cell migration and proliferation and 
thus it is conceivable that TF may also contribute to some of the beneficial 
paracrine effects seen following MSC administration [244].  A study investigating 
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the effect of TF on cardiomyocyte proliferation and growth demonstrated that 
when rat H9c2 cardiomyocytes were exposed to increasing concentrations of 
recombinant TF there was a significant effect on cell proliferation and apoptosis 
[242].  Lower concentrations of TF increased cell proliferation but intermediate 
concentrations only induced proliferation after short term exposure and caused 
apoptosis on prolonged exposure.  The highest dose of TF induced H9c2 
cardiomyocytes apoptosis as measured by both capase-3 activity and p53 nuclear 
localisation [242].  This study supports the hypothesis that TF may be beneficial 
to cardiac repair in smaller doses but may be detrimental in higher doses and 
provides insight into our study, in that although we were increasing the number of 
MSC within the myocardium there was no additional benefit with regard 
decreases in apoptosis.  It may be also possible that the prothrombotic nature of 
MSC is required for some of MSC paracrine effect observed in vivo, for example, 
when MSC come in contact with activated platelets they secrete fibrinolytic 
enzymes and display ECM remodelling activity [245]. 
5.3.2 Heparin effect on MSC procoagulative activity 
Whether heparin interacts directly and functionally with TF remains controversial, 
but its anti-coagulant activity is considered predominantly to involve allosteric 
modification of anti-thrombin III which in turn binds to and inactivates 
thrombin[246]. Accordingly, unfractionated heparin has been the standard of 
adjunctive antithrombin therapy during PCI for more than three decades [247] and 
is used to counteract acute thrombogenicity arising from mechanical plaque 
disruption along with ongoing thromboembolic events that may be potentiated by 
either guide wire or device placement in the artery [248]. The introduction of 
prothrombotic cells, such as TF-expressing MSC, into in ischemic zone, may thus 
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potentially aggravate an already unstable environment during PCI which is 
frequently complicated by no reflow following device deployment alone. 
Adjunctive unfractionated heparin therapy during MSC co-administration was 
chosen here because this strategy fits with existing clinical practice and anti-
thrombin targeting heparin includes a broad range of binding partners such ATIII, 
Factor X as well as thrombin itself [247]. Our data confirms that such an approach 
successfully counteracts all prothrombotic and procoagulant activities caused by 
intracoronary transferred MSC in the setting of acute MI.   
In other cardiac cell therapy investigations, heparin has been thought to influence 
the engraftment of bone marrow derived mononuclear cell populations through 
disruption of the SDF-1/CXCR4 ligand/receptor axis in mice [249]. These 
investigators and others [211] have suggested the use of the direct thrombin 
inhibitor bivalirudin to obviate any concerns on heparin’s impact on stem cell 
mobilization or delivery in cardiac repair.  In contrast to this however, recent 
findings published by members of the same group illustrated that heparin dose-
dependently increased HGF levels which they suggest subsequently dose-
dependently increased the mobilisation of a subset of mesenchymal cell known as 
cMABS or circulating mesoangioblasts [250] . Further studies will be needed to 
test this later hypothesis with a broader spectrum of antithrombotic agents 
including direct thrombin inhibitors, anti-coagulants and novel platelet inhibitors 
on the prothrombotic activity of MSC post intracoronary administration. Indeed, 
in trials assessing antithrombotic agents for protection against post-PCI 
microvascular dysfunction, bivalirudin and the GPIIb/IIIa antagonist eptifibatide 
were shown to synergistically improve coronary flow reserve and myocardial 
perfusion [251]. When cancer cell lines (pancreatic cell line BxPC-3, MDA-MB-
111 
 
231 breast cancer cell line, LoVo colocarcinoma cell line, SKOV-3 ovarian cancer 
cell line, malignant melanoma cell line) are cultured with heparin it has been 
shown that heparin down regulates TF through regulation of NF-κB [252]. Pre-
treatment or culturing of MSC with heparin with adjunctive bolus treatment may 
thus be an additional option to reduce potential adverse procoagulant activity 
associated with cultured MSC.  Another agent that may be applicable to prevent 
TF related adverse event which is already being used in cardiovascular medicine 
is amiodarone.  Breitenstein et al hypothesised that the beneficial effect attributed 
to amiodarone may not be solely due to their electrophysical properties but also to 
other mechanisms such as prevention of thrombus formation.  To test this theory 
Breitestein investigated whether amiodrone effects TF expression and found that 
amiodrone showed downregulation of both TF surface expression and TF activity 
on vascular cells [253].  Co-administering MSC with amiodrone could circumvent 
the bleeding risks with other anti coagulants and should be explored in future 
experiments.  
5.3.3 Tissue Factor induced Microvascular Obstruction 
In human subjects, the presence of microvascular obstruction detected within the 
infarct zone by MRI is associated with more severe infarctions, impaired LV 
remodelling and less downstream functional recovery compared to those without 
[254, 255]  Recently, a reduction in flow (as assessed by angiographic 
Thrombolytics In Myocardial Infarction (TIMI) grading) was detected after 
intracoronary cell delivery of a mesenchymal precursor Stro3+ cell isolate and it 
was suggested that a reduction in flow was associated solely with high cell 
numbers [256]. Our hypothesis that TF associated with MSC may be responsible 
for CFR reduction in vivo is supported by other studies in which IC injection of 
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recombinant TF leads to vasoconstriction and flow impairment providing a causal 
mechanistic relationship between TF antigen presentation and the reduction in 
CFR associated with MSC delivery[209]. In our experiments we determined the 
contribution of delivered MSC to microvascular thrombosis within the infarct 
territory using confocal microscopic analysis. Here we showed co-localization of 
DiI-labelled MSC and platelet-rich thrombus as well as MSC and TF 
coexpression within microvascular luminal thrombi providing evidence of an in 
vivo association between MSC delivery, TF associated prothrombotic blood 
components and thrombotically occluded microvessels. 
In conclusion, this in vivo study has identified that MSC prothrombotic activity as 
defined in vitro is associated with a loss in CFR and in situ MSC-derived 
microvascular thrombosis when MSC are administered into the porcine coronary 
circulation post MI. Co-administration of heparin successfully ameliorates all of 
these side effects of MSC delivery.  These finding highlight that the management 
of possible prothrombotic side effects of MSC should be a significant 
consideration during future investigative and clinical trials of MSC administration 
especially via the intracoronary route. 
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Chapter 6  
Long term cardiac functional benefit 
of MSC when delivered in the 
presence of heparin 
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6.1 Introduction 
Ischemia triggers a cascade of cellular and biochemical processes that drive 
functional and structural changes to the myocardium known as remodelling [28].  
The compensatory ‘reparative’ processes that occur in response to MI include, 
scar formation, infarct expansion, ventricular dilatation, fibrosis and myocyte 
hypertrophy of the non-infarcted myocardium [257]. Alterations to left ventricle 
chamber architecture is characteristic of ventricular remodelling and result in 
changes to ventricle shape from the normal elliptical shape to a more spherical 
shape (Figure 1.4) [258].  These alterations result in enlargement of the heart and 
increased LV chamber dimensions which subsequently lead to functional 
deterioration of the myocardium, decreasing the hearts ability to pump adequately 
and ending in HF.  The extent of remodelling that occurs correlates closely with 
the degree of initial myocardial damage and is consistently associated with poorer 
outcomes [258].   
For any therapy to be translatable to a clinical scenario there must be observable 
long term health benefits.  Pre-clinically MSC have demonstrated the potential to 
facilitate long term cardiac repair and regeneration [259]. The main aim of these 
experiments however, was to evaluate the long term benefits of MSC therapy and 
in particular to illustrate that delivering MSC in the presence of heparin had no 
adverse effect on the therapeutic outcomes associated with MSC delivery with 
regard to functional cardiac improvements.  In order to do this, parameters of LV 
remodelling such as LVEF, EDV, ESV, wall motion, infarct size and collagen 
deposition where analysed 6 weeks after the delivery of 25x10
6
 MSC in the 
presence of heparin in a porcine model of acute MI and compared to control, 
saline treated animals (Figure 6.1). 
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Figure 6.1 Chronic MI model 
At 6 weeks post initial procedure animals underwent a similar procedure to that 
of the acute study at 24 hours.  CT scan was obtained in order to assess functional 
improvements at 6 weeks before the animal was sacrificed.  
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6.2 Results 
6.2.1 Chronic effect of heparin assisted intracoronary MSC 
delivery on chronic infarct size and global ventricular 
remodelling 
The therapeutic efficacy of heparin-assisted intracoronary MSC delivery was 
assessed at 6 weeks post MI.  MSC treatment significantly reduced infarct scar 
size in animals when compared to saline treatment alone (Figure 6.2). Additional 
parameters of chronic remodelling, including global left ventricular End-Systolic 
Volume (ESV), Left Ventricular End-Diastolic Volume (EDV), and left 
ventricular Ejection Fraction (EF) were determined by 64-slice CT.  MSC 
delivery was associated with a ~ 20% relative improvement EF over saline treated 
group (Figure 6.3).  MSC therapy significantly decreased EDV and ESV 
compared to saline treatment providing further evidence for sustained beneficial 
effects on LV remodelling after MI. (Figure 6.4) 
6.2.2 MSC delivery in the presence of heparin improved cardiac 
wall motion at 6 week s. 
Using General Electric (GE) CT CardioIQ software infarct wall motion was 
determined at 6 weeks post infarct in the MSC and the saline treated animals.  The 
infarct territory was used for quantitative analysis.  At 6 weeks post MI, there was 
a significant increase in infarct-related wall motion in the MSC group versus 
saline control group (Figure 6.5). 
 
 
 
117 
 
 
 
 
 
 
 
 
 
Figure 6.2 MSC therapy reduces infarct size at 6 weeks post MI. 
Representative macroscopic images of TTC-stained sections of hearts six weeks 
post MI treated with saline or MSC. Methylene blue dye exclusion was used to 
highlight the area at risk of infarction. The remote territory is highlighted as blue, 
the area at risk, red and the infarct territory is highlighted as white. B: 
Quantification of the infarct area represented in A. (n=6) (*p<0.05). 
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Figure 6.3 MSC therapy significantly improves Left ventricular ejection 
fraction at 6 weeks post MI 
Evaluation of left ventricular function by CT showing that MSC delivery 
significantly increased the ejection fraction compared with saline treatment alone 
(n=6) (*p<0.05).   
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Figure 6.4 MSC therapy significantly improves left ventricular volumes at 6 
weeks post MI 
Evaluation of end systolic (ESV) and end diastolic volume (EDV) showing a 
significant reduction in both LV volumes associated with MSC delivery over 
saline delivery alone.  (n=6) (*p<0.05).    
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6.5 MSC therapy significantly improves wall motion at 6 weeks post MI 
MSC delivery improves in left ventricular wall motion (inmm2/g/cardiac cycle) 
when compared to Saline treatment alone(*:p<0.05)(n=6) 
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6.2.3 MSC delivery decreased infarct fibrosis 
Picrosirius Red staining of the infarct related region revealed decreased collagen 
deposition in the MSC treated group when compared to saline treated groups.  
This provides supportive evidence of decreased histological scar formation at 6 
weeks post MSC administration (Figure 6.6).   
 
Figure 6.6 MSC delivery is associated with decreased collagen deposition at 6 
weeks post MI 
Representative image depicting picrosirius red staining of the infarct zone 
showing a significant reduction in collagen deposition in MSC-treated animals 
compared with saline six weeks post MI (***: p<0.0001) arrowheads indicate 
areas of myocardial preservation evident in the MSC group. (n=6) Scale bar 
represents 200µm 
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6.3 Discussion 
The main necessity of this study was to demonstrate the long term efficacy of 
heparin assisted MSC delivery.  Herein it is demonstrated that MSC in the 
presence of heparin confers structural and functional benefits in both the regional 
and global myocardium at 6 week post MI.  
As mentioned in the previous chapter there has been a number of issues 
surrounding the use of heparin during cell therapy administration.  The use of 
heparin has been implicated in decreasing the ability of cells to home and migrate 
within the myocardium [260].  Heparin has been suggested to disrupt the 
CXCR4/SDF axis which has been demonstrated to impair the functional capacity 
of cells such as BM-MNC used in cardiovascular repair [249, 260].  The main 
paper supporting this concept was published by Seeger et al in 2012 [249].  Here 
it was demonstrated that heparin profoundly and dose dependently prevented 
SDF-1 induced BM-MNC migration [249].  The study revealed that if BM-MNC 
were pre-treated with heparin there was a significant reduction in the homing 
ability of injected cells in a mouse ear wound model.  From these results Seeger et 
al concluded that bivalirudin should be used instead of heparin during the delivery 
of BM-MNC in clinical studies [249].  Due to these findings, the pre-treatment of 
BM-MNCs with heparin has been used to explain to the negative results obtained 
in the TIME trial, in which, no significant clinical benefits were observed after 
BM-MNC administration in patients [261].  The SWISS-AMI trial which also 
evaluated the effect of BM-MNC post MI also showed no statistical significance 
between BM-MNC treated and control treated groups in relational to functional 
cardiac improvements [262].  Here investigators did not use heparin during cell 
administration suggesting that the lack of efficacy of BM-MNC observed in the 
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TIME trial was not necessarily due to the pre-treatment of BM-MNCs with 
heparin [262].  Our MSC study provides additional evidence that heparin does not 
impact MSCs regenerative capability by showing delivering MSC in the presence 
of heparin improved functional cardiac parameters at 6 week post MI.  
Nevertheless, although our data speaks against a negative heparin effect on MSC, 
additional studies in other models may be required comparing MSC delivery in 
both the presence and absence of heparin to fully confirm our data.  In this current 
study MSC delivery was associated with the preservation of left ventricular EF in 
treated animals.  EF relates to the volume of blood that is pumped by the left 
ventricle during each cardiac cycle and its preservation is considered a major 
determinant of patient prognosis and quality of life [257].  A reduction in EF is 
frequently accompanied by LV dilatation, an increase in systolic and diastolic 
volumes and an increase in the occurrence of lethal ventricular arrhythmias [263].  
As can be seen from this study and corroborated by others, EF is directly linked to 
infarct size.  Here we report a significant reduction in infarct scar size as well as a 
correlative reduction in EF at 6 weeks post MSC administration.  Experimentally 
it has been shown in large animal models that infarct scar size can be reduced as 
early as 3 days and sustained out to 90 days post MSC delivery [82, 264].  Hare et 
al carried out a long term allogeneic MSC study in a large animal model of MI 
and in agreement with findings in our study, reductions in infarct size associated 
with MSC delivery correlated closely with both reduction in ESV and EDV [264].  
In addition, Hare demonstrated that MSC delivery not only improved LV chamber 
volumes but also showed that the heart architecture in MSC treated animals had a 
less altered configuration which was ascribed to the observable salvation in 
cardiac pump function [264].   
124 
 
MSC have been shown to be beneficial at each stage of the repair and remodelling 
process post MI and although the exact mechanisms by which MSC delivery exert 
their therapeutic benefit is not fully understood a number of possible mechanisms 
have been proposed (Section 1.3).  Taking all possible mechanisms of actions 
related to MSC repair and regeneration into account it becomes clear that MSC do 
not work by acting on one repair pathway alone but multiple pathways are 
modulated to produce the overall repair and regeneration effect that has been 
observed within the MSC field.  The following chapter we will begin to move 
away from the idea of direct cell therapy and begin to address indirect paracrine 
mechanisms of repair.   
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Chapter 7  
MSC secreted paracrine factors and 
their role in cardiac repair 
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7.1 Introduction 
The field of cell therapy has begun to move in new directions.  As more is 
understood about the mechanisms of MSC benefit it is becoming more apparent 
that their main action may be through the secretion of paracrine factors [91] which 
act on other cells to elicit repair.  This chapter will begin to explore some of these 
secreted factors implicated in the post injury repair response.  
Recent data presented as an abstract [265] has identified a promising therapeutic 
MSC secreted factor known as SPARC-like protein 1 (SPARCL1, Hevin, SC1 
and Mast9).  SPARCL1 is a member of the SPARC gene family of extracellular 
matrix glycoproteins.  Extracellular matrix proteins are primarily expressed during 
development, during growth, in response to injury and are found in abundance in 
adult cells in which there is continued turnover, such as bone [266]. 
SPARCL1 is thought to be involved in cell migration, is localised in high 
endothelial venules where it is proposed to be involved in cell adhesion and 
facilitate lymphocyte transendothelial migration [267].  SPARCL1 has also been 
implicated in modulation of extracellular matrix synthesis and assembly and the 
deletion of SPARCL1 in a dermal wound mouse model resulted in microscopic 
and macroscopic alteration  to dermal collagen and decorin assembly [268] 
SPARCL1 has an amino acid sequence that is approximately 50% homologous to 
that of SPARC and shares an identical C terminal domain, including a Ca
2+
 
binding domain and a follistatin-like domain (Figure 7.1) [269].  SPARC 
regulates the production of ECM proteins and influences activity of growth 
factors such as PDGF, VEGF and FGF [266].  One of the main papers that 
prompted further research into the cardiac repair capabilities of SPARC and 
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SPARC like proteins was published in 2009 by Schellings et al [270].  This study 
set out to establish if SPARC played a role in infarct healing and ECM maturation 
after MI.  This group utilised SPARC-null mice and interestingly, the SPARC-
null mice exhibited a fourfold increase in mortality due to increased cardiac 
rupture after MI induction when compared to wild type mice.  In addition, over 
expression of SPARC in wild type mice showed signs of improved collagen 
maturation and prevented cardiac wall expansion and subsequently cardiac 
dysfunction after MI [270].   
 
 
Figure 7.1 SPARC and SPARCL1 homology. 
SPARCL1 shares approximately 50% of its amino acid sequence with that of 
SPARC.  This allows us to postulate similar functions to both proteins.  
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Prior work has established through conditioned media experiments that MSC 
secrete a SPARC-like protein SPARCL1 [265].  Following this discovery, in 
order to determine if SPARCL1 is cytoprotective, in vitro assays using neonatal 
rat cardiomyocytes exposed to hypoxic conditions were carried out.  Following 
the addition of varying concentrations of recombinant SPARCL1 cell viability, 
cytotoxicity, caspase activity and gene expression were analysed [265].  
SPARCL1 treatment resulted in a significant increase of cell viability and a 
decrease in apoptosis. These observations were confirmed by gene and protein 
expression which demonstrated elevated expression of anti apoptotic genes Bcl-2, 
and reduction of anti fibrotic genes, Col1 and Col3 [265].  SPARCL1 protein also 
exhibited pro-angiogenic properties by increasing tubular and capillary formation 
in an in vivo matrigel angiogenesis assay [265]. 
Based on this in vitro cytoprotective data [265] and previous published data that 
SPARCL1 modulates ECM [268] it was hypothesised that SPARCL1 would 
influence tissue regeneration, remodelling and repair post MI.  SPARCL1 was 
also selected as a paracrine factor that may exhibit both the acute prototypical 
paracrine factor that may exhibit both the acute cytoprotective and chronic matrix 
remodelling as seen in chapters 4-6.  Therefore the therapeutic effect of 
recombinant SPARCL1 was evaluated when delivered in a chronic model of MI.  
6 weeks after the delivery of the protein cardiac functional parameter including, 
EDV, ESV, EF, CO and SV were examined by CT.  In addition to this in vivo 
work, further analysis of MSC conditioned media was carried out in order to 
detect other factors secreted by MSC that may potentially augment cardiac repair 
and regeneration.   
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7.2 Results 
7.2.1 MSC secrete SPARCL1 
Analysis of MSC conditioned media collected at 48 hours by ELISA revealed that 
MSC abundantly secret SPARCL1.  Endothelial cells secreted negligible amounts 
of SPARCL1, similar in concentration to that of control basal media. (Figure 7.2) 
7.2.2 SPARCL1 has no effect on cardiac functional parameters. 
Delivery of 10µg of recombinant human SPARCL1 via the coronary artery in an 
acute porcine model of MI had no significant effect on cardiac functional 
parameters at 6 weeks post-delivery. Functional analysis was carried out by CT 
and included measurements of End Systolic Volume (ESV), End Diastolic 
Volume (EDV), Stroke Volume (SV), Cardiac Output (CO) and Ejection Fraction 
(EF). (Figure 7.3) 
7.2.3 MSC secrete a wide array of paracrine factors. 
Conditioned media analysis using RayBiotech® cytokine array assay revealed a 
large spectrum of cytokines secreted by both porcine MSC and human MSC. 
Conditioned media was collect at 48 hours and α-MEM basal media was used as a 
negative control.  Signal intensities were determine using ImageJ software and 
expressed relative to positive controls provided by manufacturer (Figure 7.4, 7.5, 
7.6, 7.7 and 7.8). Eighty different cytokines were examined of which 14 were 
identifiable in MSC conditioned media and are shown in Figure 7.4 
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Figure 7.2 MSC expression of SPARCL1 
Conditioned media from MSC and EC was collected after 48 hours in culture.  
MSC released significantly higher levels of SPARCL1 into media that of ECs 
(Control Cells).  α-MEM basal media was used as a negative control. (n=3) 
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Figure 7.3 CT functional cardiac analysis 6 weeks post SPARCL1 delivery 
Analysis of the effect of SPARCL1 on cardiac functional parameters was carried 
out 6 week post-delivery of 10µg of recombinant SPARCL1 by CT when 
compared to saline treated controls alone.  No functional benefit was observed 
with regards EF, ESV, EDV, SV and CO. (n=4)  
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Figure 7.4. MSC cytokine analysis 
Conditioned media of both porcine and human MSC.  After 48 hours, 
conditioned media was collect from pMSC and hMSC cell cultures.   MSC 
demonstrated a diverse secretory profile. α-MEM was used as a negative 
control.  Cytokine and chemokine secreted included GRO-CXCL1, I-309-
CCL1, IL-6-Interlukin 6, IL-8-Interlukin 8, MCP-1-Monocyte chemotactic 
protein 1, OncM –Oncostain M, LIF-Leukemia inhibitory factor, Osteop-
Osteopontin, Opgerin-Osteoprotegerin, TIMP- Tissue Inhibitors of 
Metalloproteinases, IL-1a-Interleukin1a, VEGF-Vascular Endothelial Growth 
Factor, BDNF- Brain-derived Neurotrophic Factor. (n=2) All values are 
normalised to the provided positive control. 
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Figure 7.5. MSC cytokine analysis 
ENA-78- C-X-C motif chemokine 5, GCSF- Granulocyte colony-stimulating 
factor, GM-CSF- Granulocyte-macrophage colony-stimulating factor, GRO-
 - C-X-C motif ligand 1, IL-1α-Interleukin 1α, IL-2- Interleukin 2, IL-3- 
Interleukin, IL-4-Interleukin 4, IL-5- Interleukin 5, IL-7- Interleukin 7, IL-10-
Interleukin 10, IL-12- Interleukin 12, IL-13- Interleukin 13, IL-15- Interleukin 
15, IFN-γ- Interferon gamma, MCP-2- Monocyte chemotactic protein 2, (n=2) 
All values are normalised to the provided positive control.  
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Figure 7.6. MSC cytokine analysis 
FGF-9- Fibroblast growth factor 9, FLT-3Lig- Fms-related tyrosine kinase 3 
ligand, GCP-2- Human granulocyte chemotactic protein-2, GDNF- Glial cell-
derived neurotrophic factor, HGF- Hepatocyte growth factor, IGFBP-1- 
Insulin-like growth factor-binding protein 1, IGFBP-2- Insulin-like growth 
factor-binding protein 2, IGFBP-3- Insulin-like growth factor-binding protein 3, 
IGFBP-4- Insulin-like growth factor-binding protein 4, IL-16-Interlukin16, IP-
10- C-X-C motif chemokine 10, LIGHT- Lymphotoxins, inducible expression, 
competes with HSV glycoprotein D for HVEM, MCP-4- Monocyte chemotactic 
protein-4. (n=2) All values are normalised to the provided positive control. 
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Figure 7.7. MSC cytokine analysis 
MCP-3-Monocyte chemotactic protein 3, MSCF-Macrophage colony-
stimulating factor, MDC-Macrophage-derived chemokine, MIG-C-X-C motif 
ligand 9, MIP-1β-Macrophage inflammatory protein-1β, RANTES-C-C motif 
ligand 5, SCF- Stem Cell Factor, IP-3α-Macrophage inflammatory protein 3α, 
NAP-2-Neutrophil-activatingprotein-2,NT-3-Neurotrophin-3,NT-4-
Neurotrophin-4, PARC- Pulmonary and activation-regulated chemokine, PIGF- 
Placental growth factor, TGF-β2- Transforming growth factor-beta 2, TGF-β2-
Transforming growth factor-beta . (n=2) All values are normalised to the 
provided positive control. 
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Figure 7.8. MSC cytokine analysis 
SDF-1- Stromal cell-derived factor 1, TARC- C-C motif ligand 17, TGF-β2- 
Transforming growth factor-beta 3, TNF-α- Tumor necrosis factor-α, EGF- 
Epidermal growth factor, Thromp- Thrombopoietin, PDGF-BB-Platelet-derived 
growth factor, BLC- B-lymphocyte chemoattractant, CK β 8-1- Macrophage 
Inflammatory Protein 3, FGF-4- Fibroblast growth factor-4, FGF-6-Fibroblast 
growth factor-6, FGF-7- Fibroblast growth factor. (n=2) All values are 
normalised to the provided positive control. 
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7.3 Discussion 
This section has begun to explore the wide variety of factors secreted by MSC, in 
particular it has highlighted the secretion of SPARCL1.  To date no published 
work has shown the release of SPARCL1 by MSC.  Before undertaking this study 
it was hypothesised that delivery of SPARCL1 would infer cardiac functional 
benefits post MI.  Despite the promising unpublished in vitro data, chronic 
analysis of animals 6 weeks after delivery of 10µg of recombinant Sparcl1 
protein, showed no functional cardiac improvements. It can also be concluded that 
the delivery of 10µg of SPARCL1 had no adverse effects on cardiac performance 
and no adverse events were noted during or after its delivery.   
Chaurasia et al described how SPARCL1 plays a pivotal role in corneal wound 
healing and that SPARCL1 may be a novel therapeutic worth pursuing past initial 
pre-clinical studies [271].  Corneal wound healing is similar to that of infarct 
healing that occurs post MI in so far as damage to the cornea causes an initial 
acute response including cellular apoptosis, the release of local pro-inflammatory 
cytokines such ad IL-1, TGF-β and PDGF, cell clearance and the activation of, 
and migration of  myofibroblasts to the site of injury [271].  These events result in 
wound contraction, ECM disorganisation, adverse remodelling and scar 
formation.  Chaurasia et al demonstrated how the exogenous topical application of 
recombinant SPARCL1 to the damaged corneas protected cells from undergoing 
apoptotic cell death, decreased inflammatory events such as MMP activity, 
reduced αSMA positive cells in the region and decreased fibrosis and irregular 
ECM production [271].  The repair process here is mechanistically similar to that 
required for MI repair however, our SPARCL1 study failed to demonstrate any 
positive results in the heart.   
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There are a number of possible reasons as to why SPARCL1 had no therapeutic 
effect on MI repair in this study.  Firstly, the timing of drug delivery may not be 
optimal, as SPARCL1 is an ECM modulating factor and has been shown to 
regulate collagen assembly [268].  The delivery of SPARCL1 may thus be more 
beneficial at later time points in the repair process, possibly after the initial acute 
injury response has completed and during the remodelling phase.  Secondly, the 
dose of SPARCL1 delivered may not be adequate to elicit functional 
improvements.  Although we extrapolated from our in vitro data to match an 
equivalent dose to that of the MSC dose that was administered in previous studies 
this SPARCL1 dose may not be sufficient.  From the successful Chaurasia study 
much higher doses of SPARCL1 were applied, 100µg of recombinant SPARCL1 
was applied for 3 days at 24 hours intervals [271].  Additional dose ranging 
studies may be required to identify if increased amounts of SPARCL1 would infer 
additional functional improvements.  Thirdly, the method of delivery of the 
protein may not be appropriate.  Again referencing the study carried out by 
Chaurasia et al topical application of recombinant SPARCL1 was capable of 
improving corneal repair suggesting that maybe alternative delivery strategies 
may need to be utilised to obtain the optimal benefit of in vivo administration of 
SPARCL1.  For instance, as SPARCL1 works predominantly on matrix then 
ECM slow release strategies for SPARCL1 delivery may be appropriate.  Other 
strategies may involve protein PEGylation, drug encapsulation and drug delivery 
from drug eluting stents or hydrogels with slow release profiles.   
In addition to identifying the expression of SPARCL1 this study has also 
elucidated other factors that are secreted by MSC.  The study compared 
conditioned media of porcine and human MSC.  Results show a disparity in 
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concentration of factors secreted by MSCs from different species and this may be 
real or in part attributed to the use of a human cytokine array.  Antibodies may not 
be as specific for porcine proteins as they would be for humans.  The cytokine 
array used was capable of identifying 70 cytokine and chemokines of which ~20% 
were identified to be secreted by MSC in the current study.  The paracrine factors 
identified have been implicated in numerous cellular processes that may 
potentially be involved in cardiac repair.  Of those identified within the 
conditioned media there is an overall suggestion these factors may be involved 
cell migration and tissue remodelling due to the presence of cytokines such as 
MCP-1, GRO, TIMP1, TIMP2, IL-8 and IL-10.  Factors known to be associated 
with angiogenesis were not present in high concentrations in the current 
conditioned media study, although there was a slight increase in the concentration 
of VEGF.   High levels of cytoprotective cytokines such as VEGF, IGF-1, bFGF 
and SDF have been present in previously reported MSC conditioned media 
experiments, especially after exposure to hypoxia.  As in vitro culture 
environment plays a significant role in the factors released by stem cells it is 
therefore difficult to find coherence between studies, however there are a number 
of putative cytokines that are reported within the literature. 
One of the most significantly secreted cytokines by MSC in the current study was 
the TIMPs.  TIMPs are associated with influencing ECM ventricular remodelling 
post MI, their absence post MI has been linked to accelerated remodelling in both 
TIMP1 and TIMP2 deficient mice [272, 273].  To date no study has looked at the 
benefits of delivering recombinant TIMP1 or TIMP2, however, a recent abstract 
showed the benefits of continuous delivery of recombinant TIMP3 by a 
degradable hyaluronic acid based hydrogel [274].  Delivery of TIMP3, 14 days 
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after MI in a large animal model prevented adverse inflammatory events and 
progression of LV dysfunction [274].  Novel anti fibrotic agents such as TIMPs 
released by MSC may be promising future therapeutics for MI remodelling as 
stand-alone agents and may warrant further research.  GRO, also known as 
CXCL1 and secreted by MSC has been shown to play a pro-inflammatory role 
post myocardial infarction due to its potent chemokine effect on neutrophils.  
GRO levels are increased post MI [275] and this GRO secreted by MSCs is of 
unclear significance in terms of additional therapeutic benefit.  Another MSC 
secreted cytokine identified was IL-10 is a known anti-inflammatory cytokine that 
has been shown to be therapeutically beneficial post MI.  Delivery of recombinant 
IL-10 attenuated both inflammation and myocardial remodelling in a mouse 
model of MI [276].  High levels of the pro-inflammatory cytokine IL-6 also 
released by MSC has been shown to increase inflammation, increase left ventricle 
adverse remodelling and to increase the incidence of HF. However, it is debatable 
whether IL-6 may be of benefit post MI, the receptor for IL-6, known as gp130, 
activation of gp130 is cardioprotective. Therefore high levels of IL-6 which 
activate gp130 should be beneficial as opposed to being disadvantageous.  This 
illustrates the difficulty in determining the mechanisms of a single factor in the 
context of multiple proteins secreted by MSC.   
Although this study has identified an array of factors, it is difficult to establish if 
MSC would have the same cytokine and chemokine profile when delivered into 
post ischemic environment of the myocardium.  Further in vitro studies beyond 
the scope of this PhD thesis are required to fully allude the significance of these 
findings.   Repair post MI is a highly dynamic process which involves multiple 
cytokines, proteins, molecules and cells being activated and deactivated in a 
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temporal and spatial continuum.  The major challenge in the paracrine field 
therefore is in determining when and how much of what factor is required in order 
to be beneficial.   
Experiments in this chapter primarily focused on SPARCL1, a relatively novel 
cytokine whose mechanism of action remain considerably unknown but showed 
promise both in vitro and in vivo in small animal studies.  Further work should 
involve higher SPARCL1 dosing, varying time points after MI and delivery 
though a variety of performance enhancing strategies including local and slow 
release agents.  With regard to MSC secretory profile, it may be useful to focus on 
classes of factors that affect early, midterm and late events post MI.   
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Chapter 8  
Discussion and Future Directions 
  
143 
 
8.1 Discussion 
8.1.1 Optimising MSC delivery 
Initial dosing studies identified that 25x10
6 
MSC
 
to be the optimal dose of MSC 
that could be administered via the coronary artery in the absence of heparin 
without any major adverse events, such as death or ventricular arrhythmias 
occurring.  In the porcine model this represents  approximately 1x10
6
MSC/kg and 
was used in all following in vivo studies.  Both preclinical and clinical studies 
have shown recently that the delivery of lower cell numbers in the range of 20-
25x10
6
 have a greater therapeutic effect than that of higher cell numbers [118, 
192, 214].  Our current study corroborates these findings by illustrating that 
25x10
6 
MSC resulted in significant cardiac functional improvements at 6 weeks 
post MI.  Although it has not been explored, delivery of higher cell numbers could 
be causing additional injury that is negating the positive effect of MSC therapy.  
Additional injury could be caused by the presence of more TF within the 
vasculature, triggering increases thrombus formation resulting in more severe 
MVO.  More advanced imaging technologies such as 3D microvessel 
reconstruction by CT may allow researchers determine more accurately the fate of 
MSC within the cardiac microvasculature, including the evaluation of 
microvascular presence of MSC over time.   
8.1.2 Safety concerns surrounding MSC therapy 
Despite no major adverse events occurring, delivery of 25x10
6 
MSC did result in 
significant reductions in coronary flow as measured by CFR after their 
administration.  This reduction in flow post MSC therapy has been prevalent 
finding in the field since the first MSC studies in vivo [277].  Reductions in 
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coronary flow as a result of downstream occlusion within the microvascular bed is 
an indicator of poor prognostic outcome in patients being associated with 
increased incidence of HF and mortality [221].  Reductions in coronary flow and 
MVO occur post MI in the absence of cell therapy but administration of cells in 
the acute phase exacerbate this pathology.  A large meta-analysis looking at 52 
pre-clinical MSC studies raised safety concerns regarding MSC therapy.  
Although this study suggested that there was no significant increase in animal 
mortality after cell administration, ~60% of the preclinical studies determined the 
presence of safety issues after cell delivery [277].  In agreement, human trials 
have not reported increased mortality after cell delivery but laboratory 
investigations on MSC surface characteristics have suggested caution is warranted 
in the clinical use of MSC.  For these reasons, the investigators of the TAC-HFT 
trial which reported one-year follow up data [278], chose to avoid intracoronary 
delivery when recently testing MSC treatment in ischemic cardiomyopathy 
patients.  Our data would suggest that when using MSC for clinical practice 
heparin therapy may be useful in avoiding adverse MSC related events. 
Although microvascular obstruction and reductions in coronary flow have been 
highlighted in the majority of studies, no study to date has investigated the causal 
mechanism surrounding MSCs effect on the microvasculature post MI.   Our 
study has demonstrated for the first time that one mechanism responsible for MSC 
causing adverse events is due to surface expression of TF, which is the most 
potent propagator of coagulation.  Not only has this study shown that MSC 
expresses TF but that the TF present is catalytically active and because of this 
MSC are capable of supporting thrombus formation and induce thrombin 
generation in vitro.  As well as providing mechanistic evidence this study has also 
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provided a clinically applicable strategy for preventing microvascular occlusion, 
decreasing myocardial haemorrhage and reduction in coronary flow associated 
with MSC delivery.  Herein it has been established that pre-treating the MSC with 
heparin can abrogate the pro-thrombotic effect of MSC both in vitro but most 
importantly in vivo.  As mentioned, untreated MSC caused significant reductions 
in coronary flow after the delivery of 25x10
6 
cells via the coronary artery.  This 
reduction in flow was associated with downstream microvascular obstruction, 
which was illustrated in this current study by being able to identify labelled MSC 
expressing TF coupled with platelet aggregation and VWF expression within 
occluded vessels 24 hours after cell delivery (Figure 5.4).  A paper published by 
Moll et al [214] suggests that cultured MSC due to their expression of TF 
triggered what the authors termed an instant blood-mediated immune reaction 
(IBMIR).  The degree of this response Moll suggests is dependent on cell dose, 
cell passage and cell donor.  Results following the intravenous administration of 
MSC revealed that MSC trigger a weak IBMIR response.  This study was 
conducted on 44 patients who received 69 infusions of 1-3x10
6
/kg of MSC for the 
treatment of life threatening conditions such as graft vs. host disease. Analysis of 
serum samples at 24 hours found a 15% platelet count drop after administration 
and a five-fold increase in both the coagulation marker TAT and the complement 
activation marker C3a.  In vitro Moll used a Chlander blood loop model to further 
investigate MSC compatibility with blood and observed that higher MSC doses 
corresponding to 1-3x10
6
/kg
 
recipient weight resulted in faster and more 
prominent clotting in comparison to a dose equivalent of 0.2-0.5x10
6
/kg
 
recipient.  
This higher dose is the same as the dose used in our in vivo studies however 
delivering the cell locally via the coronary artery rather that systemically may 
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intensify the responses observed in Moll’s in vivo study. This again highlights the 
need for definitive MSC dosing studies and underlines the need for more 
extensive analysis of what may be occurring in vivo post MSC administration.   
8.1.3 The effect of heparin on MSC 
In other cardiac cell therapy investigations, heparin has been thought to influence 
the engraftment of bone marrow derived mononuclear cell populations through 
disruption of the SDF-1/CXCR4 ligand/receptor axis in a in vitro cell migration 
assay and in a mouse ear-wound model [279]. These investigators and others 
[211] have suggested the use of the direct thrombin inhibitor bivalirudin to 
obviate any concerns on heparins impact on stem cell mobilization or delivery in 
cardiac repair.  From the data presented in this current study, heparin improves 
MSC infiltration into the infarct zone suggesting that heparin impairment of the 
SDF-1/CXCR4 system does not impact MSC uptake in this context. Moreover, 
heparin-assisted MSC delivery improved LV remodelling and function six weeks 
post MI.  In vitro, it has also been demonstrated that heparin has no effect on 
MSC proliferation or differentiation [280].  
Since management of thrombosis remains a key priority in the treatment of 
cardiac patients, further studies are required using a broader spectrum of anti-
thrombotic agents including direct thrombin inhibitors, anti-coagulants and novel 
platelet inhibitors on the prothrombotic activity of MSC post intracoronary 
administration. Other drugs that may prevent MSC prothrombic activity include 
thrombin inhibitor melagatran 137[281],  specific TF inhibitors [214] and 
activated protein C [282]. 
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8.1.4 The role of MSC associated TF 
This study has raised a number of questions surrounding the role of TF in relation 
to MSC.  Further studies are required to establish if TF expression is due to 
culture expansion of cells or whether MSC express TF intrinsically.  Previously it 
has been shown the higher the number of passages the cell has undergone the 
higher the expression level of TF [214].  It is not unreasonable to propose that the 
in vitro handling of MSC may be having a significant impact on their innate in 
vivo characteristics.  Chemicals such as trypsin, FBS and washing buffers used in 
protocols such as passaging and cryopreservation may be influencing the function 
of MSC.  Modifying culturing protocols could limit MSC TF expression without 
having to pre-treat with adjunctive drugs and may be advantageous.  If cell culture 
is an influential factor minimal in vitro expansion of cells should be utilised and 
this could be achieved through increasing volume of bone marrow at initial 
aspiration, by using autologus cells and by using lower cell numbers.  MSC cell 
sorting of TF positive and negative MSC and comparing their in vitro and in vivo 
behaviour may be a study that would provide significant insight as the role of TF 
with regard the therapeutic benefit of MSC cell therapy.  Further in depth analysis 
as to what is causing TF expression is required.   
8.1.5 Clinical implications 
In the cardiac repair cell therapy field, there are number of on-going trials 
featuring MSC delivery through an intracoronary route such as WJ-MSC-AMI 
[283], SEED-MSC (NCT 01392105), and  AMICI (NCT01781390) for acute MI. 
The management of possible prothrombotic side effects of MSC should therefore 
be a consideration during investigative and clinical MSC administration in a 
cardiovascular setting where augmented thrombogenicity may be potentially an 
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unheralded problem. Other trials targeting chronic myocardial ischemia such as 
POSEIDON [118] and PROMETHEUS utilize an intramyocardial delivery 
strategy which presumably may not give rise to this microvascular complication. 
Intramyocardial platelet activation has deleterious thrombotic and microembolic 
consequences of cardiac ischemia [284, 285] and has been effectively mitigated 
by glycoprotein IIb/IIIa targeting as shown for example, in the PROTECT TIMI-
30 trial [251]. As a potential causative agent of platelet activation when delivered 
in the coronary vascular system, therapeutic use of MSC may thus require 
additional attention to anti-platelet treatment. Thus management of possible 
prothrombotic side effects of MSC should be a strong consideration during future 
investigative and clinical MSC administration especially via the intracoronary 
route. 
The safety concerns associated with cell delivery into the ischemic myocardium 
that have been highlighted in this thesis are critical to patient safety and the 
safeguarding of positive outcomes of major efforts in cardiac cell therapy 
investigations, particularly in the light of large scale trials such as BAMI recently 
supported by European Commission Seventh Framework Programme FP7.  The 
use of anti-coagulants for the administration of cells via the coronary route may 
be imperative to prevent the occurrence of adverse events illustrated in this 
setting.   
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8.2 Future Directions 
Since their discovery, MSC when used in animal models for the treatment of MI 
have been shown to differentiate into new cardiomyocytes, promote local cardiac 
regeneration/repair, reverse cardiomyocyte death, and modulate adverse cardiac 
remodelling.  Based on these promising findings clinical trials using MSC for 
cardiac repair have been initiated.  Early clinical studies met safety endpoints and 
did show encouraging results such as improved EF [197, 286], a reduction in LV 
chamber size[197], decrease in ventricular arrhythmias and overall improvements 
in health [286].  These encouraging phase I studies prompted further new phase II 
clinical trials but unfortunately these clinical trials have not lived up to the early 
promises.  The following discussion will describe possible ways in which MSCs 
and their by-products may be manipulated to increase their therapeutic benefit 
both in relation to the data obtained in this thesis and in the broader MSC field.  
 
The disparity between results obtained in pre-clinical and clinical MSC studies 
may occur primarily due to study heterogeneity within the field.  From a pre-
clinical stand point and as can been seen from table 3.1 there is little coherence 
between MSC pre-clinical studies.  This heterogeneity prevents researchers from 
identifying the optimal therapeutic platform by which MSC exert their repair 
effect.  Despite this, clinical trials are being undertaken based on variable pre-
clinical results and it is now becoming apparent from larger MSC trials that 
results are modest and contradictory.  Pre-clinical studies are ultimately 
undertaken to try and optimise a therapy before going to a clinical trial.  They set 
out to determine early safety, feasibility, and efficacy of a therapy.  In the field of 
cell therapy however, there are more fundamental issues related to the use of cells 
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including, optimal cell number, methods of delivery, timing of delivery and 
adequacy of efficacy end point analysis.   
 
To decipher this preclinical complexity Spoel et al carried out a meta-analysis of 
52 published pre-clinical studies involving stem cells therapy in large animal 
(N=888) experiments of ischemic heart disease [277].  The main finding of the 
paper was that cell therapy (includes all cells types delivered pre-clinically) 
improves LVEF by approximately 7.5% and that this increase is due primarily to a 
decrease in ESV [277].  Further cell specific analysis concluded that MSC as 
opposed to other cells provides the most therapeutic benefit when used to treat an 
LAD infarction or chronic total occlusion models.  High cell numbers of more 
than 10
7 
delivered one week post MI also had the most beneficial effect on LVEF 
[277].  Notably, animal species and route of delivery had no effect on therapeutic 
outcomes [277].  Although this meta-analysis study highlights some important 
points it does not negate the need for consensus in pre-clinical studies.  The 
European Society of Cardiology set in place a task force to investigate the role of 
stem cell therapy in the treatment of cardiovascular disease and to suggest what 
further clinical studies were needed in the field.  In 2006 the main consensus of 
the task force was that a dose optimisation study at different time points and via 
different routes would be of great scientific interest.  However they also suggested 
that this would “take the best part of a century” and that a more pragmatic 
approach to demonstrating clinical efficacy was needed [287].  Despite these 
suggestions, not having established adequate pre-clinical data has prevented 
progression in this field and ultimately the efficacy of stem cells in human 
subjects remains unresolved.  Even with complete optimisation of a cell therapy 
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translating to the clinic will pose its own problems.  With pre-clinical studies, 
researchers in order to achieve reproducibility will use animal populations with 
minimal amounts of variability.  Animals will be of similar age, usually young, 
usually of the same sex and species and with no comorbidities.  This differs 
substantially from patient populations presenting at clinic even though they are 
required to meet inclusion criteria.  To overcome this pre-clinical work should be 
carried out on varying animal populations, with a variety of ages and sex mixes.  
In addition, clinical trials must be large enough to overcome population variance 
in order to achieve statistical significance.  Recent trials such as the BAMI 
(NCT01569178) trial which is a multinational, multicenter, randomised open-
label, controlled, parallel-group phase III study has aimed to demonstrate that a 
single intracoronary infusion of autologus bone marrow-derived mononuclear cell 
is safe and reduces all-cause mortality in patients with a left ventricular EF of ≤ 
45% after successful reperfusion for MI.  This study will recruit 3000 patients in 
over 17 European centres and is being funded by European 7 Framework with €7 
million committed in funding.  Results from this pivotal study will conclusively 
establish the efficacy of BM-MNC.  A similar trial design is now required for 
MSC.  However, before undertaking such an extensive and expansive trial, 
preclinical optimisation is essential. 
 
Due to the logistics of cell therapy, such as cell isolation, cell expansion and cell 
delivery additional research is required to fully explore the paracrine mechanisms 
of MSC therapy.  Paracrine delivery would circumvent many of the technical and 
safety issues surrounding cell delivery.  MSC appear to be therapeutically 
beneficial in a large part due to their ability to secrete a wide variety of cytokines 
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and chemokines.  Therefore, cell delivery may not be necessary for cardiac repair 
and regeneration.  If a single paracrine factor or cocktail of factors could be used, 
issues such as what dose and when this dose should be administered arise.  It 
could be speculated that when MSC are delivered in vivo their secretory profile is 
altered by their surrounding environment to provide the necessary local repair 
responses.  MSC thus provide additional repair factors that cannot be supplied by 
an overwhelmed global body response that occurs after MI.  For this concept to be 
established more studies such as those carried out in CRVB, in which the 
secretory profile of EPC under a number of physiological conditions were 
examined and led to the discovery of low dose IGF[164].  The major obstacle 
facing paracrine studies, however, is the difficulty in elucidating in vivo nature of 
cell responses.  Studies that can more accurately mimic the in vivo physiological 
environment of the heart are required.  Progress has been made in the tissue 
engineering field in which 3D engineered tissues are now available.  In particular, 
cardiac cell sheets [288] may provide a more useful physical environment to begin 
to identify the in vivo nature of MSC with regards their secretory profile.  MSC 
cultured in these bioengineered systems would be interacting with ECM proteins 
similar to those present in the myocardium.  As it is an in vitro assay external 
environments can be altered to mimic that of disease states and conditioned media 
experiments can be utilised to determine cytokine release and response profiles. 
Recently research has also begun to focus on exosomes secreted from MSC.  It 
has been suggested that cells communicate and elicit their effects by two main 
mechanisms-through cell to cell contact and through the release of secreted 
factors.  However, most recently membrane secreted vesicles known as exosomes 
or microvesicles have been proposed to mediate the signal transfer between cells 
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required for tissue repair and regeneration. Exosomes were first identified in 1981 
by Trams et al [289].  Exosomes are small vesicles of endocytic origin with a 
diameter of 40-100nm and are excreted by most cells in culture.  They are known 
to contain proteins, lipids, miRNAs and RNA.  Li et al demonstrated that 
exosomes are the main active component of MSC conditioned media [290] by 
illustrating in vivo that the delivery of exosomes significantly reduced infarct size 
in a mouse model of I/R.  Interestingly, the delivery of exosome depleted 
conditioned media had no significant effect on infarct size [290].  Arslan and 
collaborators provide additional evidence of the potent cytoprotective capabilities 
of exosomes by showing reduction in infarct size by 45% in a mouse model of 
I/R.  Analysis at 28 days also revealed that exosome treated animals showed 
significant preserved left ventricular geometry and improved contractile 
performance [291].  In addition to their cytoprotective properties exosomes can 
also influence angiogenesis and do this through direct ligand/receptor interactions 
or by augmenting local cytokines to induce endothelial differentiation, 
proliferation, migration and adhesion [292].  The biological mechanisms by which 
exosomes exert their benefits for the most part remain unknown.  It has been 
suggested the pH plays a role in exosome uptake and that during ischemia 
cadiomyocyte pH is decreased facilitating their integration.   
The main advantages of exosomes over cell therapy are their capacity to sequester 
a large array of factors within small vesicles bypassing the need for whole cell 
delivery.  In addition, their lipid bi-layer prevents rapid degradation by 
endogenous enzymes and other hydrolases [290].  Despite the small size of 
exosomes, microvascular obstruction and the expression of TF needs to assessed 
before IC delivery of these entities is contemplated [293].  Thus exosomes may be 
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a promising therapeutic prospect for future cardiac repair and regeneration.  
However, their mechanism of action needs to be further understood in vitro and 
their efficacy and safety needs to be validated in large animal models of MI before 
translation to the clinic. 
 
The inability of MSC to elicit a more potent benefit in human subjects has been 
attributed to a number of factors including low cell engraftment, the hostile 
ischemic environment and low cell survival.  Accordingly, research has tried to 
find ways to overcome these issues.  Three main methods of ex vivo modification 
have been used to increase MSC regenerative properties, including the pre-
treatment of MSC with growth factors, the pre-conditioning of MSC with external 
factors such as hypoxia and by genetically modifying MSC.  A number of pre-
treatment strategies have been explored, including exposure of MSC to growth 
factors such as IGF-1, FGF, and BMP2 during cell expansion which improved 
their cardiac retention and thus improved the efficacy of MSC transplantation 
[294].  Preconditioning of MSC with SDF-1 induced cell proliferation, decreased 
apoptosis and enhance their survival and engraftment which resulted in the 
reduction in infarct size and significant improvements in cardiac function [295].  
It has also been demonstrated that delivery of MSC pre-treated with heat shock 
protein (Hsp)-70 decreases cardiac fibrosis and apoptosis with associated 
improved left ventricular function when compared to non-treated MSC.  To date 
MSC have been modified to over express tumour necrosis factor receptor[296], 
CXCR4[297], VEGF[298], FGF[299], all of which improved cardiac function and 
recovery after transplantation.  Modification of cells before delivery is a 
promising option of enhancing the effects of MSC for cardiac repair and 
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regeneration for the treatment of MI but methods such as gene transfer and other 
strategies add to the logistical and regulatory burden of getting the cells to 
mainstream clinical practice.   
 
In conclusion, the field of regenerative medicine remains in a nascent state with 
respect to cardiac repair.  Although from a clinical perspective MSC appear to be 
safe it is clear from findings in our study and others [277] that MSC are capable of 
causing adverse events especially in the setting of acute cardiac ischemia.  Future 
studies need to address these issues by utilising either MSC by-products or by 
modifying MSC to lessen the occurrence of these events.  MSC therapy requires 
future validation in large animals models to define optimal cell number and 
delivery strategies before going to phase II/III clinical trials.   
  
156 
 
References 
1. WHO. The top 10 causes of death. 2011; Available from: 
http://www.who.int/mediacentre/factsheets/fs310/en/index.html. 
2. Smolina, K., et al., Determinants of the decline in mortality from acute 
myocardial infarction in England between 2002 and 2010: linked national 
database study. BMJ, 2012. 344: p. d8059. 
3. Jhund, P.S. and J.J. McMurray, Heart failure after acute myocardial 
infarction: a lost battle in the war on heart failure? Circulation, 2008. 
118(20): p. 2019-21. 
4. Zannad, F., N. Agrinier, and F. Alla, Heart failure burden and therapy. 
Europace, 2009. 11: p. 1-9. 
5. Gaziano, T.A., et al., Growing Epidemic of Coronary Heart Disease in 
Low- and Middle-Income Countries. Current Problems in Cardiology, 
2010. 35(2): p. 72-115. 
6. Herrick, J.B., Landmark article (JAMA 1912). Clinical features of sudden 
obstruction of the coronary arteries. By James B. Herrick. JAMA, 1983. 
250(13): p. 1757-65. 
7. Assmann, G., P. Cullen, and H. Schulte, Simple scoring scheme for 
calculating the risk of acute coronary events based on the 10-year follow-
up of the prospective cardiovascular Munster (PROCAM) study. 
Circulation, 2002. 105(3): p. 310-5. 
8. Strong, J.P., A.W. Zieske, and G.T. Malcom, Lipoproteins and 
atherosclerosis in children: an early marriage? Nutr Metab Cardiovasc 
Dis, 2001. 11 Suppl 5: p. 16-22. 
9. Anderson, T.J., et al., Systemic nature of endothelial dysfunction in 
atherosclerosis. Am J Cardiol, 1995. 75(6): p. 71B-74B. 
10. Behrendt, D. and P. Ganz, Endothelial function. From vascular biology to 
clinical applications. Am J Cardiol, 2002. 90(10C): p. 40L-48L. 
11. Williams, K.J. and I. Tabas, The response-to-retention hypothesis of early 
atherogenesis. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 551-61. 
12. Glass, C.K. and J.L. Witztum, Atherosclerosis. the road ahead. Cell, 2001. 
104(4): p. 503-16. 
13. Mestas, J. and K. Ley, Monocyte-endothelial cell interactions in the 
development of atherosclerosis. Trends Cardiovasc Med, 2008. 18(6): p. 
228-32. 
14. Stary, H.C., Natural history and histological classification of 
atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol, 2000. 
20(5): p. 1177-8. 
15. Stary, H.C., et al., A definition of initial, fatty streak, and intermediate 
lesions of atherosclerosis. A report from the Committee on Vascular 
Lesions of the Council on Arteriosclerosis, American Heart Association. 
Circulation, 1994. 89(5): p. 2462-78. 
16. Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. 
Nature, 1993. 362(6423): p. 801-9. 
17. Sakellarios, A.I., et al., Patient-specific computational modeling of 
subendothelial LDL accumulation in a stenosed right coronary artery: 
effect of hemodynamic and biological factors. Am J Physiol Heart Circ 
Physiol, 2013. 304(11): p. H1455-70. 
157 
 
18. Falk, E., P.K. Shah, and V. Fuster, Coronary plaque disruption. 
Circulation, 1995. 92(3): p. 657-71. 
19. Kaplan, Z.S. and S.P. Jackson, The role of platelets in atherothrombosis. 
Hematology Am Soc Hematol Educ Program, 2011. 2011: p. 51-61. 
20. Reimer, K.A. and R.B. Jennings, Wavefront Phenomenon of Myocardial 
Ischemic Cell-Death .2. Transmural Progression of Necrosis within the 
Framework of Ischemic Bed Size (Myocardium at Risk) and Collateral 
Flow. Laboratory Investigation, 1979. 40(6): p. 633-644. 
21. Kloner, R.A., et al., Effect of a transient period of ischemia on myocardial 
cells. II. Fine structure during the first few minutes of reflow. Am J Pathol, 
1974. 74(3): p. 399-422. 
22. Brodie, B.R., et al., Importance of time to reperfusion for 30-day and late 
survival and recovery of left ventricular function after primary angioplasty 
for acute myocardial infarction. J Am Coll Cardiol, 1998. 32(5): p. 1312-
9. 
23. Beltrami, A.P., et al., Evidence that human cardiac myocytes divide after 
myocardial infarction. N Engl J Med, 2001. 344(23): p. 1750-7. 
24. Bergmann, O., et al., Evidence for cardiomyocyte renewal in humans. 
Science, 2009. 324(5923): p. 98-102. 
25. Liehn, E.A., et al., Repair after myocardial infarction, between fantasy 
and reality: the role of chemokines. J Am Coll Cardiol, 2011. 58(23): p. 
2357-62. 
26. Frangogiannis, N.G., C.W. Smith, and M.L. Entman, The inflammatory 
response in myocardial infarction. Cardiovasc Res, 2002. 53(1): p. 31-47. 
27. Nahrendorf, M., M.J. Pittet, and F.K. Swirski, Monocytes: protagonists of 
infarct inflammation and repair after myocardial infarction. Circulation, 
2010. 121(22): p. 2437-45. 
28. Sutton, M.G. and N. Sharpe, Left ventricular remodeling after myocardial 
infarction: pathophysiology and therapy. Circulation, 2000. 101(25): p. 
2981-8. 
29. Urokinase pulmonary embolism trial. Phase 1 results: a cooperative 
study. JAMA, 1970. 214(12): p. 2163-72. 
30. Pizzetti, G., et al., Thrombolytic therapy reduces the incidence of left 
ventricular thrombus after anterior myocardial infarction. Relationship to 
vessel patency and infarct size. Eur Heart J, 1996. 17(3): p. 421-8. 
31. Keeley, E.C., J.A. Boura, and C.L. Grines, Primary angioplasty versus 
intravenous thrombolytic therapy for acute myocardial infarction: a 
quantitative review of 23 randomised trials. Lancet, 2003. 361(9351): p. 
13-20. 
32. Menees, D.S., et al., Door-to-Balloon Time and Mortality among Patients 
Undergoing Primary PCI. New England Journal of Medicine, 2013. 
369(10): p. 901-909. 
33. Verma, S., et al., Fundamentals of reperfusion injury for the clinical 
cardiologist. Circulation, 2002. 105(20): p. 2332-6. 
34. Hori, M. and K. Nishida, Oxidative stress and left ventricular remodelling 
after myocardial infarction. Cardiovasc Res, 2009. 81(3): p. 457-64. 
35. Nakamura, K., et al., Inhibitory effects of antioxidants on neonatal rat 
cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and 
angiotensin II. Circulation, 1998. 98(8): p. 794-9. 
158 
 
36. Frohlich, G.M., et al., Myocardial reperfusion injury: looking beyond 
primary PCI. Eur Heart J, 2013. 34(23): p. 1714-22. 
37. Frishman, W.H., Cardiology patient page. Beta-adrenergic blockers. 
Circulation, 2003. 107(18): p. e117-9. 
38. Pfeffer, M.A., et al., Effect of captopril on mortality and morbidity in 
patients with left ventricular dysfunction after myocardial infarction. 
Results of the survival and ventricular enlargement trial. The SAVE 
Investigators. N Engl J Med, 1992. 327(10): p. 669-77. 
39. trial, B. The effect of intracoronary reinfusion of bone 
marrow-derived mononuclear cells (BM-MNC) on all-cause mortality 
in acute myocardial infarction. 2014; Available from: http://www.bami-fp7.eu/. 
40. Asahara, T., et al., Isolation of putative progenitor endothelial cells for 
angiogenesis. Science, 1997. 275(5302): p. 964-7. 
41. Dowell, J.D., et al., Myocyte and myogenic stem cell transplantation in the 
heart. Cardiovasc Res, 2003. 58(2): p. 336-50. 
42. Tongers, J., D.W. Losordo, and U. Landmesser, Stem and progenitor cell-
based therapy in ischaemic heart disease: promise, uncertainties, and 
challenges. Eur Heart J, 2011. 32(10): p. 1197-206. 
43. Strauer, B.E. and G. Steinhoff, 10 Years of Intracoronary and 
Intramyocardial Bone Marrow Stem Cell Therapy of the Heart. Journal of 
the American College of Cardiology, 2011. 58(11): p. 1095-1104. 
44. Stamm, C., et al., Autologous bone-marrow stem-cell transplantation for 
myocardial regeneration. Lancet, 2003. 361(9351): p. 45-6. 
45. Wollert, K.C., et al., Intracoronary autologous bone-marrow cell transfer 
after myocardial infarction: the BOOST randomised controlled clinical 
trial. Lancet, 2004. 364(9429): p. 141-8. 
46. Schachinger, V., et al., Intracoronary bone marrow-derived progenitor 
cells in acute myocardial infarction. N Engl J Med, 2006. 355(12): p. 
1210-21. 
47. Meyer, G.P., et al., Intracoronary bone marrow cell transfer after 
myocardial infarction: eighteen months' follow-up data from the 
randomized, controlled BOOST (BOne marrOw transfer to enhance ST-
elevation infarct regeneration) trial. Circulation, 2006. 113(10): p. 1287-
94. 
48. Meyer, G.P., et al., Intracoronary bone marrow cell transfer after 
myocardial infarction: 5-year follow-up from the randomized-controlled 
BOOST trial. Eur Heart J, 2009. 30(24): p. 2978-84. 
49. Janssens, S., et al., Autologous bone marrow-derived stem-cell transfer in 
patients with ST-segment elevation myocardial infarction: double-blind, 
randomised controlled trial. Lancet, 2006. 367(9505): p. 113-21. 
50. Lunde, K., et al., Anterior myocardial infarction with acute percutaneous 
coronary intervention and intracoronary injection of autologous 
mononuclear bone marrow cells: safety, clinical outcome, and serial 
changes in left ventricular function during 12-months' follow-up. J Am 
Coll Cardiol, 2008. 51(6): p. 674-6. 
51. Beltrami, A.P., et al., Adult cardiac stem cells are multipotent and support 
myocardial regeneration. Cell, 2003. 114(6): p. 763-76. 
159 
 
52. Tateishi, K., et al., Clonally amplified cardiac stem cells are regulated by 
Sca-1 signaling for efficient cardiovascular regeneration. J Cell Sci, 2007. 
120(Pt 10): p. 1791-800. 
53. Chugh, A.R., et al., Administration of cardiac stem cells in patients with 
ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim 
analysis of myocardial function and viability by magnetic resonance. 
Circulation, 2012. 126(11 Suppl 1): p. S54-64. 
54. Bolli, R., et al., Cardiac stem cells in patients with ischaemic 
cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. 
Lancet, 2011. 378(9806): p. 1847-57. 
55. Makkar, R.R., et al., Intracoronary cardiosphere-derived cells for heart 
regeneration after myocardial infarction (CADUCEUS): a prospective, 
randomised phase 1 trial. Lancet, 2012. 379(9819): p. 895-904. 
56. Friedenstein, A.J., S. Piatetzky, II, and K.V. Petrakova, Osteogenesis in 
transplants of bone marrow cells. J Embryol Exp Morphol, 1966. 16(3): p. 
381-90. 
57. Friedenstein, A.J., et al., Stromal cells responsible for transferring the 
microenvironment of the hemopoietic tissues. Cloning in vitro and 
retransplantation in vivo. Transplantation, 1974. 17(4): p. 331-40. 
58. Pittenger, M.F., et al., Multilineage potential of adult human mesenchymal 
stem cells. Science, 1999. 284(5411): p. 143-7. 
59. Caplan, A.I., Mesenchymal stem cells. J Orthop Res, 1991. 9(5): p. 641-50. 
60. da Silva Meirelles, L., P.C. Chagastelles, and N.B. Nardi, Mesenchymal 
stem cells reside in virtually all post-natal organs and tissues. J Cell Sci, 
2006. 119(Pt 11): p. 2204-13. 
61. Javazon, E.H., et al., Rat marrow stromal cells are more sensitive to 
plating density and expand more rapidly from single-cell-derived colonies 
than human marrow stromal cells. Stem Cells, 2001. 19(3): p. 219-25. 
62. Pak, H.N., et al., Mesenchymal stem cell injection induces cardiac nerve 
sprouting and increased tenascin expression in a Swine model of 
myocardial infarction. J Cardiovasc Electrophysiol, 2003. 14(8): p. 841-8. 
63. Bartholomew, A., et al., Baboon mesenchymal stem cells can be 
genetically modified to secrete human erythropoietin in vivo. Hum Gene 
Ther, 2001. 12(12): p. 1527-41. 
64. Phinney, D.G., et al., Plastic adherent stromal cells from the bone marrow 
of commonly used strains of inbred mice: variations in yield, growth, and 
differentiation. J Cell Biochem, 1999. 72(4): p. 570-85. 
65. Kadiyala, S., et al., Culture expanded canine mesenchymal stem cells 
possess osteochondrogenic potential in vivo and in vitro. Cell Transplant, 
1997. 6(2): p. 125-34. 
66. Awad, H.A., et al., Autologous mesenchymal stem cell-mediated repair of 
tendon. Tissue Eng, 1999. 5(3): p. 267-77. 
67. Colter, D.C., et al., Rapid expansion of recycling stem cells in cultures of 
plastic-adherent cells from human bone marrow. Proc Natl Acad Sci U S 
A, 2000. 97(7): p. 3213-8. 
68. Wagner, W., et al., Replicative Senescence of Mesenchymal Stem Cells: A 
Continuous and Organized Process. PLoS One, 2008. 3(5): p. e2213. 
69. Rosenzweig, A., Cardiac cell therapy--mixed results from mixed cells. N 
Engl J Med, 2006. 355(12): p. 1274-7. 
160 
 
70. Dominici, M., et al., Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International Society for Cellular Therapy 
position statement. Cytotherapy, 2006. 8(4): p. 315-7. 
71. Makino, S., et al., Cardiomyocytes can be generated from marrow stromal 
cells in vitro. J Clin Invest, 1999. 103(5): p. 697-705. 
72. Saito, T., et al., Myogenic Expression of Mesenchymal Stem Cells within 
Myotubes of mdx Mice in Vitro and in Vivo. Tissue Eng, 1995. 1(4): p. 
327-43. 
73. Toma, C., et al., Human mesenchymal stem cells differentiate to a 
cardiomyocyte phenotype in the adult murine heart. Circulation, 2002. 
105(1): p. 93-8. 
74. Oswald, J., et al., Mesenchymal stem cells can be differentiated into 
endothelial cells in vitro. Stem Cells, 2004. 22(3): p. 377-84. 
75. Jiang, Y., et al., Pluripotency of mesenchymal stem cells derived from 
adult marrow. Nature, 2002. 418(6893): p. 41-9. 
76. Devine, S.M., et al., Mesenchymal stem cells are capable of homing to the 
bone marrow of non-human primates following systemic infusion. Exp 
Hematol, 2001. 29(2): p. 244-55. 
77. Wang, L., et al., Ischemic cerebral tissue and MCP-1 enhance rat bone 
marrow stromal cell migration in interface culture. Exp Hematol, 2002. 
30(7): p. 831-6. 
78. Barbash, I.M., et al., Systemic delivery of bone marrow-derived 
mesenchymal stem cells to the infarcted myocardium: feasibility, cell 
migration, and body distribution. Circulation, 2003. 108(7): p. 863-8. 
79. Orlic, D., et al., Bone marrow cells regenerate infarcted myocardium. 
Nature, 2001. 410(6829): p. 701-705. 
80. Shake, J.G., et al., Mesenchymal stem cell implantation in a swine 
myocardial infarct model: engraftment and functional effects. Ann Thorac 
Surg, 2002. 73(6): p. 1919-25; discussion 1926. 
81. Silva, G.V., et al., Mesenchymal stem cells differentiate into an endothelial 
phenotype, enhance vascular density, and improve heart function in a 
canine chronic ischemia model. Circulation, 2005. 111(2): p. 150-6. 
82. Quevedo, H.C., et al., Allogeneic mesenchymal stem cells restore cardiac 
function in chronic ischemic cardiomyopathy via trilineage differentiating 
capacity. Proc Natl Acad Sci U S A, 2009. 106(33): p. 14022-7. 
83. Gnecchi, M., et al., Paracrine mechanisms in adult stem cell signaling and 
therapy. Circ Res, 2008. 103(11): p. 1204-19. 
84. Qian, Q., et al., 5-Azacytidine induces cardiac differentiation of human 
umbilical cord-derived mesenchymal stem cells by activating extracellular 
regulated kinase. Stem Cells Dev, 2012. 21(1): p. 67-75. 
85. Koninckx, R., et al., Human bone marrow stem cells co-cultured with 
neonatal rat cardiomyocytes display limited cardiomyogenic plasticity. 
Cytotherapy, 2009. 11(6): p. 778-792. 
86. Roura, S., et al., Exposure to cardiomyogenic stimuli fails to 
transdifferentiate human umbilical cord blood-derived mesenchymal stem 
cells. Basic Res Cardiol, 2010. 105(3): p. 419-30. 
87. Kinnaird, T., et al., Marrow-derived stromal cells express genes encoding 
a broad spectrum of arteriogenic cytokines and promote in vitro and in 
vivo arteriogenesis through paracrine mechanisms. Circ Res, 2004. 94(5): 
p. 678-85. 
161 
 
88. Chen, M.Y., et al., Endothelial differentiation of Wharton's jelly-derived 
mesenchymal stem cells in comparison with bone marrow-derived 
mesenchymal stem cells. Exp Hematol, 2009. 37(5): p. 629-40. 
89. Duffy, G.P., et al., Bone marrow-derived mesenchymal stem cells promote 
angiogenic processes in a time- and dose-dependent manner in vitro. 
Tissue Eng Part A, 2009. 15(9): p. 2459-70. 
90. Haynesworth, S.E., M.A. Baber, and A.I. Caplan, Cytokine expression by 
human marrow-derived mesenchymal progenitor cells in vitro: Effects of 
dexamethasone and IL-1 alpha. Journal of Cellular Physiology, 1996. 
166(3): p. 585-592. 
91. Caplan, A.I. and D. Correa, The MSC: an injury drugstore. Cell Stem Cell, 
2011. 9(1): p. 11-5. 
92. Meirelles Lda, S., et al., Mechanisms involved in the therapeutic 
properties of mesenchymal stem cells. Cytokine Growth Factor Rev, 2009. 
20(5-6): p. 419-27. 
93. Hu, X.Y., et al., Transplantation of hypoxia-preconditioned mesenchymal 
stem cells improves infarcted heart function via enhanced survival of 
implanted cells and angiogenesis. Journal of Thoracic and Cardiovascular 
Surgery, 2008. 135(4): p. 799-808. 
94. O'Sullivan, J.F., et al., Potent long-term cardioprotective effects of single 
low-dose insulin-like growth factor-1 treatment postmyocardial infarction. 
Circ Cardiovasc Interv, 2011. 4(4): p. 327-35. 
95. Togel, F., et al., Vasculotropic, paracrine actions of infused mesenchymal 
stem cells are important to the recovery from acute kidney injury. Am J 
Physiol Renal Physiol, 2007. 292(5): p. F1626-35. 
96. Gnecchi, M., et al., Evidence supporting paracrine hypothesis for Akt-
modified mesenchymal stem cell-mediated cardiac protection and 
functional improvement. Faseb Journal, 2006. 20(6): p. 661-669. 
97. Nguyen, B.K., et al., Improved function and myocardial repair of infarcted 
heart by intracoronary injection of mesenchymal stem cell-derived growth 
factors. J Cardiovasc Transl Res, 2010. 3(5): p. 547-58. 
98. Gnecchi, M., et al., Paracrine Mechanisms in Adult Stem Cell Signaling 
and Therapy. Circulation Research, 2008. 103(11): p. 1204-1219. 
99. Matsumoto, R., et al., Vascular endothelial growth factor-expressing 
mesenchymal stem cell transplantation for the treatment of acute 
myocardial infarction. Arterioscler Thromb Vasc Biol, 2005. 25(6): p. 
1168-73. 
100. Frangogiannis, N.G., Regulation of the inflammatory response in cardiac 
repair. Circ Res, 2012. 110(1): p. 159-73. 
101. Murphy, M.B., K. Moncivais, and A.I. Caplan, Mesenchymal stem cells: 
environmentally responsive therapeutics for regenerative medicine. Exp 
Mol Med, 2013. 45: p. e54. 
102. Du, Y.Y., et al., Immuno-inflammatory regulation effect of mesenchymal 
stem cell transplantation in a rat model of myocardial infarction. 
Cytotherapy, 2008. 10(5): p. 469-78. 
103. Van Linthout, S., et al., Mesenchymal stem cells improve murine acute 
coxsackievirus B3-induced myocarditis. Eur Heart J, 2011. 32(17): p. 
2168-78. 
162 
 
104. Van Linthout, S., et al., Mesenchymal stem cells improve murine acute 
coxsackievirus B3-induced myocarditis. European Heart Journal, 2011. 
32(17): p. 2168-2178. 
105. Lozito, T.P. and R.S. Tuan, Mesenchymal Stem Cells Inhibit Both 
Endogenous and Exogenous MMPs via Secreted TIMPs. Journal of 
Cellular Physiology, 2011. 226(2): p. 385-396. 
106. Biswas, S., et al., Relation of anti- to pro-inflammatory cytokine ratios 
with acute myocardial infarction. Korean J Intern Med, 2010. 25(1): p. 44-
50. 
107. Li, L., et al., Paracrine action mediate the antifibrotic effect of 
transplanted mesenchymal stem cells in a rat model of global heart 
failure. Mol Biol Rep, 2009. 36(4): p. 725-31. 
108. Schievenbusch, S., et al., Profiling of anti-fibrotic signaling by hepatocyte 
growth factor in renal fibroblasts. Biochem Biophys Res Commun, 2009. 
385(1): p. 55-61. 
109. Mou, S., et al., Hepatocyte growth factor suppresses transforming growth 
factor-beta-1 and type III collagen in human primary renal fibroblasts. 
Kaohsiung J Med Sci, 2009. 25(11): p. 577-87. 
110. Dixon, J.A., et al., Mesenchymal cell transplantation and myocardial 
remodeling after myocardial infarction. Circulation, 2009. 120(11 Suppl): 
p. S220-9. 
111. Mias, C., et al., Mesenchymal Stem Cells Promote Matrix 
Metalloproteinase Secretion by Cardiac Fibroblasts and Reduce Cardiac 
Ventricular Fibrosis After Myocardial Infarction. Stem Cells, 2009. 
27(11): p. 2734-2743. 
112. Ohnishi, S., et al., Mesenchymal stem cells attenuate cardiac fibroblast 
proliferation and collagen synthesis through paracrine actions. Febs 
Letters, 2007. 581(21): p. 3961-3966. 
113. Li, L.L., et al., Paracrine action mediate the antifibrotic effect of 
transplanted mesenchymal stem cells in a rat model of global heart 
failure. Molecular Biology Reports, 2009. 36(4): p. 725-731. 
114. Guo, J., et al., Anti-inflammation role for mesenchymal stem cells 
transplantation in myocardial infarction. Inflammation, 2007. 30(3-4): p. 
97-104. 
115. Griffin, M.D., et al., Anti-donor immune responses elicited by allogeneic 
mesenchymal stem cells: what have we learned so far? Immunol Cell Biol, 
2013. 91(1): p. 40-51. 
116. Huang, X.P., et al., Differentiation of Allogeneic Mesenchymal Stem Cells 
Induces Immunogenicity and Limits Their Long-Term Benefits for 
Myocardial Repair. Circulation, 2010. 122(23): p. 2419-2429. 
117. Poncelet, A.J., et al., Intracardiac allogeneic mesenchymal stem cell 
transplantation elicits neo-angiogenesis in a fully immunocompetent 
ischaemic swine model. European Journal of Cardio-Thoracic Surgery, 
2010. 38(6): p. 781-787. 
118. Hare, J.M., et al., Comparison of allogeneic vs autologous bone marrow-
derived mesenchymal stem cells delivered by transendocardial injection in 
patients with ischemic cardiomyopathy: the POSEIDON randomized trial. 
JAMA, 2012. 308(22): p. 2369-79. 
163 
 
119. Freyman, T., et al., A quantitative, randomized study evaluating three 
methods of mesenchymal stem cell delivery following myocardial 
infarction. Eur Heart J, 2006. 27(9): p. 1114-22. 
120. Kraitchman, D.L., et al., Dynamic imaging of allogeneic mesenchymal 
stem cells trafficking to myocardial infarction. Circulation, 2005. 112(10): 
p. 1451-61. 
121. Amado, L.C., et al., Cardiac repair with intramyocardial injection of 
allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl 
Acad Sci U S A, 2005. 102(32): p. 11474-9. 
122. Hatzistergos, K.E., et al., Bone marrow mesenchymal stem cells stimulate 
cardiac stem cell proliferation and differentiation. Circ Res, 2010. 107(7): 
p. 913-22. 
123. Schuleri, K.H., et al., The adult Gottingen minipig as a model for chronic 
heart failure after myocardial infarction: focus on cardiovascular imaging 
and regenerative therapies. Comp Med, 2008. 58(6): p. 568-79. 
124. Williams, A.R., et al., Durable scar size reduction due to allogeneic 
mesenchymal stem cell therapy regulates whole-chamber remodeling. J 
Am Heart Assoc, 2013. 2(3): p. e000140. 
125. Hashemi, S.M., et al., A placebo controlled, dose-ranging, safety study of 
allogenic mesenchymal stem cells injected by endomyocardial delivery 
after an acute myocardial infarction. Eur Heart J, 2008. 29(2): p. 251-9. 
126. Suzuki, K., et al., Role of interleukin-1 beta in acute inflammation and 
graft death after cell transplantation to the heart. Circulation, 2004. 
110(11): p. Ii219-Ii224. 
127. Fukushima, S., et al., Choice of Cell-Delivery Route for Skeletal Myoblast 
Transplantation for Treating Post-Infarction Chronic Heart Failure in 
Rat. PLoS One, 2008. 3(8). 
128. Fukushima, S., et al., Choice of cell-delivery route for skeletal myoblast 
transplantation for treating post-infarction chronic heart failure in rat. 
PLoS One, 2008. 3(8): p. e3071. 
129. van der Spoel, T.I., et al., Transendocardial cell injection is not superior 
to intracoronary infusion in a porcine model of ischaemic 
cardiomyopathy: a study on delivery efficiency. J Cell Mol Med, 2012. 
16(11): p. 2768-76. 
130. Van der Spoel, T.I., et al., Transendocardial Cell Injection is Not Superior 
to Intracoronary Infusion in a Porcine Model of Chronic Ischemic Heart 
Disease: A Randomized Study on Efficiency Using Nuclear Imaging. 
Circulation, 2011. 124(21). 
131. Lim, S.Y., et al., The effects of mesenchymal stem cells transduced with 
Akt in a porcine myocardial infarction model. Cardiovasc Res, 2006. 
70(3): p. 530-42. 
132. Houtgraaf, J.H., et al., Intracoronary infusion of allogeneic mesenchymal 
precursor cells directly after experimental acute myocardial infarction 
reduces infarct size, abrogates adverse remodeling, and improves cardiac 
function. Circ Res, 2013. 113(2): p. 153-66. 
133. Valina, C., et al., Intracoronary administration of autologous adipose 
tissue-derived stem cells improves left ventricular function, perfusion, and 
remodelling after acute myocardial infarction. Eur Heart J, 2007. 28(21): 
p. 2667-77. 
164 
 
134. Yang, Z.J., et al., Experimental study of bone marrow-derived 
mesenchymal stem cells combined with hepatocyte growth factor 
transplantation via noninfarct-relative artery in acute myocardial 
infarction. Gene Ther, 2006. 13(22): p. 1564-8. 
135. Yang, Z.J., et al., Neovascularization and cardiomyocytes regeneration in 
acute myocardial infarction after bone marrow stromal cell 
transplantation: comparison of infarct-relative and noninfarct-relative 
arterial approaches in swine. Clin Chim Acta, 2007. 381(2): p. 114-8. 
136. Vulliet, P.R., et al., Intra-coronary arterial injection of mesenchymal 
stromal cells and microinfarction in dogs. Lancet, 2004. 363(9411): p. 
783-4. 
137. Grieve, S.M., et al., Microvascular obstruction by intracoronary delivery 
of mesenchymal stem cells and quantification of resulting myocardial 
infarction by cardiac magnetic resonance. Circ Heart Fail, 2010. 3(3): p. 
e5-6. 
138. Llano, R., et al., Intracoronary Delivery of Mesenchymal Stem Cells at 
High Flow Rates After Myocardial Infarction Improves Distal Coronary 
Blood Flow and Decreases Mortality in Pigs. Catheterization and 
Cardiovascular Interventions, 2009. 73(2): p. 251-257. 
139. Bach, R.R., Initiation of coagulation by tissue factor. CRC Crit Rev 
Biochem, 1988. 23(4): p. 339-68. 
140. Nemerson, Y., Tissue factor and hemostasis. Blood, 1988. 71(1): p. 1-8. 
141. Osterud, B. and E. Bjorklid, Sources of tissue factor. Semin Thromb 
Hemost, 2006. 32(1): p. 11-23. 
142. Key, N.S. and N. Mackman, Tissue factor and its measurement in whole 
blood, plasma, and microparticles. Semin Thromb Hemost, 2010. 36(8): 
p. 865-75. 
143. Zwicker, J.I., et al., Tissue factor-bearing microparticles and thrombus 
formation. Arterioscler Thromb Vasc Biol, 2011. 31(4): p. 728-33. 
144. Chen, T.S., et al., Mesenchymal stem cell secretes microparticles enriched 
in pre-microRNAs. Nucleic Acids Res, 2010. 38(1): p. 215-24. 
145. Chu, A.J., Tissue factor, blood coagulation, and beyond: an overview. Int 
J Inflam, 2011. 2011: p. 367284. 
146. Toomey, J.R., et al., Targeted disruption of the murine tissue factor gene 
results in embryonic lethality. Blood, 1996. 88(5): p. 1583-7. 
147. Chen, J., et al., Tissue factor as a link between wounding and tissue repair. 
Diabetes, 2005. 54(7): p. 2143-54. 
148. Xu, Z., et al., Factor VII deficiency impairs cutaneous wound healing in 
mice. Mol Med, 2010. 16(5-6): p. 167-76. 
149. Versteeg, H.H., et al., Tissue factor and cancer metastasis: the role of 
intracellular and extracellular signaling pathways. Mol Med, 2004. 10(1-
6): p. 6-11. 
150. Pittenger, M.F., Mesenchymal stem cells from adult bone marrow. 
Methods Mol Biol, 2008. 449: p. 27-44. 
151. Barry, F.P. and J.M. Murphy, Mesenchymal stem cells: clinical 
applications and biological characterization. Int J Biochem Cell Biol, 
2004. 36(4): p. 568-84. 
152. English, K., et al., IFN-gamma and TNF-alpha differentially regulate 
immunomodulation by murine mesenchymal stem cells. Immunol Lett, 
2007. 110(2): p. 91-100. 
165 
 
153. Klein, H.H., et al., Temporal and spatial development of infarcts in 
porcine hearts. Basic Res Cardiol, 1984. 79(4): p. 440-7. 
154. Doyle, B., et al., Progenitor cell therapy in a porcine acute myocardial 
infarction model induces cardiac hypertrophy, mediated by paracrine 
secretion of cardiotrophic factors including TGFbeta1. Stem Cells Dev, 
2008. 17(5): p. 941-51. 
155. De Luca, G., et al., Effects of increasing doses of intracoronary adenosine 
on the assessment of fractional flow reserve. JACC Cardiovasc Interv, 
2011. 4(10): p. 1079-84. 
156. Gould, K.L. and K. Lipscomb, Effects of coronary stenoses on coronary 
flow reserve and resistance. Am J Cardiol, 1974. 34(1): p. 48-55. 
157. MacCarthy, P., et al., Pressure-derived measurement of coronary flow 
reserve. J Am Coll Cardiol, 2005. 45(2): p. 216-20. 
158. Pijls, N.H., et al., Coronary thermodilution to assess flow reserve: 
validation in humans. Circulation, 2002. 105(21): p. 2482-6. 
159. Basic Res CardiolMacCarthy, P., et al., Pressure-derived measurement of 
coronary flow reserve. J Am Coll Cardiol, 2005. 45(2): p. 216-20. 
160. Pijls, N.H. and B. De Bruyne, Coronary pressure measurement and 
fractional flow reserve. Heart, 1998. 80(6): p. 539-42. 
161. Leone, A.M., et al., Maximal hyperemia in the assessment of fractional 
flow reserve: intracoronary adenosine versus intracoronary sodium 
nitroprusside versus intravenous adenosine: the NASCI (Nitroprussiato 
versus Adenosina nelle Stenosi Coronariche Intermedie) study. JACC 
Cardiovasc Interv, 2012. 5(4): p. 402-8. 
162. Olsson, R.A., et al., Evidence for an adenosine receptor on the surface of 
dog coronary myocytes. Circ Res, 1976. 39(1): p. 93-8. 
163. Klinger, M., M. Freissmuth, and C. Nanoff, Adenosine receptors: G 
protein-mediated signalling and the role of accessory proteins. Cell 
Signal, 2002. 14(2): p. 99-108. 
164. Hynes, B., et al., Potent endothelial progenitor cell-conditioned media-
related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-
myocardial infarction are mediated by insulin-like growth factor-1. Eur 
Heart J, 2013. 34(10): p. 782-9. 
165. Mandal, S.K., U.R. Pendurthi, and L.V. Rao, Cellular localization and 
trafficking of tissue factor. Blood, 2006. 107(12): p. 4746-53. 
166. Savage, B., E. Saldivar, and Z.M. Ruggeri, Initiation of platelet adhesion 
by arrest onto fibrinogen or translocation on von Willebrand factor. Cell, 
1996. 84(2): p. 289-97. 
167. Zwaginga, J.J., et al., Flow-based assays for global assessment of 
hemostasis. Part 1: Biorheologic considerations. J Thromb Haemost, 
2006. 4(11): p. 2486-7. 
168. Stepp, D.W., Y. Nishikawa, and W.M. Chilian, Regulation of shear stress 
in the canine coronary microcirculation. Circulation, 1999. 100(14): p. 
1555-61. 
169. Weaver, M.E., et al., A quantitative study of the anatomy and distribution 
of coronary arteries in swine in comparison with other animals and man. 
Cardiovasc Res, 1986. 20(12): p. 907-17. 
170. Zaragoza, C., et al., Animal models of cardiovascular diseases. J Biomed 
Biotechnol, 2011. 2011: p. 497841. 
166 
 
171. Dixon, J.A. and F.G. Spinale, Large Animal Models of Heart Failure A 
Critical Link in the Translation of Basic Science to Clinical Practice. 
Circulation-Heart Failure, 2009. 2(3): p. 262-271. 
172. Kim, W.G., et al., Comparison of myocardial infarction with sequential 
ligation of the left anterior descending artery and its diagonal branch in 
dogs and sheep. International Journal of Artificial Organs, 2003. 26(4): p. 
351-7. 
173. Buckley, N.M., et al., Age-Related Cardiovascular Effects of 
Catecholamines in Anesthetized Piglets. Circulation Research, 1979. 
45(2): p. 282-292. 
174. O'Sullivan, J.F., et al., Multidetector computed tomography accurately 
defines infarct size, but not microvascular obstruction after myocardial 
infarction. J Am Coll Cardiol, 2013. 61(2): p. 208-10. 
175. Theroux, P., et al., Coronary arterial reperfusion. III. Early and late 
effects on regional myocardial function and dimensions in conscious dogs. 
Am J Cardiol, 1976. 38(5): p. 599-606. 
176. Verdouw, P.D., et al., Animal models in the study of myocardial ischaemia 
and ischaemic syndromes. Cardiovascular Research, 1998. 39(1): p. 121-
135. 
177. McCall, F.C., et al., Myocardial infarction and intramyocardial injection 
models in swine. Nature Protocols, 2012. 7(8): p. 1479-1496. 
178. Suzuki, Y., et al., In vivo porcine model of reperfused myocardial 
infarction: in situ double staining to measure precise infarct area/area at 
risk. Catheter Cardiovasc Interv, 2008. 71(1): p. 100-7. 
179. Garcia-Dorado, D., Myocardial reperfusion injury: a new view. 
Cardiovascular Research, 2004. 61(3): p. 363-4. 
180. Gyongyosi, M., et al., Serial noninvasive in vivo positron emission 
tomographic tracking of percutaneously intramyocardially injected 
autologous porcine mesenchymal stem cells modified for transgene 
reporter gene expression. Circ Cardiovasc Imaging, 2008. 1(2): p. 94-103. 
181. Jiang, Y., et al., HO-1 gene overexpression enhances the beneficial effects 
of superparamagnetic iron oxide labeled bone marrow stromal cells 
transplantation in swine hearts underwent ischemia/reperfusion: an MRI 
study. Basic Res Cardiol, 2010. 105(3): p. 431-42. 
182. Schneider, C., et al., Transplantation of bone marrow-derived stem cells 
improves myocardial diastolic function: strain rate imaging in a model of 
hibernating myocardium. J Am Soc Echocardiogr, 2009. 22(10): p. 1180-
9. 
183. Wang, X., et al., Stem cells for myocardial repair with use of a 
transarterial catheter. Circulation, 2009. 120(11 Suppl): p. S238-46. 
184. Llano, R., et al., Intracoronary delivery of mesenchymal stem cells at high 
flow rates after myocardial infarction improves distal coronary blood flow 
and decreases mortality in pigs. Catheter Cardiovasc Interv, 2009. 73(2): 
p. 251-7. 
185. Perin, E.C., et al., Comparison of intracoronary and transendocardial 
delivery of allogeneic mesenchymal cells in a canine model of acute 
myocardial infarction. J Mol Cell Cardiol, 2008. 44(3): p. 486-95. 
186. Tomita, S., et al., Improved heart function with myogenesis and 
angiogenesis after autologous porcine bone marrow stromal cell 
transplantation. J Thorac Cardiovasc Surg, 2002. 123(6): p. 1132-40. 
167 
 
187. Qi, C.M., et al., Transplantation of magnetically labeled mesenchymal 
stem cells improves cardiac function in a swine myocardial infarction 
model. Chin Med J (Engl), 2008. 121(6): p. 544-50. 
188. Amado, L.C., et al., Multimodality noninvasive imaging demonstrates in 
vivo cardiac regeneration after mesenchymal stem cell therapy. J Am Coll 
Cardiol, 2006. 48(10): p. 2116-24. 
189. Schuleri, K.H., et al., Early improvement in cardiac tissue perfusion due to 
mesenchymal stem cells. Am J Physiol Heart Circ Physiol, 2008. 294(5): 
p. H2002-11. 
190. Price, M.J., et al., Intravenous mesenchymal stem cell therapy early after 
reperfused acute myocardial infarction improves left ventricular function 
and alters electrophysiologic properties. Int J Cardiol, 2006. 111(2): p. 
231-9. 
191. Halkos, M.E., et al., Intravenous infusion of mesenchymal stem cells 
enhances regional perfusion and improves ventricular function in a 
porcine model of myocardial infarction. Basic Res Cardiol, 2008. 103(6): 
p. 525-36. 
192. Hamamoto, H., et al., Allogeneic mesenchymal precursor cell therapy to 
limit remodeling after myocardial infarction: the effect of cell dosage. Ann 
Thorac Surg, 2009. 87(3): p. 794-801. 
193. Qian, H., et al., Intracoronary delivery of autologous bone marrow 
mononuclear cells radiolabeled by 18F-fluoro-deoxy-glucose: tissue 
distribution and impact on post-infarct swine hearts. J Cell Biochem, 
2007. 102(1): p. 64-74. 
194. Li, N., et al., Comparison of the labeling efficiency of BrdU, DiI and FISH 
labeling techniques in bone marrow stromal cells. Brain Res, 2008. 1215: 
p. 11-9. 
195. Hamamoto, H., et al., Allogeneic Mesenchymal Precursor Cell Therapy to 
Limit Remodeling After Myocardial Infarction: The Effect of Cell Dosage. 
Annals of Thoracic Surgery, 2009. 87(3): p. 794-802. 
196. Meluzin, J., et al., Autologous transplantation of mononuclear bone 
marrow cells in patients with acute myocardial infarction: the effect of the 
dose of transplanted cells on myocardial function. Am Heart J, 2006. 
152(5): p. 975 e9-15. 
197. Chen, S.L., et al., Effect on left ventricular function of intracoronary 
transplantation of autologous bone marrow mesenchymal stem cell in 
patients with acute myocardial infarction. Am J Cardiol, 2004. 94(1): p. 
92-5. 
198. Freyman, T., et al., A quantitative, randomized study evaluating three 
methods of mesenchymal stem cell delivery following myocardial 
infarction. Eur Heart J, 2006. 27(9): p. 1114-1122. 
199. Penn, E.C., et al., Comparison of intracoronary and transendocardial 
delivery of allogeneic mesenchymal cells in a canine model of acute 
myocardial infarction. Journal of Molecular and Cellular Cardiology, 
2008. 44(3): p. 486-495. 
200. Houtgraaf, J.H., et al., Intracoronary Infusion of Allogeneic Mesenchymal 
Precursor Cells Directly After Experimental Acute Myocardial Infarction 
Reduces Infarct Size, Abrogates Adverse Remodeling, and Improves 
Cardiac Function. Circulation Research, 2013. 113(2): p. 153-166. 
168 
 
201. Furlani, D., et al., Is the intravascular administration of mesenchymal stem 
cells safe? Mesenchymal stem cells and intravital microscopy. 
Microvascular Research, 2009. 77(3): p. 370-376. 
202. Fischer, U.M., et al., Pulmonary Passage is a Major Obstacle for 
Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect. Stem 
Cells and Development, 2009. 18(5): p. 683-691. 
203. Toma, C., et al., Fate Of Culture-Expanded Mesenchymal Stem Cells in 
The Microvasculature In Vivo Observations of Cell Kinetics. Circulation 
Research, 2009. 104(3): p. 398-U204. 
204. Ankrum, J. and J.M. Karp, Mesenchymal stem cell therapy: Two steps 
forward, one step back. Trends in Molecular Medicine, 2010. 16(5): p. 
203-209. 
205. Gao, J., et al., The dynamic in vivo distribution of bone marrow-derived 
mesenchymal stem cells after infusion. Cells Tissues Organs, 2001. 169(1): 
p. 12-20. 
206. Schrepfer, S., et al., Stem cell transplantation: The lung barrier. 
Transplantation Proceedings, 2007. 39(2): p. 573-576. 
207. Schrepfer, S., et al., Stem cell transplantation: The lung barrier. 
Transplant Proc, 2007. 39(2): p. 573-576. 
208. Savage, B., F. Almus-Jacobs, and Z.M. Ruggeri, Specific synergy of 
multiple substrate-receptor interactions in platelet thrombus formation 
under flow. Cell, 1998. 94(5): p. 657-66. 
209. Bonderman, D., et al., Coronary no-reflow is caused by shedding of active 
tissue factor from dissected atherosclerotic plaque. Blood, 2002. 99(8): p. 
2794-800. 
210. Kretz, C.A., N. Vaezzadeh, and P.L. Gross, Tissue factor and thrombosis 
models. Arterioscler Thromb Vasc Biol, 2010. 30(5): p. 900-8. 
211. Stephenne, X., et al., Bivalirudin in combination with heparin to control 
mesenchymal cell procoagulant activity. PLoS One, 2012. 7(8): p. e42819. 
212. Lupu, C., et al., Cellular effects of heparin on the production and release 
of tissue factor pathway inhibitor in human endothelial cells in culture. 
Arteriosclerosis Thrombosis and Vascular Biology, 1999. 19(9): p. 2251-
2262. 
213. Rumbaut, R.E. and P. Thiagarajan, in Platelet-Vessel Wall Interactions in 
Hemostasis and Thrombosis. 2010: San Rafael (CA). 
214. Moll, G., et al., Are therapeutic human mesenchymal stromal cells 
compatible with human blood? Stem Cells, 2012. 30(7): p. 1565-74. 
215. Tatsumi, K., et al., Tissue factor triggers procoagulation in transplanted 
mesenchymal stem cells leading to thromboembolism. Biochemical and 
Biophysical Research Communications, 2013. 431(2): p. 203-209. 
216. Aberg, M. and A. Siegbahn, Tissue factor non-coagulant signaling - 
molecular mechanisms and biological consequences with a focus on cell 
migration and apoptosis. J Thromb Haemost, 2013. 11(5): p. 817-25. 
217. Prockop, D.J., Marrow stromal cells as stem cells for continual renewal of 
nonhematopoietic tissues and as potential vectors for gene therapy. 
Journal of Cellular Biochemistry, 1998: p. 284-285. 
218. Bruder, S.P., D.J. Fink, and A.I. Caplan, Mesenchymal Stem-Cells in in 
Bone-Development, Bone Repair, and Skeletal Regeneration Therapy. 
Journal of Cellular Biochemistry, 1994. 56(3): p. 283-294. 
169 
 
219. Orlic, D., et al., Bone marrow cells regenerate infarcted myocardium. 
Nature, 2001. 410(6829): p. 701-5. 
220. Gyongyosi, M., et al., Delayed Recovery of Myocardial Blood Flow After 
Intracoronary Stem Cell Administration. Stem Cell Reviews and Reports, 
2011. 7(3): p. 616-623. 
221. Jaffe, R., et al., Microvascular obstruction and the no-reflow phenomenon 
after percutaneous coronary intervention. Circulation, 2008. 117(24): p. 
3152-6. 
222. Kloner, R.A., C.E. Ganote, and R.B. Jennings, The "no-reflow" 
phenomenon after temporary coronary occlusion in the dog. J Clin Invest, 
1974. 54(6): p. 1496-508. 
223. Rezkalla, S.H. and R.A. Kloner, Coronary No-Reflow Phenomenon: From 
the Experimental Laboratory to the Cardiac Catheterization Laboratory. 
Catheterization and Cardiovascular Interventions, 2008. 72(7): p. 950-957. 
224. Eeckhout, E. and M.J. Kern, The coronary no-reflow phenomenon: a 
review of mechanisms and therapies. Eur Heart J, 2001. 22(9): p. 729-39. 
225. Morishima, I., et al., Angiographic no-reflow phenomenon as a predictor 
of adverse long-term outcome in patients treated with percutaneous 
transluminal coronary angioplasty for first acute myocardial infarction. 
Journal of the American College of Cardiology, 2000. 36(4): p. 1202-
1209. 
226. Salerno, M. and G.A. Beller, Noninvasive assessment of myocardial 
perfusion. Circ Cardiovasc Imaging, 2009. 2(5): p. 412-24. 
227. Grieve, S.M., et al., Microvascular Obstruction by Intracoronary Delivery 
of Mesenchymal Stem Cells and Quantification of Resulting Myocardial 
Infarction by Cardiac Magnetic Resonance. Circulation-Heart Failure, 
2010. 3(3): p. E5-E6. 
228. Uemura, R., et al., Bone marrow stem cells prevent left ventricular 
remodeling of ischemic heart through paracrine signaling. Circulation 
Research, 2006. 98(11): p. 1414-1421. 
229. Hynes, B., et al., Potent endothelial progenitor cell-conditioned media-
related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-
myocardial infarction are mediated by insulin-like growth factor-1. Eur 
Heart J, 2013. 34(10): p. 782-789. 
230. Tatsumi, K., et al., Tissue factor triggers procoagulation in transplanted 
mesenchymal stem cells leading to thromboembolism. Biochem Biophys 
Res Commun, 2013. 431(2): p. 203-9. 
231. Schecter, A.D., et al., Tissue factor expression in human arterial smooth 
muscle cells - TF is present in three cellular pools after growth factor 
stimulation. Journal of Clinical Investigation, 1997. 100(9): p. 2276-2285. 
232. Steffel, J., T.F. Luscher, and F.C. Tanner, Tissue factor in cardiovascular 
diseases - Molecular mechanisms and clinical implications. Circulation, 
2006. 113(5): p. 722-731. 
233. Owens, A.P., 3rd and N. Mackman, Microparticles in hemostasis and 
thrombosis. Circulation Research, 2011. 108(10): p. 1284-97. 
234. Mendolicchio, G.L. and Z.M. Ruggeri, New perspectives on von 
Willebrand factor functions in hemostasis and thrombosis. Semin 
Hematol, 2005. 42(1): p. 5-14. 
170 
 
235. Minami, T., et al., Thrombin and phenotypic modulation of the 
endothelium. Arteriosclerosis Thrombosis and Vascular Biology, 2004. 
24(1): p. 41-53. 
236. Kranzhofer, R., et al., Thrombin potently stimulates cytokine production in 
human vascular smooth muscle cells but not in mononuclear phagocytes. 
Circulation Research, 1996. 79(2): p. 286-294. 
237. Johnson, K., et al., Potential mechanisms for a proinflammatory vascular 
cytokine response to coagulation activation. J Immunol, 1998. 160(10): p. 
5130-5. 
238. Qi, J.F., D.L. Kreutzer, and T.H. PielaSmith, Fibrin induction of ICAM-1 
expression in human vascular endothelial cells. Journal of Immunology, 
1997. 158(4): p. 1880-1886. 
239. Skogen, W.F., et al., Fibrinogen-Derived Peptide B-Beta-1-42 Is a 
Multidomained Neutrophil Chemoattractant. Blood, 1988. 71(5): p. 1475-
1479. 
240. Breitenstein, A., et al., Amiodarone inhibits arterial thrombus formation 
and tissue factor translation. Arterioscler Thromb Vasc Biol, 2008. 
28(12): p. 2231-8. 
241. Celi, A., et al., Angiotensin II, tissue factor and the thrombotic paradox of 
hypertension. Expert Rev Cardiovasc Ther, 2010. 8(12): p. 1723-9. 
242. Alkistis Frentzou, G., et al., Differential induction of cellular proliferation, 
hypertrophy and apoptosis in H9c2 cardiomyocytes by exogenous tissue 
factor. Mol Cell Biochem, 2010. 345(1-2): p. 119-30. 
243. Gudmundsdóttir, I.J., et al., Role of the Endothelium in the Vascular 
Effects of the Thrombin Receptor (Protease-Activated Receptor Type 1) in 
Humans. Journal of the American College of Cardiology, 2008. 51(18): p. 
1749-1756. 
244. Dorfleutner, A., et al., Cross-talk of integrin alpha3beta1 and tissue factor 
in cell migration. Mol Biol Cell, 2004. 15(10): p. 4416-25. 
245. Agis, H., et al., Activated Platelets Increase Fibrinolysis of Mesenchymal 
Progenitor Cells. Journal of Orthopaedic Research, 2009. 27(7): p. 972-
980. 
246. Petitou, M., B. Casu, and U. Lindahl, 1976-1983, a critical period in the 
history of heparin: the discovery of the antithrombin binding site. 
Biochimie, 2003. 85(1-2): p. 83-9. 
247. Rao, S.V. and E.M. Ohman, Anticoagulant Therapy for Percutaneous 
Coronary Intervention. Circulation: Cardiovascular Interventions, 2010. 
3(1): p. 80-88. 
248. Narins, C.R., et al., Relation Between Activated Clotting Time During 
Angioplasty and Abrupt Closure. Circulation, 1996. 93(4): p. 667-671. 
249. Seeger, F.H., et al., Heparin Disrupts the CXCR4/SDF-1 Axis and Impairs 
the Functional Capacity of Bone Marrow-Derived Mononuclear Cells 
Used for Cardiovascular Repair. Circulation Research, 2012. 111(7): p. 
854-862. 
250. Fujitaka, K., et al., Heparin Mobilizes Multipotent Human 
Mesoangioblasts. Circulation, 2011. 124(21). 
251. Gibson, C.M., et al., A randomized trial to evaluate the relative protection 
against post-percutaneous coronary intervention microvascular 
dysfunction, ischemia, and inflammation among antiplatelet and 
171 
 
antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol, 
2006. 47(12): p. 2364-73. 
252. Ettelaie, C., et al., Low molecular weight heparin downregulates tissue 
factor expression and activity by modulating growth factor receptor-
mediated induction of nuclear factor-kappa B. Biochimica Et Biophysica 
Acta-Molecular Basis of Disease, 2011. 1812(12): p. 1591-1600. 
253. Breitenstein, A., et al., Amiodarone Inhibits Arterial Thrombus Formation 
and Tissue Factor Translation. Arteriosclerosis Thrombosis and Vascular 
Biology, 2008. 28(12): p. 2231-U177. 
254. Bogaert, J., et al., Determinants and impact of microvascular obstruction 
in successfully reperfused ST-segment elevation myocardial infarction. 
Assessment by magnetic resonance imaging. Eur Radiol, 2007. 17(10): p. 
2572-80. 
255. Orn, S., et al., Microvascular obstruction is a major determinant of infarct 
healing and subsequent left ventricular remodelling following primary 
percutaneous coronary intervention. Eur Heart J, 2009. 30(16): p. 1978-
1985. 
256. Houtgraaf, J.H., et al., Intracoronary Infusion of Allogeneic Mesenchymal 
Precursor Cells Directly Following Experimental Acute Myocardial 
Infarction Reduces Infarct Size, Abrogates Adverse Remodeling and 
Improves Cardiac Function. Circulation Research, 2013. 
257. Pfeffer, M.A. and E. Braunwald, Ventricular Remodeling after 
Myocardial-Infarction - Experimental-Observations and Clinical 
Implications. Circulation, 1990. 81(4): p. 1161-1172. 
258. D'Cruz, I.A., et al., Differences in the shape of the normal, 
cardiomyopathic, and volume overloaded human left ventricle. J Am Soc 
Echocardiogr, 1989. 2(6): p. 408-14. 
259. Williams, A.R. and J.M. Hare, Mesenchymal stem cells: biology, 
pathophysiology, translational findings, and therapeutic implications for 
cardiac disease. Circ Res, 2011. 109(8): p. 923-40. 
260. Marban, E. and K. Malliaras, Mixed Results for Bone Marrow-Derived 
Cell Therapy for Ischemic Heart Disease. Jama-Journal of the American 
Medical Association, 2012. 308(22): p. 2405-2406. 
261. Traverse, J.H., et al., Effect of the Use and Timing of Bone Marrow 
Mononuclear Cell Delivery on Left Ventricular Function After Acute 
Myocardial Infarction The TIME Randomized Trial. Jama-Journal of the 
American Medical Association, 2012. 308(22): p. 2380-2389. 
262. Surder, D., et al., Intracoronary injection of bone marrow-derived 
mononuclear cells early or late after acute myocardial infarction: effects 
on global left ventricular function. Circulation, 2013. 127(19): p. 1968-79. 
263. Sutton, M.S., et al., Left ventricular remodeling and ventricular 
arrhythmias after myocardial infarction. Circulation, 2003. 107(20): p. 
2577-2582. 
264. Williams, A.R., et al., Durable Scar Size Reduction Due to Allogeneic 
Mesenchymal Stem Cell Therapy Regulates Whole-Chamber Remodeling. 
Journal of the American Heart Association, 2013. 2(3). 
265. Ismail Siti, E.F., M. Creane, M. Harte, M. Murphy, T. O’Brien, F. Barry 
Elucidating the cardioprotective role of SPARCL1 in ex vivo model of 
myocardial infarction, in Microscopy Society of Ireland. 2013: Galway, 
Ireland. 
172 
 
266. Brekken, R.A. and E.H. Sage, SPARC, a matricellular protein: at the 
crossroads of cell-matrix. Matrix Biol, 2000. 19(7): p. 569-80. 
267. Hambrock, H.O., et al., SC1/hevin. An extracellular calcium-modulated 
protein that binds collagen I. J Biol Chem, 2003. 278(13): p. 11351-8. 
268. Sullivan, M.M., et al., Matricellular hevin regulates decorin production 
and collagen assembly. J Biol Chem, 2006. 281(37): p. 27621-32. 
269. Soderling, J.A., et al., Cloning and expression of murine SC1, a gene 
product homologous to SPARC. J Histochem Cytochem, 1997. 45(6): p. 
823-35. 
270. Schellings, M.W., et al., Absence of SPARC results in increased cardiac 
rupture and dysfunction after acute myocardial infarction. J Exp Med, 
2009. 206(1): p. 113-23. 
271. Chaurasia, S.S., et al., Correction: Hevin Plays a Pivotal Role in Corneal 
Wound Healing. PLoS One, 2014. 9(1). 
272. Ikonomidis, J.S., et al., Accelerated LV remodeling after myocardial 
infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. 
Am J Physiol Heart Circ Physiol, 2005. 288(1): p. H149-58. 
273. Kandalam, V., et al., TIMP2 deficiency accelerates adverse post-
myocardial infarction remodeling because of enhanced MT1-MMP 
activity despite lack of MMP2 activation. Circ Res, 2010. 106(4): p. 796-
808. 
274. Lobb, D.C., et al., Temporal Effects of Targeted Release of Recombinant 
Tissue Inhibitor of Matrix Metalloproteinase Post Myocardial Infarction: 
Relation to Determinants of Remodeling, in AHA. 2013, Circulation: 
Dallas, TX. 
275. Ma, Y., A. Yabluchanskiy, and M.L. Lindsey, Neutrophil roles in left 
ventricular remodeling following myocardial infarction. Fibrogenesis 
Tissue Repair, 2013. 6(1): p. 11. 
276. Krishnamurthy, P., et al., IL-10 inhibits inflammation and attenuates left 
ventricular remodeling after myocardial infarction via activation of 
STAT3 and suppression of HuR. Circ Res, 2009. 104(2): p. e9-18. 
277. van der Spoel, T.I., et al., Human relevance of pre-clinical studies in stem 
cell therapy: systematic review and meta-analysis of large animal models 
of ischaemic heart disease. Cardiovasc Res, 2011. 91(4): p. 649-58. 
278. Heldman, A.W., et al., Transendocardial mesenchymal stem cells and 
mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-
HFT randomized trial. JAMA, 2014. 311(1): p. 62-73. 
279. Seeger, F.H., et al., Heparin disrupts the CXCR4/SDF-1 axis and impairs 
the functional capacity of bone marrow-derived mononuclear cells used 
for cardiovascular repair. Circ Res, 2012. 111(7): p. 854-62. 
280. Uygun, B.E., S.E. Stojsih, and H.W. Matthew, Effects of immobilized 
glycosaminoglycans on the proliferation and differentiation of 
mesenchymal stem cells. Tissue Eng Part A, 2009. 15(11): p. 3499-512. 
281. Ozmen, L., et al., Inhibition of thrombin abrogates the instant blood-
mediated inflammatory reaction triggered by isolated human islets: 
possible application of the thrombin inhibitor melagatran in clinical islet 
transplantation. Diabetes, 2002. 51(6): p. 1779-84. 
282. Contreras, J.L., et al., Activated protein C preserves functional islet mass 
after intraportal transplantation: a novel link between endothelial cell 
173 
 
activation, thrombosis, inflammation, and islet cell death. Diabetes, 2004. 
53(11): p. 2804-14. 
283. Karantalis, V., et al., Cell-based therapy for prevention and reversal of 
myocardial remodeling. Am J Physiol Heart Circ Physiol, 2012. 303(3): p. 
H256-70. 
284. Frink, R.J., et al., Coronary thrombosis and platelet/fibrin microemboli in 
death associated with acute myocardial infarction. Br Heart J, 1988. 
59(2): p. 196-200. 
285. Davies, M.J., et al., Intramyocardial platelet aggregation in patients with 
unstable angina suffering sudden ischemic cardiac death. Circulation, 
1986. 73(3): p. 418-27. 
286. Hare, J.M., et al., A randomized, double-blind, placebo-controlled, dose-
escalation study of intravenous adult human mesenchymal stem cells 
(prochymal) after acute myocardial infarction. J Am Coll Cardiol, 2009. 
54(24): p. 2277-86. 
287. Bartunek, J., et al., The consensus of the task force of the European Society 
of Cardiology concerning the clinical investigation of the use of 
autologous adult stem cells for repair of the heart. Eur Heart J, 2006. 
27(11): p. 1338-40. 
288. Sakaguchi, K., et al., In vitro engineering of vascularized tissue 
surrogates. Sci Rep, 2013. 3: p. 1316. 
289. Trams, E.G., et al., Exfoliation of membrane ecto-enzymes in the form of 
micro-vesicles. Biochim Biophys Acta, 1981. 645(1): p. 63-70. 
290. Lai, R.C., et al., Exosome secreted by MSC reduces myocardial 
ischemia/reperfusion injury. Stem Cell Res, 2010. 4(3): p. 214-22. 
291. Arslan, F., et al., Mesenchymal stem cell-derived exosomes increase ATP 
levels, decrease oxidative stress and activate PI3K/Akt pathway to 
enhance myocardial viability and prevent adverse remodeling after 
myocardial ischemia/reperfusion injury. Stem Cell Res, 2013. 10(3): p. 
301-12. 
292. Martinez, M.C. and R. Andriantsitohaina, Microparticles in angiogenesis: 
therapeutic potential. Circ Res, 2011. 109(1): p. 110-9. 
293. Park, J.A., et al., Tissue factor-bearing exosome secretion from human 
mechanically stimulated bronchial epithelial cells in vitro and in vivo. J 
Allergy Clin Immunol, 2012. 130(6): p. 1375-83. 
294. Hahn, J.Y., et al., Pre-treatment of mesenchymal stem cells with a 
combination of growth factors enhances gap junction formation, 
cytoprotective effect on cardiomyocytes, and therapeutic efficacy for 
myocardial infarction. J Am Coll Cardiol, 2008. 51(9): p. 933-43. 
295. Pasha, Z., et al., Preconditioning enhances cell survival and differentiation 
of stem cells during transplantation in infarcted myocardium. Cardiovasc 
Res, 2008. 77(1): p. 134-42. 
296. Bao, C., et al., TNFR gene-modified mesenchymal stem cells attenuate 
inflammation and cardiac dysfunction following MI. Scand Cardiovasc J, 
2008. 42(1): p. 56-62. 
297. Cheng, Z., et al., Targeted migration of mesenchymal stem cells modified 
with CXCR4 gene to infarcted myocardium improves cardiac 
performance. Mol Ther, 2008. 16(3): p. 571-9. 
174 
 
298. Gao, F., et al., A promising strategy for the treatment of ischemic heart 
disease: Mesenchymal stem cell-mediated vascular endothelial growth 
factor gene transfer in rats. Can J Cardiol, 2007. 23(11): p. 891-8. 
299. Song, H., et al., Transfection of mesenchymal stem cells with the FGF-2 
gene improves their survival under hypoxic conditions. Mol Cells, 2005. 
19(3): p. 402-7. 
 
 
  
175 
 
 
 
 
 
 
 
 
Chapter 9 Appendix 
  
176 
 
 
9.1 MSC DiI Labelling  
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9.2 7AAD Staining 
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9.3 Coronary Flow Researve Theroy[157] 
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9.4 TF Activity Assay 
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Standard Curve for TF Activity (Figure 4.4) 
y = -0.0004x2 + 0.0413x - 0.0076 
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9.5 Thrombin Generation Assay 
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Standard Curve for Thrombin generation (Figure 4.5) 
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9.6 Sparcl1 ELISA 
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Standard Curve for Sparcl1 ELISA (Figure 7.2) 
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9.7 CM Ctokine Arrays 
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9.8 Cardiac Functional Parameters 
Infarct 
Zone 
IZ 
Region of ischemia within the myocardium as 
defined as regions not stained with TTC 
Border 
Zone 
BZ 
Region with the infarcted myocardium defined as 
having 50% normal myocardium and 50% infarcted 
myocardium 
Remote 
Zone 
RZ 
Defined as normal healthy regions within the 
myocardium 
End 
Diastolic 
Volume 
EDV 
The volume of blood in each ventricle at the end of 
diastole usually about 120–130mL 
End 
Systolic 
Volume 
ESV 
The volume of blood remaining in each ventricle at 
the end of systole usually about 50–60ml 
Stroke 
Volume 
SV 
The volume of blood pumped from one ventricle of 
the heart with each beat.  SV = EDV-ESV 
Ejection 
Fraction 
%EF 
Represents the volumetric fraction of blood pumped 
out of the left and right ventricle with each heartbeat 
or cardiac cycle. 
Ef (%) = SV/EDV X 100 
Heart 
Rate  
HR 
The number of heartbeats per unit of time-typically 
beats per minute (bpm). 
Cardiac 
Output 
CO 
The volume of blood being pumped by the heart by a 
left or right ventricle in the time interval of one 
minute 
CO = SV X HR 
 
 
 
 
 
CT Measurements 
64-slice images were analyzed with CardIQ software 
(AW 4.4, GE Healthcare). End-diastolic Volume 
(EDV) and end-systolic volume (ESV) and heart rate 
(HR) were calculated by slice summation using an 
automated contour detection. Papillary muscles and 
left ventricle (LV) outflow tract were not regarded as 
part of the LV cavity. The anatomical location for 
determination of the LV volume was selected at the 
mid mitral valve. Based on the automatic detection of 
the LV volume, the EDV, ESV and ejection fraction 
were calculated by specialised software. 
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